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ABSTRACT 
Arginine vasopressin (AVP) is a hypothalamic nonapeptide which regulates the hypothalamic-
pituitary-adrenal axis response to stress by stimulating the secretion of adrenocorticotropin 
(ACTH) from corticotroph cells of the anterior pituitary. This effect is mediated by binding of 
AVP to the pituitary vasopressin receptor (V1bR). The V1bR belongs to the G protein-coupled 
receptor (GPCR) super family. Repeated stimulation of anterior pituitary cells with AVP has 
been shown to produce a loss of responsiveness to subsequent AVP stimulation. This 
phenomenon appears to be mediated by desensitisation of the V1bR, and may be due to 
phosphorylation of the receptor by G protein-coupled receptor kinase 5 (GRK5). The aim of 
this research was to establish and validate methods that would allow the role of GRK5 in the 
desensitisation of V1bR to AVP stimulation to be investigated. As no isoform specific 
inhibitors for GRK5 were available, HEK293 cells transiently transfected with the rat V1bR 
were used as a model system for this research. This allowed RNA interference (RNAi) to be 
used to knockdown GRK5 expression. The protocol for RNAi-mediated knockdown of GRK5 
was established as part of this research. Protocols for Western blotting and qRT-PCR were also 
established to allow the RNAi-mediated knockdown of GRK5 protein and mRNA to be 
measured. Transfection of HEK293 cells with 10nM GRK5-targeting small interfering RNAs 
(siRNAs) reduced the expression of GRK5 protein to 53.4% ± 3.4% (mean ± SEM) of that 
seen in untreated control cells at 84 hours after transfection, while GRK5 mRNA levels were 
reduced to 28.7% ± 1.9% (mean ± SEM) of that of control cells 48 hours after transfection.  
 
An experimental protocol was designed in this research that would coordinate the RNAi-
mediated knockdown of GRK5 with transient transfection of the HEK293 cells with the 
rV1bR. Since, activated V1bRs couple to Gq/11 and stimulate the production of inositol 
phosphates (IPs), the responsiveness of the V1bR can be determined by measuring the 
accumulation of [H
3
]-IPs in cells labelled with [H
3
]-myo-inositol. In the protocol designed, the 
effect of GRK5 knockdown on V1bR desensitisation is determined by stimulating HEK293 
cells expressing the rV1bR (and previously transfected with GRK5-targeting siRNA) with 
x 
 
0nM or 100nM AVP for 0, 5, 15, 30 or 60 minutes, and comparing the accumulation if IPs 
over time with that of cells that are not transfected with GRK5-targeting siRNA. This protocol 
can be used in future to investigate the role of GRK5 in V1bR desensitisation, and may be 
adapted to determine if other GRK isoforms are involved in V1bR desensitisation. 
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1 
INTRODUCTION 
1.1 THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 
1.1.1 The Hypothalamic-Pituitary-Adrenal axis 
Homeostasis is the process by which an organism maintains a desired and constant internal 
state by responding appropriately to challenges and fluctuations which disturb this state (Roper 
et al., 2011; Sherwood et al., 2005). Maintenance of homeostasis is crucial for the survival of 
the organism, and is regulated by a number of pathways. In mammals the endocrine response 
to ‗noxious‘ stimuli or ‗stressors‘ (Buckingham et al., 1997) is coordinated principally by the 
hypothalamic-pituitary-adrenal (HPA) axis, a neuroendocrine system which results in the 
instigation of mechanisms which allow the organism to restore homeostatic balance (Roper et 
al., 2011). Stressors may be cognitive, such as emotional disturbances, or non-cognitive, such 
as physical trauma (Buckingham et al., 1997). 
 
Stressful stimuli activate the HPA axis (see Figure 1.1), resulting in the rapid release of 
adrenocorticotropin (ACTH) from corticotroph cells of the anterior pituitary (Aguilera, 1994). 
Regulation of ACTH secretion is complexly and tightly regulated. The peptide hormones 
arginine vasopressin (AVP) and corticotrophin releasing hormone (CRH) are the most potent 
activators of pituitary ACTH secretion (Antoni, 1993). Both are released from the 
hypothalamus into the hypophysial portal system in response to stress, and are transported to 
the anterior pituitary where they interact specifically with receptors found in the plasma 
membranes of corticotroph cells (Jard et al., 1986; Perrin & Vale, 1999). These interactions 
stimulate the secretion of ACTH into the systemic blood, through which it is transported to the 
adrenal gland (Bilezikjian & Vale, 1987). In some cases, binding of CRH and AVP at the 
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anterior pituitary stimulates the biosynthesis of ACTH from its precursor proopiomelanocortin 
(POMC) (Liu et al., 1990). Secreted ACTH induces the secretion of glucocorticoid hormones 
from the adrenal cortex. Glucocorticoids regulate the peripheral stress responses, mediating the 
return to homeostasis. They do this via a number of widespread mechanisms such as energy 
mobilisation and immunomodulation (Ashwell et al., 2000; Buckingham et al., 1997; Elemkov 
& Chrousos, 1999). The secretion of ACTH from the anterior pituitary is also regulated by 
inhibitory forces, by which glucocorticoids regulate their own secretion. They do so by 
providing negative feedback to upstream components of the HPA axis (Labrie et al., 1984), 
inhibiting secretion of AVP and CRH from the hypothalamus and at the anterior pituitary; 
inhibiting the cleavage of POMC into ACTH (and other products)(Drouin et al., 1989). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Dysregulation of the HPA axis has been implicated in a number of pathological disorders 
(Buckingham et al., 1997), such as hypertension (Wirtz et al., 2007), cardiovascular disease 
Figure 1.1 The HPA axis. Schematic representation of activation of the HPA axis in response to 
stress. Solid lines represent positive stimulation, while dashed arrows represent negative feedback. 
Figure adapted from Buckingham, Gillies, and Cowell (1997)  
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(Rosmond & Björntorp, 2000), irritable bowel syndrome  (Chang et al., 2009), and many 
inflammatory diseases (Gold et al., 2005; Morand & Leech, 2001; Sternberg, 2001). 
Furthermore, recent studies have provided evidence that chronic psychological stress can 
induce DNA/RNA damage (Flint et al., 2007; Joergensen et al., 2011). 
The role of stress-induced dysregulation of the HPA-axis in the instigation of serious 
psychiatric conditions such as depression, anxiety, and bipolar disorder has been the subject of 
numerous studies, resulting in strong evidence for a causative relationship (Hammen, 2005).   
1.1.2 Vasopressinergic control of ACTH secretion 
AVP is a nonapeptide hormone (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) synthesised 
and secreted from two distinct types of hypothalamic neurons. The first type of hypothalamic 
AVP-secreting neurons are magnocellular neurons of the supraoptic (SON) and paraventricular 
nuclei (PVN), while the second class are parvicellular neurons of the PVN (reviewed in 
Antoni, 1993). There are two subdivisions of parvicellular PVN neurons; one that releases 
CRH alone, and a second that secretes both CRH and AVP packaged into the same vesicles 
(Antoni, 1993). It appears that while AVP from both groups of neurons is involved in 
regulating ACTH secretion, the origin of AVP secretion may differ between different stress 
paradigms (Antoni, 1993). Most evidence suggests that parvocelluar AVP is involved in 
regulating the HPA axis during chronic stress (Aguilera, 1994), though some acute stressors 
(such as osmotic stress) have been shown to induce AVP secretion from magnocellular neurons 
(Jackson et al., 2003).  
 
That AVP is capable of stimulating ACTH secretion has been known since the mid 1950‘s 
(Martini & Morpurgo, 1955). However, investigation into vasopressinergic regulation of 
ACTH secretion has been relatively neglected in favour of CRH. The importance of AVP in 
regulating ACTH secretion is becoming increasingly evident (Antoni, 1993). A good 
correlation has been observed between the number of pituitary AVP receptors and the ACTH 
responsiveness of corticotroph cells (Aguilera, 1994). Furthermore, the physiological 
consequences of preventing AVP signalling via the pituitary AVP receptor have been 
examined using a number of animal models in which the pituitary AVP receptor has been 
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knocked out. The results of these studies suggest that AVP signalling via this receptor plays an 
important role in regulation of the HPA axis (Itoh et al., 2006; Lolait et al., 2007a; Tanoue et 
al., 2004), in central processes such as learning, behaviour (Egashira et al., 2005; Wersinger et 
al., 2007; Wersinger et al., 2002) and social memory (Wersinger et al., 2007; Wersinger et al., 
2008), as well as peripheral responses (Daikoku et al., 2007; Fujiwara et al., 2007a; Fujiwara 
et al., 2007b; Lolait et al., 2007b). The aim of this thesis was to build on previous work from 
this laboratory (Hassan et al., 2003; Hassan & Mason, 2005), elucidating the molecular 
mechanism of AVP-stimulated secretion of ACTH from the anterior pituitary. 
 
Secretion of AVP into the hypophysial portal occurs in a pulsatile fashion (Antoni, 1993), the 
amplitude of which tends to be increased following stress rather than the frequency (reviewed 
in Mason et al., 2002). The concentration of AVP in the hypophysial portal has been shown to 
increase following numerous types of stress (Antoni, 1993). For example, in sheep, the 
hypophysial AVP concentration produced by basal AVP secretion ranges from 5 to 83pM 
(Caraty et al., 1988). Application of a stressor stimulates AVP pulses that are less than 30 
minutes long, and range in concentration from ~1nM for acute haemorrhage (Caraty et al., 
1988) to ~6nM for high-dose insulin-induced hypoglycaemia (2IU/kg) (Caraty et al., 1990).  
Both physical and emotional stressors have been shown to induce AVP secretion (Antoni, 
1993). 
  
The synergistic stimulation of ACTH secretion by concurrent stimulation of anterior pituitary 
cells with AVP and CRH is well documented both in vivo (McFarlane et al., 1995; Rivier & 
Vale, 1983)  and in vitro (Evans et al., 1996; Gilllies et al., 1982), and occurs in all mammalian 
models tested. Synergism between the two hormones appears to be caused by AVP enhancing 
CRH-mediated production of cyclic adenosine monophosphate (cAMP) (potentially by 
increasing the activity of protein kinase C (PKC) (Abou-Samra et al., 1987)), and results in 
ACTH secretion that is greater than the sum of ACTH release stimulated when AVP or CRH 
are used independently (Bilezikjian & Vale, 1987). However, the relative potency of AVP and 
CRH appears to be species-dependant (Evans et al., 1993; McFarlane et al., 1995; Vale et al., 
1983). It has been proposed that synergism between CRH and AVP allows CRH to act as a 
permissive signal, regulating the overall responsiveness of the corticotroph by setting the basal 
level of ACTH secretion and determining the amplitude of ACTH pulses (Antoni, 1993; Evans 
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et al., 1996). In this scenario, AVP acts as the dynamic regulator of ACTH section (Antoni, 
1993; Evans et al., 1996).  
1.2 MECHANISMS OF AVP-STIMULATED ACTH RELEASE BY THE 
ANTERIOR PITUITARY 
AVP and CRH stimulate ACTH secretion by binding specifically to receptors belonging to the 
G protein-coupled receptor (GPCR) super family (Perrin & Vale, 1999; Sugimoto et al., 1994) 
GPCRs are integral membrane proteins which transmit the incoming signal (reviewed in 
Kobilka, 2006) into intracellular signalling molecules by interacting or ‗coupling‘ with a 
heterotrimeric guanine nucleotide binding protein (G protein). G proteins are comprised of 3 
different subunits; α, β and γ (Strader et al., 1994), and are grouped into four subclasses: Gs, Gi, 
Gq and G12 (Ulloa-Aguirre et al., 1999). Functional diversity amongst the G protein subunits 
allows the activation of a range of signalling pathways, as interaction of a G protein with an 
agonist-bound GPCR stimulates the production of second messenger signalling molecules by 
an effector enzyme or channel (Ferguson, 2001). Binding of CRH to its CRH type 1 receptor 
(CRHR1)—located at the membrane of corticotroph cells—activates the cAMP-mediated 
signalling pathway via a Gs type G protein, by stimulating adenylyl cyclase-mediated synthesis 
of cAMP from adenosine triphosphate (ATP) (Aguilera, 1994). AVP signalling via AVP 
receptors is described below. 
1.2.1 AVP Receptors 
In addition to its role in stimulating ACTH secretion, AVP is known to exert other diverse 
biological effects. To date, three functionally distinct mammalian AVP receptors have been 
cloned. They are the V1aR, the V1bR (also known as V3R), and the V2R (Frank & Landgraf, 
2008). The three receptors share a structure typical of GPCRs; consisting of seven 
hydrophobic-transmembrane α-helices, which are linked by intracellular and extracellular 
loops (Strader et al., 1994). Despite their high level of structural homology and common 
ligand, each receptor subtype has different pharmacological properties (Jard et al., 1986). 
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These differences allow AVP to exert a range of tissue-dependant effects (Frank & Landgraf, 
2008). AVP has also been shown to bind with high affinity to receptors for oxytocin—a 
nonapeptide hormone with high structural similarity to AVP—which plays a role in lactation, 
parturition, and sexual behaviour (Holmes et al., 2003; Maybauer et al., 2008). 
 
Since its characterisation, the V1bR sequence has been cloned from the rat (Lolait et al., 1995), 
mouse (Ventura et al., 1999) and human genomes (de Keyzer et al., 1994  ; Sugimoto et al., 
1994). The human gene for V1bR (AVPR1B) is located at region q32 of chromosome 1  and 
codes for a protein 424 amino acid residues long (Rousseau-Merck et al., 1995; Sugimoto et 
al., 1994). This polypeptide has considerable homology with the human V1a, V2 and oxytocin 
receptors (45, 39, and 45% respectively), as well as with V1bR from other species (Ventura et 
al., 1999). Despite these similarities, studies directly comparing the relative binding affinities 
of the mouse and human V1bRs for AVP, vasotocin (a non-mammalian hybrid of vasopressin 
and oxytocin) and oxytocin demonstrated that significant intra-species pharmacological 
differences exist (Ventura et al., 1999). 
 
The V2R, expressed predominately in the kidneys, is involved in water reabsorption (Holmes 
et al., 2003). Like the CRHR1, the V2R is coupled to Gs an  activates adenylyl cyclase-
mediated synthesis of cAMP from ATP (Birnbaumer, 2000).  In contrast, the V1a, V1b and 
oxytocin receptor are Gq/11-coupled, recruiting phospholipase Cβ (PLCβ) to produce second 
messenger signalling molecules (Raggenbass, 2008; Roper et al., 2011; Thibonnier et al., 
1997). The V1aR is primarily expressed in vascular smooth muscle, enhancing prostaglandin 
release (Maybauer et al., 2008), and regulating blood pressure (Frank & Landgraf, 2008). It is 
this classical ‗pressor‘ action for which its ligand is named. The V1bR is predominately 
expressed in corticotroph cells of the anterior pituitary (Holmes et al., 2003) where it facilitates 
the release of ACTH as part of the HPA axis-response to stress. It has also been detected in 
peripheral tissues (Regard et al., 2008; Roper et al., 2011), of note, in the pancreatic islets 
where it is involved in the regulation of insulin secretion (Maybauer et al., 2008; Regard et al., 
2008).  
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1.2.2 V1bR-mediated activation of the phosphoinositol signalling pathway by 
AVP 
1.2.2.1 Mechanisms of GPCR signalling via Gq/11 
AVP-bound V1bR is known to activate PLCβ by coupling to the G protein Gq/11  (Sugimoto et 
al., 1994), thus transducing its signal via the phosphatidyl-inositol signalling pathway. The 
general mechanism of signal transduction common to Gq/11-coupled GPCRs is described 
below, and depicted schematically for AVP in Figure 1.2. 
 
Figure 1. 2 Activation of the phosphoinositide signalling pathway by AVP. (1) AVP binds to the V1bR at the 
membrane of corticotroph cells, inducing a conformational change in the receptor – allowing it to couple with the 
Gq G protein. (2) Interaction of Gq and ligand-bound V1bR triggers the dissociation of the Gq α subunit from the 
β & γ complex, allowing it to travel through the membrane and (3) activate PLCβ, (4) which hydrolyses PIP2 into 
second messenger molecules: IP3 and DAG. (5) IP3 is released into the cytosol where is acts to increase 
intracellular free Ca2
+
, while (6) DAG remains associated with the membrane, where it activates PKC which also 
results in an increase in the intracellular Ca
2+
 concentration.  
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Activation of a GPCR, such as the V1bR, by binding of its ligand induces a conformational 
change in the receptor structure. This allows it to interact with its G-protein (Gq/11). The 
resulting G protein-GPCR interaction catalyses the exchange of G protein-bound guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP) (Oldham et al., 2006), triggering the 
dissociation of the GTP-bound Gqα-subunit from the Gqβγ-subunits (Milligan & Kostenis, 
2006). The α-subunit then activates the effector enzyme, PLCβ (Taylor et al., 1990). PLCβ 
enables transmission of the incoming signal by catalysing the hydrolysis of the membrane 
constituent phosphatidylinositol-4,5-bisphosphate (PIP2) into two second messenger 
molecules; inositol-1,4,5-trisphosphate (IP3), which is released into the cytosol, and 
diacylglycerol (DAG) which remains associated with the membrane (Berridge & Irvine, 1984). 
Both act to increase the cytoplasmic concentration of calcium ions (Ca
2+
). IP3 does so by 
interacting with IP3 receptors at the endoplasmic reticulum, triggering the release of Ca
2+
 into 
the cytosol from intracellular stores (Berridge & Irvine, 1984), while DAG activates the second 
messenger-dependant kinase, PKC, which phosphorylates cell membrane-localised ion 
channels, resulting in an influx of extracellular Ca
2+
 (Berridge, 1985). In anterior pituitary 
cells, the V1bR-mediated increase in intracellular Ca
2+
 concentration triggers the fusion of 
ACTH-containing vesicles with the cell membrane, resulting in secretion of ACTH into the 
systemic blood.  
1.2.2.2 Mechanisms of V1bR signalling 
While the V1bR is known to couple to PLCβ in anterior pituitary cells, the mechanism of 
receptor activation has not yet been fully elucidated. However, it is likely to be similar to that 
of its fellow PLCβ-coupled GPCRs; V1aR and the oxytocin receptor with which it has 
considerable homology.  
1.2.2.2.1 V1bR activation 
AVP is thought to interact with its receptors by binding in a pocket created by the seven 
transmembrane domains, which are arranged in a ring shape. This interaction appears to be 
mediated by a large number of weak electrostatic interactions involving many amino acid 
residues, rather than via a few discrete binding regions (Barberis et al., 1998). However, 
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alanine-scanning mutagenesis studies of the V1aR N-terminal region have demonstrated that 
the residues Glu
54
 and Arg
46
 (both part of a –R(X3)L/V(X3)E(X3)L- motif conserved within the 
vasopressin/oxytocin receptor subfamily) play crucial roles in the binding of AVP to the V1aR 
(Hawtin et al., 2005)  For most GPCRs, activation is caused by a conformational change 
triggered by association of their ligand (reviewed in Kobilka, 2007). Biochemical and 
biophysical studies have suggested that common structural changes occur within GPCRs, 
particularly within their transmembrane and intracellular domains (Kobilka, 2007). These 
regions are also the most conserved between receptors, which may allow receptors for very 
different ligands to couple to the same G protein (Kobilka, 2007).  While the site of V1bR 
interaction with Gq/11 has not been confirmed, the ability of the V1aR to couple to the same G 
protein appears to involve residues located within its second intracellular loop (Barberis et al., 
1998). 
 
There is growing evidence that GPCR signalling may be more complex than depicted in the 
linear mechanism described in Section 1.2.2.1 (Albizu et al., 2010; Chini & Manning, 2007), 
with some GPCRs having been shown to form homo- or hetero-dimers under physiological 
conditions, with dimerisation potentially playing a role in their maturation (Park & Palczewski, 
2005), signalling and regulation (Albizu et al., 2010) (reviewed in Terrillon & Bouvier, 2004). 
A number of recent studies have suggested that the members of the vasopressin/oxytocin 
receptor family can form functional hetero- and homo-dimers in vivo (reviewed in Cottet et al., 
2010). Hetero-dimerisation of V1bR and CRHR1 has also been reported (Young et al., 2007). 
However formation of this dimer was constitutive not ligand dependant, and as such it is 
unlikely that heterodimerisation of the CRHR1 and V1bR alters their binding properties.  
 
Adding another layer of complexity is the recent demonstrations that some GPCRs —including 
the V1bR— can differentially couple to more than one subtype of G protein, enabling the 
activation of multiple second messenger pathways by a single receptor (Chini & Manning, 
2007). Data obtained by Orcel et al.(2009) using Chinese hamster ovary (CHO) cells, COS-7 
cells, and human embryonic kidney 293 (HEK293) cells transfected with the rat V1bR, showed 
that the V1bR was capable of simultaneously activating both the PLCβ (described above) and 
adenylyl cyclase-mediated signal transduction pathways by differentially coupling to Gq/11 and 
Gs, though not to Gi (Orcel et al., 2009). AVP was a more potent stimulator of the Gq/11-PLCβ 
- 10 - 
 
pathway, with higher concentrations of ligand required to induce Gs-mediated cAMP 
production by adenylyl cyclase (EC50 18.6 to 32.7nM depending on cell type) than Gq/11 
mediated inositol phosphate (IP) production (EC50 3.84 to 7.28nM depending on cell type). 
Though signalling was detected in all three cell types tested and at endogenous levels of 
receptor expression, it is unclear if significant activation of the cAMP pathway occurred at 
physiologically relevant concentrations of AVP.  
1.3 ATTENUATION OF THE RESPONSE TO AVP: DESENSITISATION 
Most signalling systems contain autoregulatory loops, which allow stimulated target-cells to 
modify their response to future stimuli (Lohse, 1993). In many hormonal pathways, such as the 
HPA axis, repeated or chronic stimulation leads to a reduction in system responsiveness 
(Aguilera, 1994). Aspects of this attenuation were described earlier, in the form of negative 
feedback by glucocorticoids. Similar mechanisms are also seen in GPCR-mediated intracellular 
signalling pathways, in which the activation of a receptor by binding of its ligand not only 
results in signal transduction, but also initiates desensitisation (Lohse, 1993). This loss of 
responsiveness can be due to regulation of many aspects of the signalling pathway, though 
receptor desensitisation is the predominant cause  (Krupnick & Benovic, 1998). Studies using 
primary cultures of ovine anterior pituitary cells have shown that the responsiveness of ACTH 
release to AVP stimulation undergoes rapid desensitisation (Hassan et al., 2003). Furthermore, 
desensitisation was measured following AVP treatments which closely resembled—both in 
pulse duration and concentration—endogenous AVP pulses (Hassan et al., 2003). This 
indicates that the V1bR undergoes desensitisation, and that it is likely a physiologically 
relevant phenomenon. 
1.3.1 Mechanisms of desensitisation in GPCRs 
The characteristics of β2-adrenergic receptor (β2-AR)-mediated signalling have been 
extensively studied, and have been used to generate a model for understanding general GPCR 
signalling and regulation (Ferguson, 2001). While receptor-specific differences limit the ability 
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to extrapolate, components of the mechanisms are thought to be generally relevant for all 
GPCRs and are described below. Some aspects of these mechanisms are shown in Figure 1.3.  
  
Figure 1.3 the „classical‟ model of GPCR desensitisation. (1) The ligand-bound receptor couples to its G 
protein, (2) resulting in signal transduction. (3) The activated receptor is phosphorylated by a GRK, (4) 
recruiting arrestin from the cytoplasm, which binds to the receptor, preventing it from coupling to its G 
protein. (5) The desensitised receptor is internalised, where it is either (6) resensitised and (7) returned to the 
membrane, or (8) targeted to the lysosomes for degradation resulting in receptor down-regulation. Figure 
adapted from (Kelly et al., 2008) 
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The phenomenon of GPCR desensitisation can involve three complementary mechanisms. The 
first is mediated by the ‗uncoupling‘ of the receptor from its signalling pathway, resulting in a 
loss of signal transduction. The second, ‗internalisation‘ isolates the receptor from downstream 
components of the signalling pathway in endocytotic vesicles, while the third, ‗down 
regulation‘, is mediated by a reduction in receptor numbers via receptor degradation or 
decreased synthesis (Lohse, 1993). 
1.3.1.1 Receptor uncoupling 
Phosphorylation of serine and threonine residues located in the intracellular domains of GPCRs 
results in uncoupling of the receptor from its G protein, thus preventing it from activating its 
signalling pathway (Ferguson, 2001). This form of desensitisation is rapid, occurring within 
seconds of ligand binding (Lohse, 1993). It is also readily reversed by dephosphorylation of the 
receptor (Krupnick & Benovic, 1998). GPCRs are commonly phosphorylated by two classes of 
protein kinase; second messenger-dependent kinases and G protein-coupled receptor kinases 
(GRKs).  
1.3.1.1.1. Second messenger-dependent kinases and others  
The activity of the aptly named ‗second messenger-dependant kinases‘ is stimulated by 
increases in the intracellular concentration of second messenger signalling molecules such as 
cAMP, Ca
2+
 and DAG. As well as mediating down-stream signalling events (for example see 
Figure 1.2, [6]), the activated kinases can negatively regulate receptor function by feedback 
phosphorylation of GPCRs (reviewed in Lohse, 1993). Phosphorylation of a receptor by 
second messenger-dependent kinases occurs at consensus motifs within the intracellular loops 
and C-terminal tail, and appears to directly prevent the interaction of the receptor with its G 
protein as it is sufficient to induce desensitisation. Second messenger-dependent kinases are 
capable of simultaneously inducing both ‗homologous‘ desensitisation, by phosphorylation the 
ligand-bound receptors which stimulated their activation, and ‗heterologous‘ desensitisation, 
by phosphorylating inactivate receptors, which may also be of a different type (Ferguson, 
2001). There is also evidence that other kinases, such as casein kinase 1α (CK1α) (Budd et al., 
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2000) and tyrosine kinases (reviewed in Ferguson, 2001), may play a more limited role in 
GPCR regulation.   
1.3.1.1.2 G protein-coupled receptor kinases (GRKs) 
G protein-coupled receptor kinase (GRK)-mediated phosphorylation of GPCRs (depicted in 
Figure 1.3) differs from that induced by second messenger-dependant kinases in that is not 
sufficient, in and of itself, to prevent receptor-G protein interactions. Instead, GRK-mediated 
phosphorylation of the receptor recruits an additional protein from the arrestin family (such as 
β-arrestin-1 or -2) from the cytosol to the plasma membrane. β-arrestin binds to the 
phosphorylated receptor, thus sterically inhibiting further interaction with its associated G-
protein (Lohse et al., 1990). This results in decreased receptor responsiveness (Han et al., 
2001). GRK-mediated desensitisation is classed as ‗homologous‘, as GRKs preferentially 
phosphorylate ligand-bound receptors (Penn et al., 2000). This homologous desensitisation is 
often referred to as ‗classical‘ desensitisation (depicted in Figure 1.3), and is a common 
mechanism of regulation among GPCRs (Kelly et al., 2008).  
 
To date, seven GRK isoforms have been identified, which can be divided into three groups 
based on structural and functional homology (alternative names are given in parentheses): 1) 
GRK1 (rhodopsin kinase) and GRK7 (cone opsin kinase); 2) GRK2 and GRK3 (β-AR kinases 
1 and 2 respectively); and 3) GRK4, 5 and 6 (known collectively as the GRK4 subfamily). 
GRK2, 3, 5 and 6 are ubiquitously expressed, while expression of GRK4 is limited to the testis, 
and GRK1 and 7 to the retina (Ferguson, 2001). The general structure of GRKs is conserved, 
consisting of a central catalytic region flanked by an N-terminal regulators of G protein 
signalling (RGS) domain, and a C-terminus of variable length (Penn et al., 2000). The C-
terminal domain is thought to determine the cellular location of the GRK, and/or its 
recruitment to plasma membrane, either through internal regulatory domains (GRK2, 3 and 5) 
or post-translational modifications (GRK1, 7, 4 and 6) (reviewed in Penela et al., 2003). The 
N-terminal domain is thought to be involved in recognition of the receptor (reviewed in Penn et 
al., 2000). Regulation of GRK activity may occur via a number of mechanism, such as 
autophosphorylation, and is reviewed in Pitcher et al. (1998) and Penela, Ribas, and Mayor 
(2003). 
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The rules governing specificity of GRK-GPCR interactions are unclear, with an apparently 
high level of functional redundancy between isoforms and with each isoform interacting with a 
diverse range of GPCRs (Ren et al., 2005). However, case-by-case analysis of GPCR 
desensitisation does suggest that preferential relationships exist between GRK isoforms and 
members of the GPCR family. For example, Ren et al. (2005) recently demonstrated in vitro 
using knockdown studies, that phosphorylation of the V2R by GRK2 or 3 promoted much 
stronger β-arrestin recruitment than that of GRK5 or 6. Furthermore, the rate of evolution had 
differed dramatically between GRK isoforms, suggesting that at least some of the GRK 
isoforms have specialised functions (Premont et al., 1999).  
1.3.1.2 Receptor internalisation 
Receptor internalisation isolates the receptor from its down-stream G protein dependent 
signalling pathway, and can be involved in both the desensitisation and/or resensitisation of 
GPCRs. Investigation into β2-AR signalling has shown that the β-arrestin isoform 1 (β-arrestin-
1) plays an important role in coordinating receptor internalisation following agonist-induced 
desensitisation (Han et al., 2001). β-arrestin-1 regulates receptor internalisation via a series of 
protein-protein interactions. One such interaction is with adaptor protein-2 (AP-2), a membrane 
bound protein which acts as a major binding hub, recruiting accessory proteins from the 
cytosol to clathrin-coated pits, specialised sites in the membrane at which coat proteins 
assemble for endocytosis. Association of the receptor-arrestin complex with AP-2 targets the 
complex to clathrin-coated pits. From here, it is sequestered into endocytotic vesicles and 
internalised (Barki-Harrington & Rockman, 2008; Milano et al., 2002). Clathrin interacts with 
AP-2 at a site which signficantly overlaps with the β-arrestin-1 binding site, causing β-arrestin-
1 displacement once the receptor-arrestin complex has reached a clathrin coated pit. This frees 
β-arrestin-1 to interact directly with clathrin, leading to arrestin-receptor complex 
internalisation (Laporte et al., 2002; Schmid et al., 2006). The β-arrestin-1-dependent 
recruitment of c-src (a tyrosine kinase) to the activated receptor is also important for 
endocytosis as c-src-dependant phosphorylation of dynamin is essential for the final pinching 
off of vesicles from clathrin coated pits (Ahn et al., 1999; Milano et al., 2002). Without 
functional dynamin, internalisation of agonist-activated receptors cannot be completed leaving 
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the accumulated receptor-arrestin complexes in limbo at the plasma membrane. The 
internalised receptors can be recycled back to the plasma membrane following resensitisation, 
or targeted to lysosomes for degradation, depending of the stability of their interaction with the 
β-arrestin. For some receptors, internalisation has been shown to play a key role in their 
resensitisation (reviewed in Krupnick & Benovic, 1998). Resensitisation appears to involve 
acidification of the endosomes, which induces ligand dissociation, and enables receptor 
dephosphorylation by activating protein phosphatases 2A and 2B (PP2A and PP2B) (Böhm et 
al., 1997). 
1.3.1.3 Receptor down-regulation 
Down-regulation of the receptor also results in an attenuated response, by decreasing the 
number of receptors expressed by the cell (Lohse, 1993). Down-regulation is caused by the 
degradation of internalised receptors, and/or by decreasing the rate of transcription and/or 
translation of new receptors (Bouvier et al., 1989; Hadcock & Malbon, 1993). Compared with 
uncoupling and internalisation, down-regulation is a slow process, taking hours for 
degradation-mediated down-regulation, and up to several days for transcriptionally-regulated 
down-regulation (depending on the turnover rate of the receptor) (Lohse, 1993). 
Resensitisation following down-regulation is also slow, as it requires new receptors to be 
synthesised (Böhm et al., 1997).  
1.3.2 Desensitisation of V1bR 
1.3.2.1 Current knowledge 
Various stressful stimuli, such as osmotic stress, have been shown to produce regulatory 
changes to V1bR signalling in vivo (reviewed in Mason et al., 2002), resulting in a decrease in 
ACTH responsiveness. Numerous in vitro studies have also induced desensitisation of the 
ACTH response to AVP, by exposing the V1bR to repeated or prolonged stimulation with 
AVP (Mason et al., 2002). Furthermore, V1bR desensitisation has been induced in primary 
cultures of anterior pituitary cells by AVP treatments that approximated endogenous AVP 
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secretion (Hassan et al., 2003). Pre-treatment with as little as 2nM AVP was seen to be capable 
of significantly reducing the responsiveness of the cells to further AVP stimulation. This 
desensitisation was rapid (reaching completion within 10 minutes) and readily reversible. 
While the mechanisms of V1bR desensitisation have not been fully elucidated, some inferences 
can be made based on what is known. 
 
Primarily, rapid and reversible desensitisation of a GPCR (such as that observed for the V1bR) 
is commonly caused by uncoupling of the receptor from its G protein. This process is typically 
mediated by phosphorylation of the receptor by GRKs or second messenger-dependent kinases, 
such as PKC (see Section 1.3.1.1). An immunoprecipitation/immunoblotting study by Berrada 
et al. (2000) investigating the interaction of GRK and PKC isoforms with green fluorescent 
protein-tagged AVP receptors reported a direct physical interaction between GRK5 and the 
V1bR (Berrada et al., 2000). This interaction was induced only in response to AVP-stimulation 
and was rapid: occurring after ~30 seconds of agonist stimulation. The interaction was also 
transitory, with no physical association detected at later time-points. There was no evidence of 
an association between the V1bR and other GRK isoforms. A physical interaction was detected 
between the PKC isoform PKCα and the V1bR. Like that seen with GRK5, this interaction was 
induced by agonist stimulation of the receptor and was not seen with inactivate receptors. 
PKCα-V1bR association was less sensitive to receptor activation than that involving GRK5, 
occurring only after 2 minutes of agonist stimulation. Collectively, these data indicated a 
possible involvement of both GRK5 and PKCα in the regulation of V1bR signalling. Around 
the same time, a second study by Budd et al. (2000) demonstrated the involvement of CK1α-
mediated phosphorylation in regulating the magnitude of the agonist-dependent response 
elicited in a different Gq/11-coupled GPCR, the m3-muscarinic receptor. This phosphorylation 
did not, however, cause desensitisation. This suggested CK1α as an additional candidate kinase 
for phosphorylation of the V1bR.  
 
Previous studies from the Mason laboratory examined the desensitisation of the ACTH-
response to AVP in primary cultures of ovine anterior pituitary cells, using perifusion of the 
cells with various pharmacological agents to elucidate the roles of the kinases PKC and CK1α, 
the protein phosphatases type 1A (PP1A), PP2A and PP2B, and receptor internalisation in 
V1bR desensitisation and resensitisation (Hassan et al., 2003; Hassan & Mason, 2005). 
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Inhibition of PP1A and PP2A activity did not affect the rate of receptor desensitisation or 
resensitisation. However, inhibition of PP2B-mediated dephosphorylation produced a marked 
decrease in the rate of receptor resensitisation, indicating that phosphorylation was likely 
involved in receptor desensitisation. However, as numerous other protein components of the 
AVP signalling pathway may also subject to phosphorylation-mediated regulation, it is 
possible that phosphorylation of the receptor itself was not responsible for this effect. 
Inhibition of CK1α activity had no effect on the extent of desensitisation measured. The role of 
PKC in desensitisation was also examined. Perifusion of the ovine anterior pituitary cells with 
the PKC-inhibitor Ro 31-8220 did not reduce the extent of desensitisation measured, nor did 
use of the PKC-activator 1,2-dioctanoyl-sn-glycerol increase the extent of desensitisation. This 
indicated that while phosphorylation was likely to be involved in V1bR desensitisation, it is 
not mediated by PKC and CK1α (Hassan & Mason, 2005).  
 
In some receptors, endocytosis of the activated receptors is a critical part of their 
desensitisation and/or resensitisation (see Section 1.3.1.2). Hassan and Mason (2005) examined 
the role of receptor internalisation in the desensitisation and resensitisation of ACTH 
responsiveness to AVP by blocking endocytosis. Blockade resulted in a decrease in the extent 
of desensitisation, though this effect was partial. It was unclear whether the concentration of 
endocytosis-inhibitor used was sufficient to induce full blockade of internalisation. If full 
inhibition was obtained, these results would indicate that the remaining desensitisation 
measured was mediated by non-internalisation based mechanism. However, partial inhibition 
of internalisation would also account for the partial inhibition of desensitisation measured 
(Hassan & Mason, 2005). Blockade of endocytosis did not appear to have any effect on the rate 
of resensitisation. 
 
From this study, it appears that both phosphorylation (by an unidentified kinase) and 
internalisation of the V1bR are involved in desensitisation of the ACTH-response to AVP in 
anterior pituitary cells. The interaction between these two aspects is unclear, however it is 
possible that internalisation is the actual desensitising mechanism, and phosphorylation of the 
V1bR acts as a signal to promote internalisation. 
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1.3.2.2 Aims of this study 
Current information from the Mason laboratory indicates that phosphorylation is involved in 
the desensitisation of the V1bR (Hassan & Mason, 2005). However, inhibition of two kinases 
responsible for GPCR phosphorylation (PKC and CK1α), has been shown to have no effect on 
the rate or extent of V1bR desensitisation (Hassan & Mason, 2005). As described in Section 
1.3.1.1.2, GPCR desensitisation can also be produced by GRK-mediated receptor 
phosphorylation. In particular, there is evidence that the GRK5 isoform may be able to 
physically interact with the V1bR (Berrada et al., 2000). 
 
One aim of the research reported in this thesis was to establish and validate the methods 
required to determine if GRK5-mediated phosphorylation of the V1bR is involved in 
desensitisation of the receptor to AVP stimulation. As described above, the mechanisms of 
V1bR desensitisation have previously been examined in the Mason laboratory by using 
pharmacological agents to alter the activity of key enzymes or cellular processes. Primary 
cultures of ovine anterior pituitary cells were used for those experiments and the level of AVP-
induced ACTH secretion was used as a measure of V1bR responsiveness. As there are 
currently no GRK5 isoform-specific pharmacological inhibitors available, an alternative 
approach was required to investigate possible involvement of GRK5 in V1bR desensitisation.  
 
The approach was to use RNA interference (RNAi) techniques to specifically reduce the 
expression of GRK5. RNAi exploits a homology-dependant silencing system found in all 
eukaryotes (Agrawal et al., 2003) to induce post-transcriptional silencing of specific genes 
(Fire et al., 1998). RNAi is not practical for use in primary cell cultures, as they are difficult to 
obtain, culture and transfect. As such, the use of RNAi to knockdown GRK5 expression 
necessitated the use of a model cell system in place of primary cultures of anterior pituitary 
cells. Sequences for specific short interfering RNAs (siRNAs) targeted against human GRK5 
have previously been published by others (Chen et al., 2009; Kim et al., 2005; Ren et al., 
2005) and commercial antibodies for human GRKs are available. These factors made the use of 
a cell line originating from human tissue a prudent choice. HEK293 cells transiently 
transfected to express the rat V1bR were used as a model cell line in which the V1bR could be 
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expressed. Its activity could be monitored by labelling with [
3
H]myo-inositol and measuring 
[
3
H]-inositol phosphate production following AVP stimulation . 
 
This research consisted of the optimisation and validation of protocols needed to:  
1. Induce RNAi-mediated knock down of GRK5 expression (Chapter 5) 
2. Demonstrate the knockdown of GRK5 mRNA using quantitative reverse-transcriptase 
polymerase chain reaction (Chapter 4), and 
3. Demonstrate the knockdown of GRK5 protein using Western blotting (Chapter 3) 
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2  
METHODS FOR USE OF HEK293 CELLS AS A MODEL CELL 
SYSTEM FOR ANTERIOR PITUITARY CELLS: CELL CULTURE, 
TRANSFECTION WITH rV1bR AND IP ASSAY 
2.1 INTRODUCTION 
In this research, HEK293 cells transiently transfected to express the rat V1bR (rV1bR) were 
used as a model cell line for human anterior pituitary cells.  
2.1.1 HEK293 cells 
The HEK293 cell line was developed by Graham et al (1977) by transfecting a primary culture 
of HEK (human embryonic kidney) cells with fragments of human adenovirus 5 DNA. 
HEK293 cells are an immortal adherent cell line, which divide to produce a monolayer on the 
plating surface (Figure 2.1). They were initially assumed to have descended from an embryonic 
kidney epithelial cell, however, since the mid 1990‘s multiple groups have observed and 
reported the presence of neuronal phenotypes in HEK293 cells (Anderson et al., 1995; Daaka 
et al., 1997; Dautzenberg et al., 2000; He & Soderlund, 2010; Schachter et al., 1997; van 
Koppen et al., 1996; Zhu et al., 1998). In 2002, Graham and colleagues published an in-depth 
investigation into the expression profile of HEK293 cells (Shaw et al., 2002a; b), 
http://www.mbi.ufl.edu/~shaw/293.html). This study confirmed the expression of neuron-
specific proteins by HEK293 cells and demonstrated that the pattern of their expression of 
vimentin, and keratins 8 and 18 was characteristic of that seen in early differentiating cells. 
These findings, coupled with evidence that neuronal cells are preferentially transformed by 
adenovirus 5 (Shaw et al., 2002b), suggested that a neuronal stem cell within the original HEK 
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cell primary culture was the most likely parent cell of the HEK293 cell line. This heritage 
makes HEK293 cells particularly suitable for use as a model of neuronal cells.  
2.1.2 Expression of the rV1bR 
HEK293 cells do not appear to express the V1bR (Atwood et al., 2011). As such, its 
expression was induced for this research by transfecting the cells with a plasmid containing the 
rat V1bR gene (Cummings, 2011). No selection pressure for maintenance of the plasmid was 
applied, making this expression transient (<7 days). Transient transfection is a common 
method for inducing the expression of a protein of interest, and has previously been used by 
others to study mechanisms of GPCR signalling and regulation. For example, transiently 
transfected HEK293 cells have been used to look at the involvement of GRKs in signalling by 
the H1 histamine receptor (Iwata et al., 2005); the angiotensin II receptor (Kim et al., 2005); 
and the V2 vasopressin receptor (Ren et al., 2005).  
2.1.3 Measurement of V1bR activity   
As described in Chapter 1, AVP-induced activation of the V1bR results in the production of 
the second messenger signalling molecules DAG and IP3 by PLCβ (Antoni, 1993; Maybauer et 
al., 2008). The production of IP3 can be measured using an inositol phosphate assay (IP assay) 
(Tobin et al., 1997). For this analysis, the cells are labelled with [
3
H]myo-inositol prior to 
receptor stimulation. The [
3
H]myo-inositol is incorporated into the IP metabolic pathway, and 
allows the inositol phosphates (IPs) produced in response to receptor activation to be measured 
based on the radioactivity of the isolated IPs. IP assays have previously been used in this 
laboratory to measure the desensitisation of both transiently and stably expressed rV1bR, in 
HEK293 cells (Cummings, 2011; Gatehouse, 2008). IP assays have also been used by others to 
assess the desensitisation of numerous PLCβ-coupled receptors, including investigating the 
role of various GRKs (Dale et al., 2000; Price et al., 2002).  
 
Crucially for this research, HEK293 cells do not appear to express the V1a or oxytocin 
receptors which also interact with PLCβ via Gq/11 in response to AVP stimulation, activating 
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the inositol phosphate second messenger signalling pathway (Atwood et al., 2011; Shaw et al., 
2002b). This means that any AVP-stimulated IP response detected is solely due to stimulation 
of the transiently expressed rV1bR.  
2.2 MATERIALS 
For the source of all materials referred to in this chapter, see Appendix A 
2.3 SOLUTIONS AND MEDIA 
For details of all solutions and media referred to in this chapter, see Appendix B 
2.4 METHODS 
2.4.1 Maintenance of HEK293 cells in culture 
Sterile glassware and plastic ware, and aseptic working technique were used for cell culture. 
American Type Culture Collection (ATCC) recommendations for culture were followed 
whenever possible. HEK293 cells were cultured in 75cm
2
 culture flasks with vented seal 
caps in Eagle‘s Minimum Essential Medium containing sodium pyruvate, sodium bicarbonate 
and GlutaMAX, (pH 7.1) supplemented with 10% foetal bovine serum (FBS) (MEM+). Cells 
were incubated at 37
o
C in a humidified 95% air, 5% CO2 environment (NuAIRE
™
 IR autoflow 
CO2 water jacketed incubator) and sub-cultured (passaged) to maintain the cell density 
between 15 and 80% confluent. Cell cultures underwent between eight and ten passages before 
being discarded and a new cryopreserved cell aliquot thawed. 
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2.4.1.1 Thawing 
An aliquot of HEK293 cells was removed from liquid nitrogen storage and thawed by shaking 
the tube gently in a 37
o
C water bath. Once thawed, the aliquot was transferred into a 75cm
2
 
flask containing 19mL MEM+ which had been equilibrated in a humidified 95% air, 5% CO2 
environment and pre-warmed to 37
o
C. The cells were then cultured as described above. 
2.4.1.2 Sub-culturing 
Flasks were passaged (or sub-cultured) when the cell monolayer reached 50-80% confluence. 
For a 75cm
2
 flask, 3mL of pre-warmed 0.25% Trypsin/ 0.39g/L EDTA.4Na (T/E) solution was 
added, and the flask was tilted to cover the cells with solution. The flask was then righted, and 
the excess T/E vacuum aspirated. The flask was incubated at room temperature for 
approximately 8 minutes lying flat on the microscope stage until the cells were seen to 
dissociate from each other and the flask surface. The flask was tapped firmly once on each 
side, and the cells were washed from the base of the flask with 4mL of MEM+. The cell 
Figure 2.1 HEK293 cells showing typical adherent 
monolayer conformation. Scale bar is 20μm. 
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suspension was repipetted three times with a sterile plastic pipette to dissociate clumps, and 
transferred to a 50mL screw top centrifuge tube. A 50μL aliquot was mixed 1:1 with Trypan 
blue working solution and incubated at room temperature for 2 minutes to stain dead cells, 
before being loaded onto a haemocytometer slide for counting. Viability ranged from 96-
100%. A volume of cells containing 0.4 x 10
6
 to 0.7 x 10
6
 cells was added to a 75cm
2
 flask 
containing in total a volume of 15mL. After 24 hours, the medium was aspirated and replaced 
with fresh MEM+. 
2.4.1.3 Freezing  
The following volumes were used for cryopreservation of cells harvested from one 75cm2 
flask passaged at 80% confluence. Following passaging, the cell suspension was spun at 140 x 
g for 8 minutes at room temperature (Jouan CR412 Centrifuge) to pellet the cells. During the 
spin, freezing medium was prepared by combining 1.2mL of MEM without FBS (MEM-), 
0.4mL FBS, and 0.4mL dimethyl sulfoxide (DMSO) in a sterile beaker. The supernatant was 
removed from the cells via vacuum aspiration, and the bottom of the tube tapped to loosen the 
cell pellet. The pellet was resuspended in 2mL of MEM-, and 2mL of the freezing medium 
added in a drop wise fashion, swirling thoroughly between additions. One millilitre aliquots of 
the cell suspension were transferred to Nunc cryo-tubes, which were then placed in a Nalgene 
cell freezer and incubated at -80
o
C overnight. The following day, the cryo-tubes were 
transferred to a liquid nitrogen canister for long term storage and their details entered in the 
cell line inventory. 
2.4.2 Transient transfection of HEK293 cells to express the rV1bR 
HEK293 cells were transiently transfected to express the rat V1bR (rV1bR) (Lolait et al., 
1995), using the pN1-rV1bR plasmid (Section 2.4.2.1) and the transfection reagent FuGENE
®
 
6 as described previously (Cummings, 2011). FuGENE
®
 6 is a non-liposomal carrier molecule 
which interacts with the DNA, increasing its uptake by the cell and so increases the efficiency 
of the transfection. FuGENE
®
 has been shown to have low cytotoxicity, making it suitable for 
transfection of cells at a lower confluence (Nagy & Watzele, 2006).  
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2.4.2.1 Plasmid details 
The pN1-rV1bR plasmid (Figure 2.2, D) was previously generated in this lab by Siobhan 
Cummings (Cummings, 2011) by combining elements of the plasmids pEGFP-N1 (Figure 2.2, 
C) which contains a neomycin/kanamycin resistance gene, and pALTER-rV1bR, (Figure 2.2, 
B) (Young et al., 2007) which contains the rat V1bR sequence (Lolait et al., 1995).  
 
 
 
 
 
 
Briefly, the section of pEGFP-N1 encoding EGFP was excised via restriction enzyme cleavage 
with Sal1 and Not1, and replaced with the rat V1bR sequence from pALTER-rV1bR. The 
resulting plasmid, pN1-V1bR, containing both the gene of interest and antibiotic resistance 
Figure 2.2 Plasmid details. A) Schematic representation of the pALTER-MAX vector, used  as the vector for 
pALTER-rV1bR  B) pALTER-rV1bR details, C) schematic representation of pEGFP-N1 plasmid details 
structure, showing the Not1 restriction site and the multiple cloning site (MCS) containing the Sal1 restriction 
site. D) pN1-rV1bR details. 
- 26 - 
 
genes, was ~6.9kb. Generation of the plasmid was confirmed via gel electrophoresis of the 
products of its digestion with Sal1 and Not1. Banding was seen as expected at ~4.4kb, 
representing the destination vector, and ~2.5kb, representing the V1bR insert. pN1-rV1bR was 
stored at -20
o
C and diluted to 0.1µg/µL for use. 
2.4.2.2 Transient Transfection protocol 
To induce the expression of the rV1bR, HEK293 cells were transiently transfected with the 
pN1-rV1bR plasmid using FuGENE
®
 6 36 hours after plating, and, if applicable, reverse 
transfection with siRNA (see Chapter 5). Typically, the cells were between 45% and 80% 
confluent when transfected with the pN1-rV1bR.  
 
At the time of transfection, the volume of medium in each culture vessel was 600µL for wells 
of a 24-well plate, and 3mL for a 35mm-diameter dish. The cells were transfected with the 
FuGENE
®
 6/DNA transfection complex as described below. An appropriate volume of master 
mix was prepared, depending on the number of wells/plates used in the experiment. For clarity, 
the relative volumes of the transfection complex components are shown in Table 2.1.  
 
Reagent Volume per well of 24-
well plate 
Volume per 35mm-
diameter dish 
MEM - 19.4µL 97µL 
FuGENE
®
 6 0.6µL 3µL 
pN1-V1bR (0.1µg/µL) 2µL (0.2µg) 10µL (1µg) 
Total volume 22µL 110µL 
Table 2.1 Relative volumes of transfection complex components. 
 
The FuGENE
®
 6 was warmed to room temperature, and diluted in MEM without FBS (MEM-) 
in a 1.7mL microtube. Care was taken to ensure that the undiluted FuGENE
®
 6 did not come 
into contact with the plastic tube as it can bind to the plastic — limiting transfection efficiency 
(Roche, 2006). The solution was vortexed for 1 second to mix and incubated at room 
temperature for 5 minutes after which the pN1-V1bR plasmid DNA was added. The solutions 
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were mixed by tapping the tube vigorously, and the tube was spun briefly to collect the liquid 
in the bottom. The transfection solution was incubated at room temperature for 30 minutes. 
Immediately following this incubation, the transfection complex was added to the cells in a 
drop-wise fashion. The volume of transfection complex added was 22µL for each well of the 
24 well cell culture plates, and 110µL for a 35mm-diameter plate. The plates were then swirled 
gently in both a clockwise and anti-clockwise direction to ensure thorough mixing. The time at 
which the cells were returned to the incubator was noted.  
2.4.3 Measurement of V1bR responsiveness via inositol phosphate assay  
The IP assay described below is based on assays previously performed in this lab (Cummings, 
2011; Gatehouse, 2008). A flow diagram of the relative timing of each step is shown in Figure 
2.3 
2.4.3.1 Labelling of cells with [
3
H]myo-inositol  
HEK293 cells were grown in inositol-free medium spiked with [
3
H]myo-inositol for 20 hours 
prior to the IP assay.  
 
Twenty eight hours after transfection with the pN1-rV1bR plasmid, the standard culture 
medium was removed from the cells via vacuum aspiration, and each well washed once with 
0.8mL inositol-free DMEM. This was followed by the addition of 0.5mL pre-warmed inositol-
free DMEM plus 0.1% BSA, 2mM GlutaMAX (DMEM+) containing [
3
H]myo-inositol/mL 
(2.5µL/10mL medium) to each well. The cells were then incubated at 37
o
C for 20 hours before 
the functional assay was performed.  
2.4.3.2 rV1bR functional assay 
Stimulation with 100nM AVP was used as the rV1bR functional assay. The duration of 
stimulation differed between experiments and is indicated in the text (Sections 6.3.2.6, 6.4.2, 
and 6.6). The functional assay was performed as close to 20 hours after labelling as possible 
(Gatehouse, 2008). Lithium chloride (LiCl) was included in the wash and treatment media to 
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inhibit the degradation of IP1 to free inositol by inositol monophosphatase. This  resulted in the 
accumulation of [
3
H]-labelled IP metabolites for counting (Berridge, 1985). 
 
Immediately prior to the assay, the labelling medium was removed from the wells via vacuum 
aspiration. Each well was then washed once with 0.8 mL MEM (+0.1% BSA and 10nM LiCl) 
to remove unincorporated label from the wells. The cells were treated with MEM (+0.1% BSA 
and 10nM LiCl) or MEM (+0.1% BSA and 10nM LiCl) ± 100µM AVP as required. 
 
At the end of the assay, 0.5mL of ice cold stop solution was added to each well, and the plates 
incubated at room temperature for at least 1 minute. If necessary, the cells could then be stored 
at 4
o
C for a number of hours before isolation of the [
3
H]-labelled inositol phosphates.  
2.4.3.3. Isolation of [
3
H]-labelled inositol phosphates  
The [
3
H]-labelled inositol phosphates were isolated from the cell lysates using a column-based 
anion-exchange system.  
2.4.3.3.1 Preparation of the columns 
Bio-Rad AG1-X8-resin (formate form) columns (one column per well) with a bed depth of 
approximately 2cm  were prepared by pipetting 2mL of resin slurry (prepared by mixing the 
resin 1:1 with NPH2O) into Polyprep® chromatography columns (Bio-Rad), and allowing the 
water to drip through before use. 
2.4.3.3.2 Preparation of the cell lysates 
To return the cell lysates to ~pH 7.0, 0.5mL of ice-cold neutralisation solution was added to 
each well immediately before they were loaded onto the columns. Neutralization of the 
samples was required for effective functioning of the basic anion-exchange resin (Bio-Rad 
AG1-X8) (Bio-Rad, 2000) used to isolate IPs. Due to the presence of phenol red in the MEM, 
the pH of the medium in each well could be estimated by its colour. At pH 7.0 MEM is a light 
salmon pink. However very small variations from pH 7.0 cause quite distinct colour changes, 
- 29 - 
 
ranging from an orange/yellow (slightly acidic), to a bright pink (slightly alkali). It has been 
reported that this variation in pH does not have a noticeable effect on the IP assay results 
(Gatehouse, 2008). The cells in each well were then thoroughly scraped and the lysates were 
homogenised by repipetting vigorously six times with a Gilson P1000 pipette.  
2.4.3.3.3 Isolation of the inositol phosphates from the cell lysates 
The contents of each well were loaded onto a column with a P1000 Gilson pipette (one column 
per well) as follows: the end of the P1000 Gilson pipette tip was placed on the side of the 
column just above the resin and the solution released slowly and evenly in order to minimise 
disruption of the resin bed. The columns were washed with 10mL of NPH2O, and 8mL of 
elution buffer II to elute free inositol and glycerophosphoinositides, respectively. Both elutions 
were discarded. Finally, 3mL of elution buffer VI was loaded onto each column to elute the 
total inositol phosphates, which were collected in 35mL polypropylene vials. 
2.4.3.3.4 Regeneration of columns  
If necessary, packed columns could be regenerated and reused the same day. Columns to be 
reused were washed with 10mL of regeneration solution, followed by 30mL of NPH2O. It has 
been reported that the use of regenerated columns does not significantly affect the results of the 
IP assay (Gatehouse, 2008). 
2.4.3.4 Detection and measurement of [
3
H]myo-inositol-labelled IP‘s 
The level of [
3
H]myo-inositol-labelled IPs in each sample was measured via liquid scintillation 
counting  
2.4.3.4.1 Preparation of the samples and scintillation counting 
The eluted inositol phosphates from each sample were diluted 1:10 with OPTIPHASE 
‗HISAFE‘ 3 scintillation cocktail (Perkin-Elmer) in labelled 20mL scintillation vials as 
described below. Care was taken not to touch the sides of the vials during set up, as the counter 
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reads from this area. One millilitre of each sample was transferred to the appropriately labelled 
vial using a P1000 Gilson pipette. Ten millilitres of scintillation cocktail was then added to 
each vial using a pump dispenser. The vials were capped and shaken thoroughly to mix. An 
initial burst of chemiluminescence is produced by mixing the reagents and can interfere with 
the accuracy of the counts. To avoid this, the vials were kept in the dark overnight before 
counting, allowing the chemiluminescence to clear. Samples were counted using the CPM 
function of a Packard 1900 CA Tri-Carb Liquid Scintillation Analyser for 10 minutes each.  
2.4.3.5 Analysis of the IP Assay  
Certain components of the elution solution or scintillation cocktail can reduce the CPM 
detected by absorbing either the β energy itself, or the photons it produces. This is 
phenomenon is called quenching. The spectral quench parameter (SQPI) for H
3
, which 
indicates the level of quenching occurring in each sample, was calculated by and corrected for 
automatically by the counter. Prior to data analysis, the SQPI was checked for consistency 
across all samples.  Variation in SQPI of ± 0.5 between samples was typical. 
 
For each treatment, the CPM for all replicates was analysed and graphed, using GraphPad 
Prism 4.0 to determine the mean and SEM. Mean CPM from wells stimulated with 100nM 
AVP were then expressed as a fold increase of the CPM for control cells (0nM AVP).  
2.4.3.6 Disposal of IP assay waste 
Several types of waste which required special disposal were generated during the IP assay. The 
treatment of each type is described below. 
 
Diluted tracer left over from labelling the cells was disposed of down the sink with cold 
running water. The sink and pipes were then flushed with cold water for at least 30 minutes. 
Plastic ware that came into contact with radioactivity only was placed in a dedicated 
radioactive waste bin. Glassware that came into contact with radioactivity only was rinsed 
under cold running water for at least 10 minutes, then rinsed with distilled H2O and washed as 
usual. The radioactive resin was rinsed from the columns with NPH2O and collected. Plastic 
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ware, such as pipette tips, that came into contact with both radioactivity and biohazardous 
material (i.e. HEK293 cells) were collected and soaked overnight in 1% Virkon and then 
placed in a dedicated radioactive waste bin. Liquid waste containing both cells and 
radioactivity was treated with 1% Virkon overnight, and disposed of down the sink. The sink 
and pipes were flushed with water for at least 30 minutes after disposal of waste. 
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3 
WESTERN BLOTTING PROTOCOLS FOR THE DETECTION OF 
GRK5 AND ACTIN EXPRESSION 
3.1 INTRODUCTION 
To validate the results from RNAi experiments (described in Chapters 5 & 6), it was necessary 
to  measure the reduction in the level of GRK5 protein expression in cells treated with GRK5-
targeted siRNA compared to that of control cells. 
 
Western blotting is a technique by which proteins separated based on their molecular 
weight/length are identified via immunoblotting (Burnette, 1981; Renart et al., 1979; Towbin 
et al., 1979). It is commonly used in medicine in the diagnosis of diseases such as HIV 
(Schneppenheim & Rautenberg, 1987), Lyme disease (Dressler et al., 1993) and bovine 
spongiform encephalopathy (Schaller et al., 1999), and in research to monitor induced changes 
in protein expression, for example, by RNA interference (Agrawal et al., 2003).  
 
Immunoblotting utilises members of the immunoglobin (Ig) family of blood-plasma proteins 
called antibodies, which are produced by vertebrates as part of the immune response geared 
against infection by foreign substances (Garrett & Grisham, 2005). Introduction of a foreign, or 
‗antigenic‘, molecule into the blood stream stimulates the production of antibodies that 
specifically recognise that molecule. The majority of antibodies produced during an immune 
response are G-class Igs (IgG) (Garrett & Grisham, 2005). Western blotting is an indirect 
method of immunoblotting, as it is dependent on the use of two different antibodies (Figure 
3.1) to detect the protein of interest. The first, the primary antibody, is raised against a part or 
the whole of the protein of interest and is used to locate it. The second, the secondary antibody, 
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is raised against a single class of immunoglobin from the species used to produce the primary 
antibody, for example, against rabbit IgG. The secondary antibody is coupled to a detection 
system and allows visualisation of the target protein by binding specifically to its antigen, i.e. 
the primary antibody. The detection system can be direct, e.g. a flurophore or radiolabel, or 
indirect e.g. an enzyme-conjugate (such as alkaline phosphatase or horseradish peroxidase 
(HRP)), that converts an added substrate to a visible product (Figure 3.1) (Sambrook et al., 
1989). Due to the antigenic-specificity of the primary and secondary antibodies, Western 
blotting can be used to detect the expression of the protein of interest in a sample containing 
the full component of cellular proteins (Sambrook et al., 1989).   Western blots are primarily 
qualitative, not quantitative. However, they can be used to identify relative changes in the 
target protein across samples. Important parameters to consider when optimising Western 
blotting protocols are discussed in Section 3.3.1. 
 
 
 
 
In this research, a Western blotting protocol was used to measure the effect of transfecting 
HEK293 cells with GRK5-targeting siRNA (see Chapters 5 & 6) on cellular GRK5 protein 
levels. The Western blotting protocol used for the detection of GRK5 is described in Section 
3.2. Detection of actin, a structural protein whose expression should not be altered by the 
presence of GRK5-directed siRNA, was included in the protocol to control for loading errors 
Figure 3.1 Schematic representation of immunological detection of a target protein using HRP as a 
detection symbol. A) The primary antibody (black) binds specifically to its antigen, the target protein (red). 
B) The HRP-conjugated secondary antibody (blue) then interacts specifically with its antigen, the primary 
antibody. C) The antigen-antibody complex is visualised via processing of an imaging substrate to a 
chemiluminescent product by the HRP enzyme.   
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and uneven transfer. The optimisation and validation of the Western blotting protocols used in 
this research are described in Section 3.3. 
3.2 WESTERN BLOTTING METHODS 
3.2.1 Materials 
For the source of all materials referred to in this chapter, see Appendix A 
3.2.2 Solutions and Media 
For details of all solutions and media referred to in this chapter, see Appendix B 
3.2.3 Cell Lysis  
Cell lysis allows the extraction of whole cell protein for analysis by dissolution of the cellular 
membranes. This process also releases proteolytic enzymes from the liposomes which can 
degrade proteins, thereby affecting sample quality. To limit protein degradation, all protein 
work was done on ice, and a protease inhibitor was added to the lysis buffer.  
 
HEK293 cells cultured in 35mm-diameter dishes as described in Sections 2.4.1, 3.3.3, 5.2.6, 
and 6.3.2 were lysed as follows. The culture medium was removed by vacuum aspiration. Each 
dish was washed twice with 1mL of pre-warmed PBS to remove traces of medium. Fifty 
microlitres of 1 X SDS lysis buffer was added to each dish, and the dish tilted to ensure even 
coverage of the cells with lysis buffer. The cells were then incubated for ten minutes at 37
o
C. 
Following the lysis incubation each dish was scraped thoroughly with a plastic cell scraper 
(Greiner Bio-One). The cell lysates were transferred by scraping into labelled 15mL centrifuge 
tubes and stored on ice or at -20
o
C until sonication. Each sample was sonicated at 21V for 30 
seconds using a Sonics Vibra-Cell
™ 
sonicator. Sonication was performed in a pulsatile fashion 
with alternating 9 second pulses of on and off (sonication took 57 seconds in total, comprising 
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of a cumulative 30 seconds on and 27 seconds off). The tube was tilted after sonication to 
confirm sample fluidity. This shearing step was necessary to reduce sample viscosity caused by 
aggregation of chromosomal DNA released from the nucleus during cell lysis. The samples 
were then transferred using a P1000 Gilson pipette to labelled 1.7mL micotubes and stored at   
-80
o
C until use. The protein concentration of each sample was determined via bicinchoninic 
acid (BCA) assay (Section 3.2.4). 
3.2.4 Protein quantification via BCA assay 
To compare the expression of the target protein between samples using Western blotting it is 
necessary to accurately determine the concentration of total protein in each sample so equal 
quantities can be analysed. The BCA assay (Smith et al., 1985) is a colourimetric test which 
uses bicinchoninic acid to detect Cu
1+
. Under alkaline conditions peptide bonds reduce Cu
2+
 to 
Cu
1+
, which is then chelated by BCA molecules (at a ratio of two BCA molecules per cuprous 
ion) to form a bright purple solid with a maximum absorption at 562nm (Figure 3.2, A). This 
reaction has been exploited to produce commercially available kits which, when coupled with a 
standard curve, can be used to determine the concentration of total protein in a solution. 
 
Traditionally, BCA assays are performed using optical cuvettes and a UV spectrophotometer. 
Cuvette-based protocols require large amounts of sample for protein quantification (Walker, 
1996), so they are incompatible with analysis of samples of limited volume (50-100µL) such as 
those obtained in this study. For this reason, a microplate-adapted protocol for determination of 
protein concentration via BCA assay was used. 
  
The microplate-adapted BSA assay used in this research was performed using standard 
NUNC
™
 96-well plates (Thermo Fisher Scientific) and a BCA
™
 Protein Assay Kit (Thermo 
Fisher Scientific). A standard curve showing absorbance levels at known protein 
concentrations (Figure 3.2, B) was generated in duplicate for each assay by diluting 2mg/mL 
bovine serum albumin (BSA) with NPH2O to 0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2μg/µL BSA in a 
total volume of 20μL. Four microlitres of each sample was diluted 1/5 to a final volume of 
20µL with NPH2O (also in duplicate). BCA working reagent was prepared by mixing BCA 
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Reagents A and B at a ratio of 50:1, and 200μL of the working reagent was added to each well. 
The plate was then covered using a BarSeal
™
 adhesive cover and incubated at 37°C for 30 
minutes. Absorbance was read at 560nm using a FLUOstar OPTIMA plate reader. The data 
were analysed using Microsoft Office Excel software to determine the protein concentration of 
each sample from the standard curve (Equation 3.1). 
 
Equation 3.1  μg/μl sample = ((mean absorbance - intercept) / slope)  x dilution factor 
 
 
 
 
 
 
 
 
3.2.5 SDS-Polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a method by which linearised 
proteins are electrophoretically separated in a size dependent manner (Laemmli, 1970).  
 
Protein samples are treated with an anionic surfactant called sodium dodecylsulfate (SDS), 
which disrupts protein folding by forming strong interactions with polypeptide chains via its 
hydrophobic tail. Addition of reducing reagents such as beta-mercaptoethanol acts to eliminate 
stronger disulfide bonds, resulting in linearised polypeptide chains (Laemmli, 1970). As the 
extent of SDS binding is directly proportional to the length of the polypeptide, the resulting 
Figure 3.2 BCA assay for determining the protein concentration.  A) Formation of the 
coloured compound during BCA assay (from Smith et al., 1985).  B) Example of a typical 
standard curve. 
A B 
 
0.00 0.25 0.50 0.75 1.00 1.25 1.50
0.0
0.5
1.0
1.5
2.0
BSA (mg/uL)
A
5
6
0
n
M
- 37 - 
 
charge-to-mass ratio is constant (Steele & Nielsen, 1978). Any intrinsic charge associated with 
the polypeptide itself is overwhelmed by the accumulated negative charge resulting from SDS-
binding. The electrophoretic mobility of each protein is therefore determined by its molecular 
weight or length. Smaller proteins will migrate through the porous gel faster than large proteins 
(Garrett & Grisham, 2005; Steele & Nielsen, 1978) as their movement is less retarded by the 
matrix of polyacrylamide fibres. Ladders containing proteins of known molecular weights can 
be used to estimate the molecular weight of a particular protein band (Webb et al., 1977).  
3.2.5.1 Sample Preparation  
Though 40μg of protein per lane was used during the majority of the protocol set up, 25µg of 
protein per lane was determined to be sufficient for detection of GRK5 and actin by Western 
blotting during knockdown experiments. Lowering the minimum amount of protein loaded 
allowed the use of a low loading volume (20µL), which decreased the probability of overflow 
between lanes, thus improving the reliability of the Western blot analysis. The amount loaded 
was consistent across wells within the same gel, but ranged from 25-40µg of protein per well 
between gels, depending on the concentration of the samples. As each lane was quantified 
relative to the control lane on the same gel (see Section 3.2.8.3.2), the differences in protein 
loaded between gels did not compromise the ability to compare results between gels. The 
volume of each sample required for loading the designated amount of protein was combined 
with 1μL each of bromophenol blue (0.1%) and beta-mercaptoethanol in 1.7mL microtubes, 
and the volume made up to 20μL with 1XSDS buffer (see Appendix B; final concentrations: 
bromophenol blue 0.005%, β-mercaptoethanol 5%). The tubes were sealed with parafilm to 
prevent sample evaporation and contain beta-mercaptoethanol fumes. The tubes were spun 
briefly in a bench top centrifuge to deposit the solution components, vortexed to mix, and spun 
again to collect the mixed solution at the bottom of the tube. The samples were then denatured 
by heating at 95
o
C for 10 minutes, and placed on ice prior to loading.  
 
3.2.5.2 Gel Electrophoresis 
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A Mini-PROTEAN 3 casting frame (Bio-Rad) was used to cast 1mm Tris-glycine gels, 
consisting of a 5% stacking gel and an 8% resolving gel (see Appendix A). A ten well comb 
was inserted into the stacking gel immediately after pouring to produce wells (see Appendix B 
for further casting details). Immediately prior to loading, the samples were collected by brief 
centrifugation, vortexed to mix, and spun again. The samples were loaded into the allocated 
wells with a P20 Gilson pipette. Multiple loadings were allowed to ensure the entirety of the 
samples were loaded. Six microlitres of PageRuler™ Prestained Protein Ladder (Fermentes) 
was loaded into an adjacent well to allow identification of bands by molecular weight. The gels 
were run at 100V in a Bio-Rad Mini PROTEAN
®
 3 Cell electrophoresis unit containing 
running buffer for 1.5-2 hours, until the 17kDa band of the ladder had run off the bottom of the 
gel.  
3.2.6 Electrophoretic transfer of protein bands to a nitrocellulose membrane 
Transfer of proteins to a membrane is advantageous as it exposes the bands, allowing for more 
efficient immunological probing (Towbin et al., 1979). The membrane is also more durable 
than the gel, improving ease of handling. In electrophoretic transfer, the gel is sandwiched 
against a membrane which non-specifically binds proteins, and fully submerged in buffer. An 
electric current is used to mobilize the protein bands, moving them out of the gel and onto the 
membrane.  
3.2.6.1 Set-up and Transfer 
The transfer buffer was chilled at -20
o
C for approximately 1 hour prior to use. The components 
of the transfer cassette (one piece of nitrocellulose membrane, six pieces of filter paper and two 
fibre pads per gel) were equilibrated in transfer buffer at 4
o
C for at least 40 minutes before 
transfer. Following SDS-PAGE, the gel was removed from its glass casing and equilibrated in 
cold transfer buffer for 5-10 minutes before transfer. The cassette was assembled for transfer as 
shown in Figure 3.3, with air bubbles removed by rolling each new layer flat onto the stack 
with a smooth glass tube. The cassette was inserted in the buffer tank so that it was submerged 
in transfer buffer. The proteins were then electrophoretically transferred (Bio-Rad Mini-
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PROTEAN
®
 II Cell) to the HYBOND-C-Extra nitrocellulose membrane (Amersham 
Biosciences) for 2 hours at 100V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.6.2 Evaluation of Transfer efficiency 
To evaluate transfer efficiency, the membrane-bound protein was stained by incubating the 
membrane in 0.01% Ponceau S for 1 minute. The membrane was rinsed with NPH2O to 
remove excess stain, and checked for variation in protein transfer between lanes. A soft pencil 
was used to outline and number the lanes and excess membrane was trimmed off. The Ponceau 
S stain was removed via washing in PBS with 0.1% Tween-20 (PBST) for 5 minutes. The gel 
was stained with 1% Coomassie Brilliant Blue G for 1 hour to show untransferred protein, and 
was destained overnight at 4
o
C in Coomassie Brilliant Blue G destain solution.  The gel was 
imaged using a Syngene Chemigenius 2 Charged-Coupled Device (CCD) camera set to ‗High 
Resolution‘, ‗No Filter‘, with the light source set as ‗Lower White‘. 
Figure 3.3 Arrangement of components in the transfer cassette. The gel is placed face down to 
maintain lane orientation on the membrane. The concave side of the membrane is placed against the gel. 
Fibre pad (x1) 
Fibre pad (x1) 
Filter Paper (x3) 
Filter Paper (x3) 
NC membrane (x1) 
Gel (x1) 
Black side of cassette casing 
Clear  side of cassette casing 
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3.2.7 Immunoblotting 
3.2.7.1 Blocking 
As antibodies are themselves proteins, a blocking step is required to prevent non-specific 
binding of the antibodies to the nitrocellulose membrane during immunoblotting. The 
membrane was incubated in 20mL of PBST with 2% milk powder (PBSTM 2%) for 2 hours at 
room temperature with agitation. The milk protein ‗blocks‘ the membrane by binding non-
specifically to all unoccupied binding sites. Following blocking, the membrane was rinsed with 
PBS and the excess fluid was removed by gently shaking the membrane. This was done to 
prevent carryover of milk proteins into the primary antibody solution. The membrane was then 
cut horizontally at approximately 34, 50, and 95kDa (as guided by the molecular weight 
ladder) in preparation for immunoblotting (see Figure 3.4) 
3.2.7.2 Primary antibody incubation. 
For detection of GRK5, membrane segment A (see Figure 3.4) (spanning 50-95kDa) was 
placed in rabbit α-human GRK 5 (C-20) antibody from Santa Cruz Biotechnology (sc-565) 
diluted 1:500 in PBST (final antibody concentration 3920.00ng/mL). For detection of actin, 
membrane segment B (spanning 34-50kDa) was placed in rabbit α-human actin antibody from 
Sigma-Aldrich (A2066) diluted to 1:2000 in PBSTM 1% (final antibody concentration 
349.83ng/mL). The membrane segments were incubated in their respective primary antibody 
solutions on a tilt rocker (Bellco Biotechnology) at a speed of 25rpm overnight (approximately 
16 hours) at 4
o
C (or alternatively, for 2 hours at room temperature). Following primary 
antibody incubation, the membrane segments were rinsed in PBST followed by three 15 
minute washes (also in PBST) before being transferred to the appropriate secondary antibody 
solution.  
3.2.7.3 Secondary antibody incubation 
For detection of GRK5, membrane segment A (50-95kDa) was transferred to a solution of 
donkey α-rabbit IgG HRP-conjugated secondary antibody from GE Amersham (NA934) 
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diluted to 1:1000 in PBSTM 1% (final antibody concentration 159.84ng/mL).  For detection of 
actin, membrane segment B (34-50kDa) was transferred to a solution of goat α-rabbit IgG 
HRP-conjugated secondary antibody from Sigma-Aldrich (A0545), diluted to 1:30,000 in 
PBSTM 2% (final antibody concentration 349.99ng/mL).  
 
The membrane segments were incubated in their respective secondary antibody solutions for 2 
hours at room temperature on a tilt rocker (Heidolph DUOMAX 1030) at 25rpm. Following 
secondary antibody incubation, the membrane segments were rinsed with PBST followed by 
three 15 minute washes in PBST to remove unbound antibodies. A final rinse and 5 minute 
wash with PBS removed traces of Tween-20 from the membrane. This was necessary as 
Tween-20 can interfere with the HRP-catalysed production of chemiluminescence. 
3.2.8 Analysis 
3.2.8.1 Image Capture 
The SuperSignal West Pico Chemiluminescence Reagent (ThermoScientific) was used for 
detection of antibody labelled bands. The working reagent was prepared by mixing Reagent A 
170 
130 
95 
72 
55 
43 
34 
26 
kDa 
GRK5   A 
Actin            B 
Fig 3.4 Membrane strips used for immunoblotting. The membrane was cut into strips   
prior to immunoblotting to allow the detection of actin and GRK5 to be performed 
simultaneously.  
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and Reagent B at a 1:1 ratio in a foil-covered microtube. The working reagent was applied, and 
the membrane tilted gently to ensure full and even coverage (approximately 0.1mL of working 
reagent per cm
2
 of membrane) and incubated in the dark for 5 minutes. The membrane pieces 
were then shaken gently to remove excess working reagent, sandwiched between two sheets of 
clear overhead projector plastic and photographed using a Syngene Chemigenius 2 CCD 
camera. The target protein is visualised via the following mechanism: the working reagent is 
processed by the secondary antibody-conjugated HRP enzyme into a chemiluminescent 
product. The resulting photons are detected by the CCD sensor pixel wells, giving each well an 
electron charge that is directly proportional to the amount of fluorescence detected. At the end 
of the exposure, the accumulated electron charges are converted to a digital signal. This signal 
is displayed as a digital image that can be analysed to quantitate differences in the intensity 
between bands (SYNGENE, 2009). The camera settings used were: ‗No Filter‘, ‗No Light‘, 
‗and Medium Sensitivity‘. Exposure times were 5 minutes for actin detection and 10 minutes 
for GRK5 detection.  
3.2.8.2 Band quantification 
The intensity of each band was detected by analysis of the collected digital images with 
GeneTools software from Syngene. The ‗Manual Spot Blot Analysis‘ program set to 
‗Fluorescence‘ was used. Each band to be analysed was fitted tightly with a sampling box. The 
digital signal contained within the sampling box was classified as the ‗band intensity‘. The 
placement of the sample boxes was finalised prior to conversion of the signal to numerical 
form, in an effort to prevent operator bias. The automatic background setting was used to 
generate a value for the background intensity of each box, and this value was subtracted from 
the measured intensity of the bands. 
3.2.8.3 Analysis of GRK5 expression  
3.2.8.3.1 Normalisation to internal control 
The background-corrected data were used for normalisation. The intensity of the 45kDa actin 
band detected in each sample was determined as described above, and examined for variation. 
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These values were used to adjust the values measured for the GRK5 bands to account for errors 
in loading. To normalise the measured intensity of the GRK5 bands for variability in the 
internal controls, the intensity of the GRK5 band for each lane was divided by the intensity of 
its actin band, as shown in Equation 3.2, where χ is the normalised band intensity.  
    
Equation 3.2    χ  = GRK5 intensity / Actin intensity  
3.2.8.3.2 Measuring changes in GRK5 expression 
To quantify RNAi-induced changes in the expression of GRK5, the χ values for GRK5-
targeted siRNA treated samples were expressed relative to the χ values for ―medium-only‖ 
controls, as shown in Equation 3.3.   
 
Equation 3.3   
GRK5 band intensity relative to control = (χ GRK5-siRNA treated  /  χ Medium Control) 
 
 The effect of treatment with GRK5-targeted siRNA was examined for all bands detected. 
3.3 OPTIMISATION OF WESTERN BLOTTING 
3.3.1 Important parameters for optimisation of Western blotting protocols 
The aim of optimising a Western blotting protocol is to deliver a method that i) is specific to its 
target protein, ii) is sensitive iii) is reliable and reproducible, iv) allows relative antigen 
expression to be quantitated, and v) is economical. These parameters are discussed below. 
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3.3.1.1 Specificity 
The specificity of an ideal Western blotting protocol would allow the detection of a single 
target antigen within a population of non-target antigens. Assay specificity is dependent on i) 
the specificity of the primary and secondary antibodies for their antigens, and ii) the reaction 
conditions used. The interaction between an antibody and its antigen is based on shape- or 
‗lock and key‘-complementarity between the interacting surfaces of the antigen and the 
antigen-binding site of the antibody (Kumagai & Tsumoto, 2010). The bonds formed between 
the antibody and its antigen are generally non-covalent hydrophobic interactions, such as 
electrostatic interactions (e.g. hydrogen bonds), van der Waals interactions and salt bridges 
(Kumagai & Tsumoto, 2010; Ramos-Vara, 2005). Induced fit, a phenomenon observed 
between enzyme active sites and bound substrates, also appears to occur between the antibody 
and its antigen. These conformational changes to the antigen-binding site upon antigen binding 
may be necessary to achieve an interaction that has high specificity and affinity (Kumagai & 
Tsumoto, 2010).  
 
Specificity of the secondary antibody for its antigen (the primary antibody) can be tested by 
determining the binding pattern it produces in the absence of the primary antibody. If the 
secondary antibody is specific, no bands will be produced under these conditions. Specificity 
of the primary antibody however is more difficult to confirm. A commonly used test is 
preabsorption of the primary antibody with its immunising antigen. This treatment should 
result in a marked decrease or even elimination of its ability to interact with membrane-bound 
antigen. However, this control does not distinguish between the ‗selective‘ and ‗specific‘ 
binding of the primary antibody. For example, a primary antibody may bind ‗selectively‘ to the 
epitope of its immunizing antigen, yet bind to non-target antigens present in the protein sample 
being probed, meaning it is not ‗specific‘ to its target protein. An advantage of Western 
blotting is that the molecular weight of the detected protein band can be determined. Whether 
or not the molecular weight of the bands detected conform to that predicted for the target 
protein can also be used as indication of primary antibody specificity. This is not possible in 
more ‗quantitative‘ immunoassays such as ELISA which measure total chemiluminescence. 
The availability of antibodies of appropriate quality is a primary limiting factor in producing a 
specific Western blotting assay. 
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In addition to the intrinsic specificity of the antibodies, the reaction conditions can also affect 
the specificity of antibody binding. Increasing the stringency of the reaction decreases the 
probability of off-target antibody interactions happening by chance, as only interactions of high 
affinity/avidity would be able to form. The stringency can be increased by decreasing the 
antibody concentrations, increasing the duration of blocking, and/or increasing the amount of 
protein in the blocking solution and antibody diluents. Furthermore, the characteristics of the 
antigen and antigen-binding sites involved in their interaction, e.g. shape and size, may be 
altered under different conditions. As such, the formation of interacting epitopes may be 
‗conditional‘ (Willingham, 1999). An example of a conditional epitope was described by 
Josephsen, Smith and Nanci (1999), who noted during immunocytochemical screening of rat 
incisor odontoblasts that crosslinking of enamel proteins by glyceraldehyde fixation generated 
an epitope that was recognised with high selectivity by an antibody raised against the protein 
vimentin. The conditionality of the epitope is an important factor for consideration when 
selecting antibodies and Western blotting protocol details, with regard to the use of reducing or 
native conditions, and buffer selection.   
3.3.1.2 Sensitivity   
The sensitivity of an assay is determined by a combination of numerous factors, such as 
antigen concentration, the affinity and/or avidity of the antibodies for their antigens, antibody 
concentration, signal production, and signal detection, and may be defined as the ability of the 
assay to detect the target protein. The more sensitive the assay, the lower the minimum amount 
of antigen required to produce a signal. In Western blots where the expression level of the 
target protein is too low to easily detect, high antibody concentrations, or overloading the wells 
with protein can increase the detection of the antigen, but can also produce a reciprocal 
decrease in assay specificity. Similarly, decreasing the stringency of the assay conditions can 
increase its sensitivity, but may result in lower specificity. For an optimised assay, it is 
important to strike a balance between sensitivity and specificity. 
  
The sensitivity of an assay can also be affected by the use of chemicals which interfere with 
production of a signal. For example, sodium azide —commonly used in buffers as a 
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preservative— is not appropriate when HRP-conjugated secondary antibodies are used. While 
sodium azide extends the life of antibody solutions it has been shown to irreversibly inhibit 
HRP enzyme activity (Ortiz de Montellano et al., 1988; Richardson et al., 1983).  
3.3.1.3 Consistency and error identification. 
Assessing the consistency of Western blot is an important step in its validation. Due to 
constraints relating to the number of wells in a gel and the potential for large inter-gel 
variation, samples are generally assessed in singlet. As technical replication is not a practical 
option, it is crucial to assess the consistancy of the assay, and to monitor the progress of the 
Western blot carefully to identify potential sources of artefacts. Frequently in Western blotting, 
a second protein is detected as an internal control. Commonly, structural proteins such as actin 
or β-tubulin are used for this purpose. The expression of the test protein, in this case GRK5, is 
then assessed by normalising its expression to that of the internal control protein. This allows 
artefacts caused by processing and loading errors, and uneven transfer to be corrected for. The 
expression of the internal control should not be altered by the experimental treatment. The 
consistency of the assay can be assessed by calculating the coefficient of variation for each 
Western blot. The effect of the experimental treatment on the internal control can be 
determined by checking for treatment-based changes in the CV values produced  (Liu & Xu, 
2006).  
3.3.1.4 Quantifiability  
 Western blotting is at best, a semi-quantitative technique, better suited to determining the 
relative expression of the target protein across samples than quantifying the amount of antigen 
in each sample. Use of Western blotting for the semi-quantitative determination of relative 
expression requires the use of an internal control against which the target gene can be 
normalised. Furthermore it is important to determine the dynamic range of the assay, i.e. the 
range of relative concentrations over which the target protein can be detected, and changes can 
be measured. The dynamic range can be determined by serial dilution of a sample, and is 
shown graphically in Figure 3.5 The lower end of the dynamic range is limited by the amount 
of antigen present and the sensitivity of the assay or detection system. At the higher end (where 
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the lanes are overloaded with protein) the signal is saturated, preventing different quantities of 
antigen from being distinguishable from each other. The dynamic range is the middle section 
of the curve, at which the realationship between the increase in antigen and the increase in 
intensity is approximately liner.  
 
3.3.2 Western Blot Optimisation: Additional protocols 
Large volumes of homogenous whole cell lysate were prepared, and used for optimisation of 
the Western blotting protocol. This was done to prevent the introduction of unnecessary 
variables when trialling different Western blotting conditions. No significant differences in 
quality or relative GRK5 expression were seen between preparations. Cells grown for bulk 
preparations were not allowed to become over-confluent, as GRK5 expression may be up-
regulated under these conditions (Gatehouse, 2008). Unless otherwise stated, steps were 
performed on ice. 
3.3.2.1. Plating and culture 
For each bulk protein preparation, HEK293 cells were plated into ten 35mm-diameter
 
sterile 
culture dishes (Becton Dickinson Biosciences) at a density of 20,000 cells/cm
2
 (2 x 10
5
 
cells/dish). A plating volume of 2.5mL was used. The medium was removed 24 hours after 
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Figure 3.4 Graphical representation of th  dynamic range of a Western blotting assay, in 
which the signal is saturated by overloading with protein, and limited by insufficient 
antigen, sensitivity and/or the detection limit of the imaging system. 
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plating by vacuum aspiration and replaced with 2.5mL of fresh MEM+. The cells were 
cultured for 3 days until 80-90% confluent.  
3.3.2.2 Lysis and protein measurement  
The protocol for lysis described in Section 3.2.3 was followed with the following exceptions: 
i) the culture medium from up to three dishes was removed to each 15mL centrifuge tube, ii) 
following sonication the cell lysates were pooled and repipetted to produce a single large 
sample. The bulk sample was aliquoted into 100µL volumes and stored at -20
o
C until used.  
The protein concentration of each preparation was determined via BCA assay as described in 
Section 3.2.4. Protein concentrations for these bulk preparations ranged from 2.2-3.5µg/µL. 
3.3.3 Western blotting optimisation: GRK5  
The optimisation and validation of a protocol for GRK5 detection via Western blotting 
occurred in two parts. The first set of experiments was largely unsuccessful and is described 
briefly in Section 3.3.3.1. The second set, described in Section 3.3.3.2, constituted the majority 
of the optimisation of the protocol described in Section 3.2, and is therefore described in more 
detail. Only elements of the Western blotting protocol altered during optimisation of GRK5 
detection are described below. For unspecified details refer to the optimised protocol (Section 
3.2). 
3.3.3.1 Western blotting for GRK5 detection protocol optimisation: Part One  
This section describes experiments that were unsuccessful in producing a protocol suitable for 
measuring the relative expression of GRK5 by Western blotting. 
3.3.3.1.1 Antibodies 
Initial attempts to produce an optimised protocol for GRK5 detection via immunoblotting were 
made using a polyclonal rabbit anti-human GRK5 (C-20) affinity purified antibody from Santa 
Cruz Biotechnology (Product Number: sc-565, Batch Number: D0208), in combination with a 
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goat anti-rabbit IgG (whole molecule) horseradish-peroxidase conjugate from Sigma-Aldrich 
(Product Number: A0545, Lot Number 078K4844).  
3.3.3.1.2 Variables tested 
Multiple experimental conditions were varied. Their effect on the intensity of the GRK5 signal 
is described below. 
3.3.3.1.2.1 Antigen quantity 
Initially, 40µg of whole cell protein was loaded per lane for GRK5 Western blotting protocol 
optimization, and resulted in GRK5 bands of low intensity. Increasing the amount of protein 
loaded to 60µg of protein per lane resulted in modest increases in signal intensity. Based on the 
increased intensity of the bands detected, loading 60µg per lane was used for the initial 
experiments.  
3.3.3.1.2.2 Transfer duration 
The effect of the duration of the electrophoretic transfer of proteins from the gel to the 
membrane was also examined. Transfer times of 90, 120 and 150 minutes were trailed. As the 
maximum capacity of the transfer system was two cassettes, the 90 minute and 150 minutes 
transfers were separately compared to the 120 minute transfer. A symmetrically loaded gel was 
cut in two vertically following SDS-PAGE. Two separate transfer cassettes were set up as 
described in Section 3.2.6.1, but with two layers of nitrocellulose membrane between the gel 
and filter paper. The cassettes were transferred concurrently. When the shorter transfer time 
had elapsed (i.e. 90 minutes or 120 minutes), the transfer was halted and a single cassette 
removed. Transfer of the remaining cassette was then completed, and the transfer evaluated as 
described in Section 3.2.6.2. This technique was used to ensure that transfer conditions were 
keep as consistent as possible between cassettes. Inclusion of a second layer of membrane in 
the transfer cassettes allowed capture of any GRK5 passing though the first membrane, which 
would indicate that the transfer duration was too long. Both sets of membrane were then 
immunologically probed for GRK5, using the primary antibody at a dilution of 1:500 in 
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PBSTM 0.5%, and the secondary antibody at a dilution of 1:1000 in PBSTM 0.5%. When a 
transfer time of 90 minutes was used, no GRK5 was detected on the second membrane. This 
indicated that significant quantities of GRK5 had not passed through the first membrane during 
transfer. However, the GRK5 signal detected on the first membrane was less intense than that 
seen after a 120 minute transfer. No GRK5 was detected on the second membrane following 
transfer for 120 minutes. Transfer for 150 minutes resulted in GRK5 bands on the first 
membrane that were equal intensity to those seen after 120 minutes, but GRK5 bands also were 
clearly detected on the second membrane. Heating of the transfer unit is increased by longer 
transfer times, and can affect the quality of the transfer. For this reason the shorter transfer time 
of 120 minutes was selected for future experiments. 
3.3.3.1.2.3 Blocking buffers 
Differences in the blocking efficiencies of milk proteins and BSA were examined. Milk 
powder is often used as a blocking agent as it is inexpensive and readily available. The ability 
of PBST with 2% (wt/vole) milk powder to prevent non-specific binding of antibodies in 
various diluents was compared with that of PBST with 2% (wt/vole) BSA (PBSTBSA 2%). In 
all cases, membranes blocked with PBSTM 2% showed fewer instances of non-specific 
binding than membranes blocked in PBSTBSA 2%. PBST with milk at 2% was shown to be 
preferable to both PBSTM 1% and 5% as it produced an acceptable compromise between band 
specificity and band intensity (sensitivity).  
3.3.3.1.2.4 Antibody diluents 
Both the primary and secondary antibodies (see Section 3.3.3.1.1 for details) were found to be 
sensitive to changes in the type and concentration of protein in their diluent. The presence of as 
little as 0.1% protein in the GRK5 primary antibody diluent resulted in dramatic decreases in 
the intensity of GRK5-specific banding. PBST with no protein was therefore used as the 
diluent for the anti-GRK5 primary antibody. Dilution of the secondary antibody with PBST 
containing 2% FBS or BSA, or PBSTM of less than 2% resulted in an increase in non-specific 
banding. PBSTM 2% was chosen as the most appropriate diluent for the anti-rabbit IgG HRP-
conjugated secondary antibody.  
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3.3.3.1.2.5 Antibody dilutions 
Both the primary and secondary antibodies were tested over a range of dilutions. GRK5-
specific banding was seen with combinations of primary antibody diluted
 
1:100 with secondary 
antibody diluted 1:1000-1:10,000, and primary antibody diluted
 
1:200 with secondary antibody 
diluted 1:1000. The strongest GRK5 signal was detected with primary antibody diluted 1:100 
in PBST with secondary antibody diluted 1:1000 in PBSTM 2%. However, even at such high 
concentrations of antibody, the assay was extremely variable, and GRK5 could not be 
consistently detected. This combination produced primary antibody-dependant bands within 
the membrane section probed (see Section 3.2.7) at ~55, ~68, and ~90kDa. The predicted 
molecular weight of GRK5 is 68kDa. The significance of the additional bands is discussed in 
Section 3.3.3.2.7.1. 
3.3.3.1.2.6 Image capture 
Serial image capture, in which the signal derived from each exposure is added to that of 
previous exposures, was used to track the development of the GRK5 signal over time. For 
example, in a six image series, image two would contain the digital signal captured in both 
exposures one and two, while image six would contain the digital signal captured during all six 
exposures. Multiples of 10 minute exposures were used. An exposure time of 90 minutes was 
set as the longest feasible exposure time. For all conditions trialled (see above) a set of nine 10 
minute exposures produced the best images, which were used for analysis 
3.3.3.1.3 Evaluation 
The best conditions found for visualising GRK5 with the antibody combination described in 
Section 3.3.2.1.1 were as follows: loading of 60μg protein per lane, electrophoretic transfer for 
2 hours, blocking of the membrane with PBSTM 2%, dilution of the primary anti-GRK5 
antibody to 1:100 in PBST, dilution of the secondary HRP-conjugated antibody to 1:1000 in 
PBSTM2%, and an exposure time of 1.5 hours for image capture. This protocol was not 
considered to be fit for purpose as i) it lacked reproducibility - with large run-to-run variability 
seen under the same conditions, ii) the primary antibody concentration required was very high 
compared to those reported in the literature for the same antibody, and iii) the long exposure 
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times required were impractical. While the complete details of Western blotting protocols were 
not routinely included in published articles, multiple papers were found which reported the use 
of the sc-565 antibody at a 1:500 dilution for detection of GRK5 (Bezard et al., 2005; Bychkov 
et al., 2008; Iyer & Canty Jr, 2005; Metaye et al., 2002; Voigt et al., 2004). In addition to use 
of this lower concentration, some of the above groups also reported the use of more stringent 
binding conditions (Voigt et al., 2004), substantially lower secondary antibody concentrations 
(Bychkov et al., 2008), and lower antigen levels (Iyer & Canty Jr, 2005) than obtained with the 
protocol described above. 
 
The discrepancy between the literature and our experience suggested that there might be an 
issue with the quality of the particular lot of sc-565 antibody we were using. This was 
supported by a statement made in a recent paper by members of Dr Robert Lefkowitz‘s 
research group (Zidar et al., 2009), that the ―GRK5 expression could not be assessed reliably 
by using available antibodies‖. As the Lefkowitz group had previously published papers using 
the sc-565 antibody for analysis of GRK5 expression (Kim et al., 2005; Ren et al., 2005; 
Violin et al., 2008; Violin et al., 2006), we considered that this statement might be relevant to 
our problems with reliable GRK5 detection. In response to our enquires, Dr S. Ahn of the 
Lefkowitz group reported that they had found substantial variability in the performance of 
different batches of the sc-565 antibody, including the number of bands produced. Dr Ahn 
went on to say that they did not currently have a batch with which they could produce Western 
blots of acceptable quality. In light of this feedback, a second batch of the sc-565 antibody (Lot 
Number: B1610) was obtained from Santa Cruz and its performance compared to our original 
batch (Lot Number: D0208) in the hope that it would produce better results. 
 
 
 3.3.3.1.4 Conclusion 
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While these trials were unsuccessful in producing a suitable protocol, they were useful in 
illustrating the effects of each part of the protocol on the signal outcome, and informed the 
successful optimisation of the final protocol as described below. 
3.3.3.2 Western blotting for GRK5 detection protocol optimisation: Part two 
This section describes experiments which directly led to the production of the optimised 
protocols described in Section 3.2 
3.3.3.2.1 Primary antibody selection 
As discussed in Section 3.3.3.1.3, a second batch (Lot Number: B1610) of the sc-565 anti-
GRK5 primary antibody was obtained after initial attempts to establish a protocol for Western 
blotting of GRK5 (Section 3.3.3.1) were unsuccessful. Information supplied by the Lefkowitz 
group suggested that the quality of the original batch (Lot Number: D0208) might be the cause 
of this failure, and that substitution with an alternative batch (B1610) of sc-565 batch might 
improve the results.  
 
Both batches were trialled using the protocol described in Section 3.3.3.1.3. Substantial 
differences were seen between the banding patterns produced by batch D0208 and batch 
B1610. Both batches resulted in visible bands at ~55, ~68, ~80, ~95, ~110, ~115, ~130, and 
~170kDa. However the relative intensities of the bands differed greatly (Figure 3.6). The most 
intense bands produced by batch B1610 were (in descending order) at ~170, ~130, and 
~95kDa. The brightest band produced by batch D0208 was at ~68kDa followed closely by that 
at ~55kDa. As the bands seen with D0208 corresponded better to both the predicted molecular 
weight of GRK5, and the molecular weight of bands identified in the literature as GRK5 (Jones 
et al., 2002), batch D0208 was selected for subsequent use. However, this did not solve the 
lack of reproducibility and the requirement for very high primary antibody concentrations 
associated with this batch of sc-565 
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3.3.3.2.2 Examination of the affinity of the Sigma-Aldrich Secondary antibody for the anti-
GRK5 sc-565 primary antibody 
Western blotting is a form of indirect immunoblotting, requiring strong specific interactions to 
occur between both primary and secondary antibodies and their antigens. The possibility that 
GRK5 detection was being limited by a poor interaction between the secondary antibody and 
its antigen, the rabbit anti-GRK5 sc-565 primary antibody, was investigated by comparing the 
intensity of its banding with that produced by two alternative secondary antibodies when used 
in combination with sc-565. 
 
The three anti-rabbit IgG HRP-conjugated secondary antibodies tested were diluted to 1:1000 
in PBSTM 1% and used in combination with batch D0208 of sc-565 rabbit anti-GRK5 primary 
antibody. The secondary antibodies were i) a goat anti-rabbit IgG (whole molecule) HRP-
conjugate from Sigma (Product Number: A0545, Batch Number: 078K4844), ii) a goat 
polyclonal anti-rabbit IgG HRP-conjugate from Novus Biologicals (Product Number: NB730-
H, Lot number P30), and iii) a donkey anti-rabbit IgG (whole molecule) HRP-conjugate from 
Amersham (Product Number: NA934, Batch Number: 384359). Both the Amersham (Figure 
3.8) and Novus biological (Figure 3.7, A&B) secondary antibodies produced bands at ~68kDa 
and ~55kDa that were substantially brighter than those produced by the Sigma-Aldrich 
secondary antibody used in the initial optimisation experiments (Section 3.3.3.1). This 
suggested that the Amersham and Novus Biologicals secondary antibodies were able to interact 
Figure 3.6 Comparison of banding pattern produced by alternate batches of the sc-565 anti-
GRK5 primary antibody from Santa Cruz. On the left, batch B1610 produced multiple bands in 
addition to the predicted band at ~65kDa. On the right, batch D0208 produced a similar banding 
pattern; however the relative intensity of the bands at each molecular weight differed between 
batches 
D0208 
55kDa 
72kDa 
95kDa 
130kDa 
170kDa 
B1610 
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with the anti-GRK5 primary antibody with higher affinity and/or avidity than the Sigma-
Aldrich secondary antibody, and supports the hypothesis that the previous inability to reliably 
detect GRK5 was due to a poor interaction between the primary antibody and Sigma-Aldrich 
secondary antibody. The performance of the Amersham and Novus Biologicals secondary 
antibodies was examined further. This analysis is found in Section 3.3.3.2.3, and was used to 
inform the selection of the secondary antibody to be used for detection of GRK5. 
3.3.3.2.3 Secondary antibody selection: Evaluation of the Amersham and Novus Biological 
secondary antibodies. 
The banding produced by the Novus Biologicals and Amersham secondary antibodies was 
examined over a range of concentrations and diluents, and in the absence of primary antibody. 
3.3.3.2.3.1 Novus Biologicals secondary antibody 
The Novus Biologicals secondary antibody was trialled at 1:1000, 1:2000, and 1:3000 (in 
PBSTM 2%) with anti-GRK5 sc-565 primary antibody at dilutions of 1:400, 1:500 and 1:600 
(in PBST). (Figure 3.7, C). All combinations trialled produced bright bands at ~68kDa and 
~55kDa. However, they also produced an additional smeared band from ~72-95kDa.  
 
Antibodies are known to form non-specific interactions when the stringency of the binding 
conditions is too low. Increasing the stringency should preferentially reduce non-specific 
interactions due to the lower affinities/avidities of the participants for each other. Attempts 
were made to remove the 72-95kDa band produced by the Novus Biologicals secondary 
antibody by increasing the stringency of the assay. This was done by i) decreasing the 
concentration of the secondary antibody, and ii) increasing the concentration of milk protein in 
the secondary antibody diluent. The effect of antibody dilution on assay specificity was 
examined as follows. The Novus Biologicals secondary antibody was diluted in PBSTM 2% to 
1:1000, 1:2000, 1:5000, and 1:10,000 and used in combination with the primary antibody at 
1:500 in PBST. Decreasing the secondary antibody concentration did decrease the ~72-95kDa 
band, but only to the same extent that it decreased the ~68kDa and ~55kDa bands.  
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The effect of increasing the concentration of milk protein in the secondary antibody diluent to 
3.5% and 5% (primary antibody 1:500 in PBST, secondary antibody 1:1000) was also 
examined. This resulted in a small decrease in the intensity of the 71-95kDa band. However in 
all instances above, the ~55kDa band was more intense than the ~68kDa band.  
 
Figure 3.7 Evaluation of Novus Biological secondary antibody. A) Comparison of Novus antibody (left lane) to 
signal produced by the Sigma-Aldrich secondary antibody (right lane) under identical conditions, B) with contrast 
adjusted so Sigma-Aldrich antibody-produced bands are visible, C) banding patterns produced by multiple 
combinations of different primary antibody dilutions with different dilutions of Novus Biological secondary 
antibody, D) effect of diluting secondary antibody on the specificity of antibody binding, E) the effect of 
concentration of milk protein in secondary antibody diluent of specificity of antibody binding, and F) the banding 
pattern produced by the Novus Biological antibody in the absence of primary antibody. 
 
F
55kDa
72kDa
95kDa
130kDa
170kDa
43kDa
34kDa
26kDa
55kDa
72kDa
95kDa
B
A
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
1:400 1:500 1:600
1o Ab dilutions
2o Ab dilutions
C
2o Ab diluent 
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
E
55kDa
72kDa
95kDa
D
1:500
1o Ab dilution
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
2o Ab dilutions
55kDa
72kDa
95kDa
55kDa
72kDa
95kDa
55kDa
72kDa
95kDa
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
F
55kDa
72kDa
95kDa
130kDa
170kDa
43kDa
34kDa
26kDa
55kDa
72kDa
95kDa
B
A
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
1:400 1:500 1:600
1o Ab dilutions
2o Ab dilutions
C
2o Ab diluent 
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
E
55kDa
72kDa
95kDa
D
1:500
1o Ab dilution
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
2o Ab dilutions
55kDa
72kDa
95kDa
55kDa
72kDa
95kDa
55kDa
72kDa
95kDa
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:1
0
0
0
1
:2
0
0
0
1
:3
0
0
0
1
:3
0
0
0
1
:2
0
0
0
1
:1
0
0
0
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
5
%
 P
B
S
T
M
3
.5
%
 P
B
S
T
M
2
%
 P
B
S
T
M
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
1
:1
0
0
0
1
:5
0
0
0
1
:1
0
,0
0
0
- 57 - 
 
The primary antibody-dependency of the bands produced by the Novus Biologicals secondary 
antibody was determined by immunoblotting the full length of the membrane with secondary 
antibody only, diluted to 1:1000 in PBSTM 2% (see Figure 3.7, F). In the absence of primary 
antibody the Novus biological secondary antibody produced multiple bands, representing 
substantial off-target binding. The majority of these bands fell below ~50kDa and so would not 
interfere with the detection of GRK5. However, the brightest of the off-target bands was found 
at ~55kDa, and two faint bands at ~68kDa and ~72kDa were also detected.  
3.3.2.2.3.2 Amersham secondary antibody 
The Amersham secondary antibody was trialled at 1:1000 and 1:2000 (in PBSTM 2%) with the 
primary antibody at 1:500 (in PBST). Both concentrations produced bands at ~68kDa and 
~55kDa (Figure 3.8, B). The bands produced by the more concentrated secondary antibody 
solution were preferable. To determine if the bands detected by the Amersham secondary 
antibody were primary antibody-dependent, a full length strip of membrane was incubated in 
secondary antibody only, diluted to 1:1000 in PBSTM 2%. In the absence of primary antibody, 
the Amersham secondary antibody did not produce any bands (Figure 3.8, A), indicating that 
the ~55kDa and ~68kDa bands seen earlier represented proteins to which the primary antibody 
had bound.  
 
The intensities of the bands, while brighter than those seen with the Sigma-Aldrich secondary 
antibody, were substantially less than those of the bands produced with the Novus Biologicals 
secondary antibody (Figure 3.8, B).  
As illustrated in Section 3.3.3.1.2 the conditions of antibody incubation, such as the quantity of 
protein in the antibody diluent, has an impact on its ability to bind to its antigen. As no non-
specific binding of the Amersham secondary antibody was detected, the milk protein content of 
its diluent was decreased in an attempt to increase the intensity of the bands. The Amersham 
antibody was diluted to 1:1000 in PBST, PBSTM 2% and PBSTM 1%, and used in 
combination with sc-565 α-GRK5 primary antibody. Decreasing the protein in the secondary 
antibody diluent from 2% to 1% resulted in a modest increase in the intensity of both the 
~55kDa and ~68kDa bands and the appearance of a faint band at 72kDa (Figure 3.8, D).  In the 
absence of protein in the diluent however, the Amersham secondary antibody produced bands 
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at ~55, ~68, and ~72kDa that were comparable in intensity to those seen with the Novus 
Biological secondary antibody (Figure 3.8, C).   
 
As decreasing the protein content of the Amersham secondary antibody diluent from 1% to 0% 
had such a marked effect, a range of concentrations between these two values were trialled in 
an attempt to establish a milk protein concentration at which the band intensity was increased  
 
 
 
 
 
without the introduction of off-target binding. The secondary antibody was diluted to 1:1000 in  
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Figure 3.8 Evaluation of the Amersham secondary antibody. (A) The banding pattern produced in the 
absence of primary antibody, (B) comparison of band intensity when used at 1:1000 and 1:2000 compared 
with the Novus Biologicals secondary antibody at the same dilutions, (C  and D) the effect of decreasing 
the protein content of the secondary antibody diluent on band intensity. For the evaluation of the 
Amersham secondary antibody, the primary antibody was used at 1:500 in PBST, except in (A) where no 
primary antibody was used. The Amersham antibody was used at 1:1000 in PBSTM (2%) unless indicated 
otherwise. 
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PBSTM 1, 0.5, 0.3, 0.1 and 0% (Figure 3.8, D). No significant difference was seen in the 
intensity of the bands produced when PBSTM 0.3, 0.5, and 1% was used as the diluent. All 
produced a clear bright band at ~68kDa. A faint band was also seen at ~55kDa, as well as 
additional bands between 72kDa and 95kDa. The intensities of all bands were comparatively 
increased when PBSTM 0.1% was used as the secondary antibody diluent.   
3.3.3.2.4 Secondary antibody selection 
The Novus Biological secondary antibody produced substantially brighter bands than those 
seen with the Amersham antibody. However, unlike the Amersham secondary antibody it also 
produced primary antibody-independent bands (Figure 3.7 F). Furthermore, in blots produced 
with the Amersham antibody, the ~68kDa band was brighter than the ~55kDa band (Figure 3.8 
D, and Figure 3.9). This relationship was reversed with Novus biological antibody (Figure 3.7 
E, and Figure 3.9). As the predicted molecular weight of GRK5 is 68kDa and the identity of 
the additional bands, including that at ~55kDa, is undetermined, the banding pattern produced 
by the Amersham antibody was preferable. The Amersham antibody was selected for use.  
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Effect of PBSTM concentration on the band intensities produced by a combination of the 
anti-GRK5 primary antibody and (A) the Novus Biologicals secondary antibody, or (B) the 
Amersham secondary antibody, also showing the relationship between the intensity of the 68kDa and 
55kDa band for both antibody combinations 
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3.3.3.2.5 Selection of antibody concentrations  
3.3.3.2.5.1 Primary antibody concentration 
 Due to the relative faintness of the bands produced in the experiments described above, 
primary antibody dilutions greater than 1:500 were not trialled with the Amersham secondary 
antibody. A primary antibody dilution of 1:500 was found to produce bands that were strong 
enough to allow decreases in GRK5 expression to be quantified. Furthermore, this dilution was 
more consistent with the use of the sc-565 α-GRK5 antibody reported in the literature (Bezard 
et al., 2005; Bychkov et al., 2008; Iyer & Canty Jr, 2005; Metaye et al., 2002; Voigt et al., 
2004). As such, a dilution of 1:500 was selected for use of the anti-GRK5 antibody in 
combination with the Amersham secondary antibody. 
3.3.3.2.5.2 Secondary antibody concentration 
The Amersham secondary antibody was trialled at dilutions of 1:1000 and 1:2000 in 
combination with primary antibody at a 1:500 dilutions (Figure 3.8, B). A secondary antibody 
dilution of 1:1000 was chosen as it resulted in more intense banding. 
3.3.3.2.6 Selection of Antibody diluents 
3.3.3.2.6.1 Primary antibody diluent 
Experiments performed in Part 1 of the GRK5 Western blotting protocol optimisation (Section 
3.3.3.1.2.4) illustrated the sensitivity of primary antibody to the presence of very small 
concentrations of milk protein in the primary antibody diluent. Addition of as little as 0.1% 
(wt/vol) milk powder resulted in substantial decreases in the intensity of the primary antibody 
dependant bands. As such, PBST without protein was used as the primary antibody diluent. 
 
 
- 61 - 
 
3.3.3.2.6.2 Secondary antibody diluent 
The effect of secondary antibody diluent on band intensity is described in Section 3.3.3.2.3.2.  
Decreasing the protein content of the diluent resulted in increased band intensity. However, 
this effect was not specific to the ~68kDa band which corresponds to the GRK5, and resulted 
in a proportionately large increase in the intensity of additional bands, in particular the ~55kDa 
band. Dilution of the secondary antibody to 1:1000 in PBSTM 1% produced an acceptable 
compromise between band intensity and specificity. PBSTM 1% was selected as the secondary 
antibody diluent for detection of GRK5.  
3.3.3.2.7 Assessment of protocol 
3.3.3.2.7.1 Assessment of assay specificity 
As described in Section 3.3.3.2.3.2 the primary antibody-dependency of the bands detected for 
GRK5 was assessed by incubating a piece of membrane in the Amersham secondary antibody 
without primary antibody. No bands were present in the absence of the primary antibody 
(Figure 3.8, A).  
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Figure 3.10 Effect on band intensity of preabsorbing the α-GRK5 primary 
antibody with increasing concentrations of blocking peptide. The intensity of the 
bands detected at 115kDa, 95kDa, 68kDa, and 55kD treated with preabsorbed 
antibodies were compared with the intensity of equivalent bands in the control (1:0, i.e. 
no blocking peptide) 
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The specificity of the primary antibody for its antigen was also examined. The immunizing 
antigen used to produce sc-565 was a short peptide which corresponds to the 20 C-terminal 
amino acids of the human GRK5 polypeptide. This was purchased from Santa Cruz 
Biotechnologies (sc-565-P, Lot #E172) and used to pre-absorb the primary antibody prior to 
immunoblotting. This was done by mixing the  primary antibody and immunizing antigen at a 
ratio of 1:9 (Yi et al., 2005) or 1:19, and incubating the mixture at room temperature for 1 
hour, followed by incubation overnight at 4
o
C. It was then centrifuged at maximum speed for 5 
minutes. A control was prepared is the same manner as the pre-absorbed treatment, but without 
the immunizing antigen. 
Anti-GRK5 primary antibody-dependent bands were routinely detected at 55, 68, 95, and 
115kDa bands. All bands detected with the sc-565 were seen to decrease in the presence of the 
immunizing antigen. Increasing the relative concentration of the immunizing antigen resulted 
in further decreases in band intensity (Figure 3.10)  
 
There are multiple possible explanations for the presence of unexpected bands in a Western 
blot.   
 
Additional bands are often seen when the assay stringency is too low. As described above, the 
stringency of the assay was increased by increasing the amount of milk protein in the antibody 
diluent. However, these changes did not result in a drop-off in the intensity of additional bands 
relative to the 68kDa band, as would be expected if they were caused by random opportunistic 
binding of the antibodies. Furthermore, preabsorption of the antibody with its immunizing 
antigen reduced the intensity of all the bands detected. As shown in Figure 3.10, the relative 
decrease in band intensity of both the 95 and 115kDa bands was greater than that seen for the 
~68kDa band. This suggests that the antibody is binding selectively, though perhaps not 
specifically to GRK5 (Pradidarcheep et al., 2008).  
 
The anti-GRK5 antibody (sc-565) was raised against an oligopeptide corresponding to the 20 
C-terminal amino acids of GRK5. This sequence was presumably chosen due to the extensive 
homology between the remainder of the GRK5 polypeptide and the other members of the 
GRK4 family (GRKs 4 and 6) (Penela et al., 2003). If this sequence is present in other 
proteins, it would be unsuitable for use as a GRK5 antigen. An advantage of using synthetic 
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peptides as an immunizing agent is that the amino acid sequence is known. This allows a 
degree of selection to avoid cross-reactivity between isoforms of the target protein, or other 
proteins containing a similar sequences (Ramos-Vara, 2005). Basic Local Alignment Search 
Tool (BLAST) searches for sequences with homology to the GRK5 C-20 oligopeptide antigen, 
and/or the whole GRK5 amino acid sequence were performed, and confirmed the specificity of 
this peptide sequence to GRK5.  
 
The selective binding of the primary antibody below the expected molecular weight could also 
be due to protein degradation. However, these bands are more likely to be smeared than 
discrete as seen here. To minimise degradation, protease inhibitors were included in the lysis 
buffer, and the samples kept on ice at all times. As no evidence of protein degradation was seen 
in the internal control actin, it is unlikely that protein degradation is the cause of the additional 
bands detected here. Furthermore, protein degradation would not explain the presence of bands 
above the expected weight. 
 
An alternative explanation for the presence of additional bands is the detection of multiple 
GRK5 isoforms. Alternative splicing of the GRK5 pre-mRNA could result in bands of 
different molecular weights. While no GRK5 splice-variants have currently been positively 
identified by biochemical techniques, a number of published GRK5 Western blots show 
multiple bands, though these are generally unaccompanied by molecular weight ladders or an 
explanation (Bychkov et al., 2008; Horie & Insel, 2000; Martini et al., 2008; Matkovich et al., 
2006; Ren et al., 2005). Splice variants of other members of the GRK family, including the 
closely related GRK4 and GRK6, have, however, been documented (Premont et al., 1999).  
 
Post-translational modification involving the addition of molecules, such as phosphate groups, 
would increase the molecular weight of the peptide, and could alter the running characteristics; 
resulting in band at alternative molecular weights. As discussed in Chapter1, phosphorylation 
of GRK5 is a crucial aspect in regulating both its activity and localisation within the cell. 
GRK5 is known to be phosphorylated at multiple sites, most of which fall outside the C-
terminal twenty amino acids used as the immunizing antigen for the primary anti-GRK5 
antibody used in this research. As such, it would be possible for the Western blotting protocol 
described in Section 3.2  to detect GRK5 in multiple different phosphorylation states.  In their 
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2002 paper, Jones, Baker, and Greenhaff detected bands at approximately 59, and 68kDa, and 
identified both as GRK5. These authors reported that the ratio of the intensities of the two 
bands differed between tissues, and suggested that they represented alternative phosphorylation 
states.  
 
Recently, the crystal structure of GRK6 was determined by Lodowski et al (2006). At the high 
concentrations of protein required for crystallisation, GRK6 was seen to form a homodimer by 
interaction of its regulator of G protein signalling homology domains. This region is highly 
conserved between GRKs, suggesting that dimerisation may be possible for other GRK 
isoforms such as GRK5. While it is unclear if GRK dimerisation is physiologically relevant, 
dimerisation of extracted GRKs in cell lysates may result in the appearance of unexpected 
bands on a Western blot. A ~130kDa band was consistently detected when α-GRK5 antibodies 
were used. This corresponds with the molecular weight expected from a GRK5 dimer 
(~136kDa), based on the molecular weight of the monomer (~68kDa). 
3.3.3.2.7.2 Assessment of assay consistancy 
The reproducibility of the assay was tested by loading the same amount of protein from the 
same sample into multiple wells (the intensity of the bands produced should be consistant 
across these lanes), and calculating the coefficient of variation (CV) for the intensity of the 
bands detected. The CV is a statistical measure of the variation within a data set, and is the 
ratio of the standard deviation of the mean. CV values are expressed as a percentage, and can 
be used to compare the amount of variation between data sets in which the means are very 
different. CV values are calculated as follows; 
 
Equation 3.4   CV = ( standard deviation / mean ) * 100 
 
The CV of the GRK5 assay was determined by loading 40μg of the same sample into 4-6 lanes 
of an SDS-PAGE gel, and immunoblotting using the protocol described in Section ???. This 
was repeated 3 times. The Mean CV calculated for the GRK assay was 20.6% ± SEM 6.0%.  
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3.3.3.2.7.3 Assessment of assay sensitivity and dynamic range 
The purpose of the Western blotting assay for GRK5 detection described above is to detect 
RNAi-induced changes in GRK5 expression. To test the sensitivity of the assay, and determine 
the range over which it is capable of detecting changes in GRK5 quantity between samples, 
serial dilutions between 40 and 4μg of a single protein sample were separated by SDS-PAGE, 
transferred to a NC membrane and immunoblotted as described in Section 3.2. The band 
intensities with the background subtracted were quantitated as described in Sections 3.2.8, and 
plotted against the amount of whole protein loaded in each lane. 
 
 
   
As shown in Figure 3.11, the GRK5 assay was able to detect a measurable signal when as little 
as 4µg of whole cell lysate was loaded. This suggests that the described protocol is sufficiently 
sensitive to detect GRK5 in cells in which GRK5 expression has been reduced by up to 90%.  
To determine the dynamic range of the assay, the data was analysed with GraphPad Prism 4.00 
using a linear regression to plot the line of best fit. A linear relationship was detected between 
Figure 3.11 Assessment of GRK5 Western blot assay, showing assay sensitivity, range and relationship 
between the amount of protein loaded and the relative intensity detected. The idealised data points 
represent a hypothetical data set with the ideal relationship between the intensity of the band produced and 
the amount of antigen present. For the GRK5 data set, n= 4 for ‗40‘, ‗20‘, ‗10‘, n=3 for ‗30‘, and n=1 for 
‗4‘μg protein. SEM are shown. A liner regression was used to plot the lines of best fit. The slope of the 
measured (solid line) and idealised (broken line) trends were not significantly different (two-tailed p value 
=0.9559).  
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the intensity of the signal measured and the amount of antigen present (R
2
= 0.8924), indicating 
that the assay could be used to detect changes in relative GRK5 expression between samples. 
The slope of the line of best fit for the measured intensity data was compared to that generated 
from an idealised data set (in which loading 25% less protein would result in a band 25% less 
intense) using a two-tailed t test. No significant difference was seen between the measured and 
idealised slopes (two-tailed p value = 0.9559). All points of the serial dilution use appear to be 
within the dynamic range of the assay, and loss of signal was not seen at the lowest quantity of 
protein loaded (4μg), and saturation was not seen at the highest quantity used (40μg). 
3.3.3.2.8 Conclusions 
The optimisation described in part II produced a protocol for detecting GRK5 which was 
sensitive, and could detect changes in the amount of GRK5 present. The consistency of the 
assay however was less than ideal, with a CV value of 20.6% ± 4.5% (mean ± SEM). Changing 
from the Sigma-Aldrich secondary antibody to the Amersham secondary antibody resulted in a 
marked increase in both the intensity of the bands, and the reproducibility of the assay. The 
Amersham secondary antibody was shown to bind specifically to the primary antibody, based 
on the absence of bands when the secondary antibody was used without the primary antibody. 
The specificity of the primary anti-GRK5 antibody is less certain, as multiple additional bands 
were detected, the intensity of which was not decreased relative to the 68kDa band by 
increasing the stringency of the assay. The final protocol employed primary anti-GRK5 
antibody (batch D0208) diluted 1:500 in PBST, with Amersham secondary antibody diluted 
1:1000 in PBSTM 1%. This protocol was deemed to be appropriate for be used to evaluate 
protein knockdown following GRK5-targeted siRNA treatment. 
3.3.4 Western blotting optimisation: Actin, for use as an internal control 
To ensure observed changes in the intensity of the GRK5 bands are due to changes in GRK5 
expression rather than uneven loading or transfer, it is recommended that a second protein is 
detected to act as an internal control. The expression of this protein should not be altered by the 
test treatment (in this case siRNA-induced knockdown of GRK5 expression), and so should be 
constant between the control and test samples. Variation in the intensity of bands 
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corresponding to this protein would then act as an indicator that unequal amounts of test and 
control samples were loaded onto the gel. Actin is commonly reported in the literature as the 
internal control (Ren et al., 2005) and was evaluated for use in this thesis. 
 
 Elements of the Western blotting protocol altered during optimisation of actin detection are 
described in Section 3.3.4.2. For unspecified details refer to the optimised protocols (Section 
3.2). 
3.3.4.1 Antibodies for actin detection 
For immunodetection of actin, a rabbit anti-human actin affinity-isolated antibody from Sigma-
Aldrich (Product Number A2066, Lot Number 048K4861) was used as the primary antibody. 
The goat α-rabbit IgG (whole molecule) horseradish-peroxidase conjugate also from Sigma-
Aldrich (Product Number A0545, Lot Number 078K4844) was used as the secondary antibody. 
Use of this Sigma-Aldrich secondary antibody in combination with the α-GRK5 primary 
antibody (Section 3.3.3.1) resulted in poor GRK5 detection, however based on the intensity of 
the actin bands it interacts with the anti-actin primary antibody with high affinity.  
3.3.4.2 Variables tested during optimisation 
3.3.4.2.1 Antigen quantity 
Loading 80, 60, 40, 30, and 20µg of whole protein per lane was trialled. All quantities 
produced strong clear bands. Loading of 20µg of protein was selected as sufficient for 
detection of actin in knockdown experiments. Due to problems encountered during the initial 
attempts to optimise the detection of GRK5 (described in Section 3.3.3.1) 60µg of protein was 
used during some parts of the optimisation described below. For clarity, the quantity of protein 
loaded at each stage is specified.   
3.3.4.2.2 Blocking    
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The intensity of actin bands on immunoblots blocked in PBSTM containing 1% and 2% milk 
were compared (60µg protein loaded). No difference was seen in band intensity between the 
two conditions and both appeared to provide sufficient blocking, as shown by the lack of non-
specific bands in either condition (Figure 3.12, A). Blocking with BSA 2% (wt/vol) was also 
trialled, and resulted in an increase in non-specific banding (not shown). PBSTM 2% was 
selected for blocking membranes for actin-detection in all subsequent immunoblots.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4.2.3 Antibody concentrations 
In selecting antibody concentrations a balance must be struck between signal specificity, signal 
intensity, and signal durability. For example, lowering the antibody concentration reduces the 
signal intensity, but improves signal specificity. To identify appropriate antibody 
concentrations for actin detection, six different combinations of primary and secondary 
antibody dilutions (Figure 3.12, B) were trialled. Both antibodies were diluted in PBSTM 2%, 
and the membrane was imaged for approximately 12 minutes. All six combinations produced a 
single band at approximately ~42 kDa, the predicted molecular weight for actin. This suggests 
that in all combinations both antibodies are interacting with their intended antigens in a 
specific manner. The band intensities produced by the primary antibody diluted to 1:2000 were 
sufficient for actin detection, and preferable to a dilution of 1:1000  as they were i) more cost 
Figure 3.12 Optimisation of Western blotting protocol for actin. (A) The effect of protein concentration 
in blocking reagent on band intensity and specificity, (B) the band intensity produced by various 
combinations of primary and secondary antibody concentrations, and (C) the bands produced in a typical 
assay (using 1:2000 primary antibody in PBSTM1%  and 1:30,000 secondary antibody in PBST2%). 
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effective, ii) potentially more specific, and iii) less prone to over-saturation which can impair 
the accuracy of signal quantification. A combination of primary antibody at 1:2000 and 
secondary antibody at 1:30,000 was selected for use. This combination typically produced a 
band stronger than that shown in Figure 3.12, B. As such, bands representative of those 
typically produced are shown in Figure 3.12, C.  
3.3.4.2.4 Antibody Diluents 
The effect of reducing the amount of milk powder present in the primary and secondary 
antibody diluents was examined. Decreasing the amount of milk protein in the primary 
antibody diluent to less than 1% resulted in an increase in off-target interactions, as shown by 
the appearance of additional bands. For this reason PBSTM 1% was selected as the diluent for 
the anti-actin primary antibody. Reduction of the amount of milk protein in the secondary 
antibody diluent to less than 2% caused a reduction in the specificity of the assay. This was 
shown by an increase in the occurrence of off-target bands. Multiple immunoblots using 
primary antibody diluted 1:2000 in PBSTM 1% with secondary antibody diluted 1:30,000 in 
PBSTM 2% confirmed that this combination could be used to specifically and reproducibly 
detect actin (Figure 3.12). 
3.3.4.3 Assessment of protocol 
3.3.4.3.1 Assessment of assay specificity 
A single band of expected weight of ~42kDa was detected using the α-actin primary antibody, 
suggesting that this antibody was binding specifically to its target antigen. The specificity of 
the secondary antibody under the immunoblotting conditions used was evaluated by incubating 
a piece of membrane corresponding to a single lane of protein with secondary antibody only, 
and comparing it to lanes incubated in both primary and secondary antibody (Figure . No 
signal was detected in the absence of the primary antibody.  
3.3.4.3.2 Assessment of assay consistency 
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The consistency of the assay was assessed as described in Section 3.3.3.2.7.2. The CV of the 
actin was calculated for four assays in which 40μg of untreated protein was run in 4-6 lanes of 
the same gel, and immunoblotted as described in Section 3.2.7, producing a mean CV of 8.8 ± 
SEM 4.5% 
3.3.4.3.3 Assessment of assay sensitivity 
The sensitivy and dynamic range of the Western blotting assay for actin was tested as 
described in Section 3.3.3.2.7.3, by running serial dilutions of protein ranging from 40 to 4μg 
on a gel and immunoblotting as described in Section 3.2.  
 
  
As shown in Figure 3.13, the actin assay was able to detect a measurable signal when as little 
as 4µg of whole cell lysate was loaded. The data generated from serial dilution of protein was 
analysed with GraphPad Prism 4.00 using a linear regression to plot the line of best fit. A 
strong linear relationship was detected between the intensity of the signal measured and the 
amount of antigen present (R
2
= 0.9307), indicating that the assay could be used to accurately 
detect changes in relative actin expression between samples. The slope of the line of best fit for 
Figure 3.13 Assessment of Actin Western blot assay, showing assay sensitivity, range and relationship 
between the amount of protein loaded and the relative intensity detected. The expected data points represent 
the hypothetical ideal relationship between the intensity of the band produced and the amount of antigen present. 
For the Actin data set, n= 4 for ‗40‘, ‗20‘, ‗10‘, n=3 for ‗30‘, and n=2 for ‗4‘μg protein. SEM are shown. The 
slopes of the measured (solid line) and ideal (broken line) lines were not significantly different (two-tailed p value 
=0.409)  
 
Actin replicates
0 10 20 30 40
0
25
50
75
100 Actin
expected
µg Protein
R
e
la
ti
v
e
 b
a
n
d
 i
n
te
n
s
it
y
 (
%
) Acti
Idealis
R2 Actin: 0.9307
- 71 - 
 
the measured intensity data was compared to that generated from an idealised data set (in 
which loading 25% less protein would result in a band 25% less intense) using a two-tailed t 
test. No significant difference was seen between the measured and idealised slopes (two-tailed 
p value = 0.409).  As with the GRK5 assay, all points of the serial dilution used appear to be 
within the dynamic range of the assay, as loss of signal was not seen at the lowest quantity of 
protein loaded (4μg), and saturation was not seen at the highest quantity used (40μg). 
3.3.4.4 Conclusions 
The final protocol for the detection of actin via Western blotting involved the loading of 40µg 
of protein, blocking of the membrane in PBSTM 2%, and use of the Sigma-Aldrich anti-actin 
primary antibody diluted 1:1000 in PBSTM 1% in combination with the Sigma-Aldrich 
secondary antibody diluted to 1:30,000 in PBSTM 2%.  This protocol was able to reproducibly 
detect actin and was sensitive to changes in the amount of actin present over a large dynamic 
range, and was consistent (as assessed by CV analysis).  
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4 
DEVELOPMENT OF A QUANTITAVE REVERSE 
TRANSCRIPTASE PCR PROTOCOL FOR ASSESSING HUMAN 
GRK5 mRNA EXPRESSION IN HEK293 CELLS 
4.1 INTRODUCTION 
To confirm the siRNA-mediated knock down of GRK5 during RNA interference experiments 
(Chapters 5 & 6), it was necessary to compare the level of GRK5 mRNA present in control and 
treated cells. Qualitative real-time PCR (qPCR) is a form of polymerase chain reaction (PCR) 
in which the formation of PCR products is measured at the end of each amplification cycle. 
This information is then used to calculate the quantity of the gene of interest in the template. 
Quantitative reverse transcriptase PCR (qRT-PCR) is a variant of qPCR in which the template 
is produced by the reverse transcriptase (RT)-catalysed conversion of RNA to complementary 
DNA (cDNA) (Nolan et al., 2006). qRT-PCR is the favoured method for quantifying steady-
state mRNA expression as it is fast, accurate, reproducible, and highly sensitive (Bustin, 2002; 
Radonic et al., 2004). qRT-PCR is commonly used in assessing the effect of RNA interference 
on the mRNA expression of the target gene. 
 
In the qRT-PCR protocol described below, the generation of PCR products could be tracked 
due to the inclusion of SYBR green in the reaction mix. SYBR green is a reporter dye that 
fluoresces when bound to double-stranded DNA. The interaction between SYBR green and 
DNA is not sequence specific, meaning that any DNA present in the reaction tube will 
contribute to the level of fluorescence detected. For this reason, SYBR green is only suitable 
for ‗single-plexing‘ reactions, in which a single target is detected per well. 
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The fluorescence generated by SYBR green binding to DNA is measured at the end of every 
amplification cycle, giving real-time updates on product accumulation. The point at which the 
measured fluorescence rises above the background fluorescence level is termed the threshold 
cycle (Ct) and is used to calculate the gene expression. The Ct value has an inverse relationship 
with the quantity of the target transcript in the starting template, i.e. the more target transcript 
present, the lower the Ct value, as it requires less amplification cycles to reach a detectable 
level (Radonic et al., 2004).  
 
In the qRT-PCR protocol described in this chapter, the reverse transcriptase (RT) reaction and 
the qPCR are performed separately. The qRT-PCR methods used to assess the expression of 
human GRK5 mRNA in HEK293 cells are given in Section 4.2. The purpose of the work 
presented in Section 4.3 of this chapter was the set up and validation of these methods. 
4.2 qRT-PCR PROTOCOLS AND MATERIALS 
4.2.1 Materials 
For details of materials referred to in this section see Appendix A. 
4.2.2 Solutions and Media 
For details of solutions and media referred to in this section see Appendix B. 
4.2.3 Maintaining RNase-free Conditions 
To avoid contaminating the samples and solutions with ribonuclease enzymes (RNases) which 
degrade RNA, all techniques described in this chapter were performed using dedicated 
equipment, reagents and consumables. Glass sheets were used as work surfaces, and were 
prepared before each experiment by treating with RNase-Away (Invitrogen) as per the 
manufacturer‘s instructions. Gloves were worn and changed frequently during experiments. 
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Glassware, plastic ware, spatulas and magnetic stirring bars were baked at 150
o
C for 2 hours 
before being used to prepare RNase-free solutions. Nuclease-free, low-retention, filtered 
pipette tips from Axygen and MPbio were used to avoid contamination of the pipettes by 
aerosols, which could lead to the contamination of later samples. 
4.2.4 Isolation of RNA from Cells 
4.2.4.1 RNA Extraction 
Total RNA was extracted from HEK293 cells using a TRIzol
®
Plus RNA Purification Kit 
(Invitrogen). The medium was removed from each well using a Gilson P1000 pipette and 
replaced with 200μL of TRIzol® per well. Samples were then either processed immediately, or 
the plate was taped closed and stored at -80
o
C until a later date. After the addition of TRIzol
®
 
(and thawing if necessary), each well was thoroughly scraped with a Gilson P1000 pipette tip, 
and its contents vigorously repipetted 6 times to draw cells into suspension and wash the 
surface of the well. The cell suspension was transferred into a labelled 1.7 mL centrifuge tube. 
Duplicate wells were pooled at this point. The cells were homogenized by vigorously 
repipetting the cell suspension twenty times with a Gilson P1000 pipette set to 95% of the total 
volume, then incubated at room temperature for 5 minutes. Next, 20µL of bromo-
chloropropane (BCP) per 200µL TRIzol
®
 was added to each tube, and the tubes were shaken 
vigorously by hand for twenty seconds. Samples were then incubated at room temperature for 5 
minutes. The tubes were spun at 12,000 x g for 15 minutes at 4
o
C (Eppendorf centrifuge 5417), 
and the resulting aqueous phase removed and combined with an equal volume of 70% ethanol 
to give a final ethanol concentration of 35%. Following mixing, each sample was loaded onto a 
TRIzol
®
Plus Purification Kit Spin Cartridge with collection tube and spun at 12,000 x g for 15 
seconds at room temperature. The column was washed once with 700μL of Wash Buffer I, and 
once 500μL of Wash Buffer II, spun at 12,000 x g for 15 seconds at room temperature after 
each addition. The flow through discarded each time. The Spin Cartridge was then transferred 
to a new collection tube and washed a second time with 500µl of Wash Buffer II, spinning as 
above and the flow through discarded. The membrane was then dried by centrifuging the Spin 
Cartridge at room temperature for 1 minute at 12,000 x g. The Spin Cartridge was transferred 
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to a 1.5mL elution tube and 30μl of RNase-free water was applied directly to the membrane. 
This was incubated at room temperature for 1 minute. The Spin Cartridge was then centrifuged 
for 2 minutes at 12,000 x g (also at room temperature), to elute the RNA with the water. 
4.2.4.2 Analysis of RNA 
The concentration and purity of the eluted RNA in each sample was determined using a 
ND1000 NanoDrop spectrophotometer (ThermoScientific). RNase-free NPH2O was used both 
to clean the spectrophotometer platform before use, and as a blank to zero the 
spectrophotometer before sample analysis. The RNA concentration (ng/µL) of each sample 
was determined by the NanoDrop software based on its absorbance at 260nm. The purity of 
each sample was shown by the 260/280 and 260/230 absorbance ratios.  
4.2.5 Reverse Transcriptase reaction 
The SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen) was used as per 
the manufacturer‘s instructions to convert the extracted RNA to complementary DNA (cDNA), 
using an RNA-dependant DNA polymerase enzyme called reverse transcriptase (RT). An 
Eppendorf Mastercycler® gradient or ep gradient S PCR machine was used for the heating 
steps, during which the lid was headed to 105
o
C to avoid evaporation. 
 
Each RT reaction was set us as shown in Table 4.1 A. This RNA mixture was denatured by 
incubation at 65
o
C for 5 minutes. The mix was then placed on ice for at least 1 minute to allow 
the oligo(dT)20 primers to anneal. Ten microlitres of cDNA synthesis mix, shown in Table 4.1 
B, was added to the RNA mix, and the 2 solutions mixed by gently tapping the reaction tube. 
The combined solution was collected by brief centrifugation and incubated at 50
o
C for 50 
minutes, during which cDNA synthesis occurred. The RT reaction was terminated by heating 
the solution to 85
o
C for 5 minutes. The quantity of cDNA produced by the RT reaction is 
indeterminable, so it was assumed to be equal to the quantity of RNA used as a template, i.e. 
400ng (20ng/μL). The cDNA was stored at -80oC. 
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400ng RNA  2µL 10X RT buffer 
1µL 50µM oligo(dT)20 primers 4µL 25mM MgCl2 
1µL 10mM dNTP mix 2µL 0.1M DTT 
NPH2O to make volume up to 10µL 1µL 40U/µL RNaseOUT  
 1µL 200U/µL SuperScript III RT enzyme 
Table 4.1 Master mixes for RT reaction. A) Components of the RNA RT reaction mixture, B) components 
of the cDNA synthesis mix. 
4.2.6 qPCR Assay 
The qPCR segment of the qRT-PCR protocol, in which selected transcripts in the template 
were amplified and quantified, was performed using a Stratagene Mx3005P™ real time qPCR 
machine. cDNA was used as a template (see Section 4.2.5 for synthesis details).  
4.2.6.1. Experimental Design  
SYBRGreenER qPCR SuperMix Universal from Invitrogen was used according to the 
manufacturer‘s instructions. This mix contains Taq polymerase, SYBR green, and other 
components required for qPCR. The Taq polymerase present in this mix is of the ‗hot-start‘ 
variety i.e. it has been chemically modified to make it inactive at ambient temperatures. This 
increases the specificity of the assay as it prevents amplification being primed by non-specific 
interactions which can occur during set up (Bustin, 2002). The polymerase activity was 
restored by 10 minute incubation at 95
o
C at the start of PCR cycling.  
 
The expression level of GRK5, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein-zeta polypeptide (YWHAZ) and tata box binding protein (TBP) was 
measured for each template, and all reactions were run in duplicate. Each 20µL reaction was 
set us as described in Table 4.2. The templates were diluted 1/37.5 before use to minimise the 
concentration of RT reaction components in the qPCR reaction mix. This resulted in template 
solutions with a cDNA concentration of 0.533ng/µL. Non-template controls (NTC) were run 
for each primer set (see Table 4.2) 
A B 
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Gene 
Reagent GRK5 YWHAZ TBP NTC 
SYBRGreenER SuperMix Universal 10µL 10µL 10µL 10µL 
cDNA template (3ng) 5.63uL 5.63µL 5.63µL 0µL (0ng) 
NPH2O 3.57µL 3.57µL 3.17µL 8.8 µL or 9.2µL 
10µM F primer 0.4µL 0.4µL 0.6µL 0.4 µL or 0.6µL 
10µM R primer 0.4µL 0.4µL 0.6µL 0.4 µL or 0.6µL 
TOTAL VOLUME 20μL 20μL 20μL 20μL 
Table 4.2 Volumes of each component for test and non-template control qPCR reactions 
 
The final F and R primer concentrations were 200nM for reactions measuring GRK5 or 
YWHAZ expression, and 300nM for TBP reactions. Master mixes were used where possible to 
reduce the potential for pipetting errors. 
 
The following 2 step thermal profile was used: 50
o
C for 2 minutes, 95
o
C for 10 minutes to 
activate the Taq polymerase, followed by 40 cycles of denaturation at 95
o
C for 15 seconds, and 
annealing and extension at 60
o
C for 60 seconds. Nucleic acids of different lengths melt at 
different temperatures. The dissociation curves of a reaction in which a single product was 
amplified will show a single clean peak. If additional products or primer-dimers are formed, 
the curve will contain multiple peaks. Dissociation curve analysis with a thermal profile of 1 
minute at 95
o
C, 30 seconds at 55
o
C, and 30 seconds at 95
o
C was performed at the end of PCR 
thermocycling.   
4.2.6.2 Analysis 
Normalisation of target gene expression to endogenous controls is advantageous as the 
reference genes and target genes are exposed to identical preparation conditions. This accounts 
for differences in template amount and quality between samples caused by differences in RNA 
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extraction, RT reaction efficiency (Radonic et al., 2004) cell number, and experimental 
treatment (Schmittgen & Zakrajsek, 2000). Though many papers have been published using a 
single reference gene, the use of multiple reference genes for each assay is preferable (Bustin, 
2002; Radonic et al., 2004).  Ideally reference genes are expressed at similar levels to the target 
gene, and are not influenced by the experimental treatment. YWHAZ and TBP were used as 
reference genes for assays measuring changes in GRK5 expression.  
 
The baseline fluorescence, Ct values, and dissociation curves for each reaction were 
automatically determined by the Stratagene Mx3005P qRT-PCR software. The Ct values were 
used to determine the expression levels of GRK5, TBP, and YWHAZ in each sample. The 
dissociation curves were examined for the presence of additional products and primer dimers.  
 
REST© 2009 software (Pfaffl et al., 2002) was used to calculate the relative expression level 
of GRK5 across samples, using the expression of TBP and YWHAZ as endogenous controls. 
The Ct values of both the target gene and reference genes were adjusted using the calculated 
efficiencies of their primer sets, as determined from their standard curves (Section 4.3.2.5.2). 
Statistical analysis of the calculated changes in gene expression was also performed as part of 
the REST© 2009 software analysis. The statistical significance of detected changes in the 
expression of each gene between the control and test samples was determined using a 
hypothesis test, and expressed as a p value. 
4.3 DEVELOPMENT OF QRT-PCR PROTOCOL 
4.3.1 Materials and solutions 
For the sources of all materials used in this chapter, refer to Appendix A. For the details of all 
solutions used in this chapter, refer to Appendix B.   
4.3.2 Methods 
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4.3.2.1 Template generation 
To prevent unnecessary template variability during qPCR protocol development, RNA and 
cDNA were produced in large quantities for use in primer analysis experiments. 
4.3.2.1.1 RNA Extraction for qPCR protocol optimisation 
The standard RNA extraction protocol described in Section 4.2.4 was followed, with the 
following exceptions: 
i) HEK293 cells were plated at 60,000 cells/well in 9 wells of a 24-well culture plate, ii) RNA 
was harvested when the cells had reached 80-100% confluence, iii) following resuspension of 
the cells in TRIzol
®
, the contents of three wells were pooled into a single 1.7mL microfuge 
tube, iv) the aqueous phase from each of the 3 tubes was individually combined with an equal 
volume of 70% alcohol, and the resulting mixtures were loaded onto a single Spin Cartridge, 
and eluted in 30µL of NPH2O. The RNA yield from two such preparations ranged from 0.557 
to 1.0576 µg/µL.  
4.3.2.1.2 Reverse Transcriptase Reaction for qPCR development 
The standard RT protocol found in Section 4.2.5 was followed with the following exceptions: 
i) 3µg RNA (RNA extraction described in Section 4.3.2.1.1) was used as the template for the 
RT reaction, and ii) after reaction termination, the sample was collected by brief centrifugation 
and 130µL of RNase-free water was added, giving a total volume of 150µL and a 
concentration of 20ng cDNA per µL (based on RNA input). 
4.3.2.2 Selection of candidate primer sets 
DNA polymerases require an existing 3‘ end to synthesise DNA (Watson et al., 2004). PCR 
techniques make use of synthetic primers to ‗prime‘ polymerisation and select the section of 
template to be amplified. Primers are short (~20bp) stretches of single stranded DNA which 
hybridise by Watson-Crick base pairing to their target within the template cDNA in a 
sequence-dependant manner. This provides the 3‘ ends required for DNA polymerase-mediated 
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DNA synthesis (van Pelt-Verkuli et al., 2008). The primers are effectively consumed by the 
PCR as they are extended into the PCR products. 
4.3.2.2.1 Primer sets for amplification of GRK5 
Numerous primers pairs for GRK5 have been published in the literature for use in both end-
product and quantitative PCR.  Nine published primer pairs for GRK5 taken from the literature 
were screened for complementarity to the human GRK5 mRNA sequence using the NCBI 
BLAST nucleotide alignment engine (http://blast.ncbi.nlm.nih.gov/Blast.cg). Of these, three 
pairs (designated here as GRK5 RTP, GRK5 ZhC, and GRK5 Vgt) were shown to have 
sequence complementarity, and were selected for further assessment, along with 3 sets of PCR 
primer pairs for human GRK5 previously designed in this laboratory (designated GRK5 MG, 
MG1 &MG2) by Michelle Gatehouse (Gatehouse, 2008), and 3 primer pairs (designated 
GRK5 PB1-3) from the Harvard Primerbank (http://pga.mgh.harvard.edu/cgi-
bin/primerbank/search.cgi) (Spandidos et al., 2010). Details for each GRK5 primer set tested 
are shown in Table 4.3. The alignment of the selected primer sets with the GRK5 cDNA 
sequence is shown in Appendix C.  
4.3.2.2.2 Primer sets for amplification of reference genes 
Primer pairs for 11 reference genes were selected for in silico assessment, upon 
recommendation from Dr Aaron Jeffs (Department of Pathology, University of Otago). The 
primer pairs tested were for; β-Actin (ACTB) (Metaye et al., 2002), TBP (Dallol et al., 2002), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase 
(HMBS), hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1), 60S ribosomal protein 
LI3a (RPLI3A), succinate dehyrogenase complex (subunit A, SDHA), ubiquitin C (UBC) and 
YWHAZ (Vandesompele et al., 2002), guanine nucleotide-binding protein subunit beta-2-like-
1 (GNB2L1) (Jeffs et al., 2009), and peptidyl isomerase B (PPIB) (Prof. M. Eccles, 
Department of Pathology, University of Otago: unpublished). Primer details for candidate 
reference genes are shown in Table 4.4 
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4.3.2.3 In silico assessment of candidate primer sets 
The mRNA sequences for GRK5, ACTB, GAPDH, HMBS, HPRT1, PPIB, RPL13A, SDHA, 
TBP, UBC, and YWHAZ were retrieved from the Genebank data base 
(www.ncbi.nlm.nih.gov). Reference gene NCBI accession numbers are shown in Table 4.4.  
The NCBI accession number for GRK5 is NM_005308.2. 
4.3.2.3.1 Primer specificity 
The use of specific primer sets is important for accurate quantitative PCR. If primers have poor 
specificity, i.e. the sequence targeted by the primer is not unique to the target gene, they may 
also prime the amplification of off-target sequences. To determine the specificity of each 
primer pair for its target sequence, the BLAST search engine 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to predict off-target interactions, by 
searching each pair against the mRNA sequence of their template gene and the NCBI human 
transcript reference sequence database (organism limited to Homo sapiens). Expect (E) values 
were generated by the BLAST search engine, and indicated the likelihood of interactions 
occurring simply by chance. The larger the E value, the lower the likelihood that the interaction 
will occur. Primers with off-target reactions with E values <1 were eliminated. 
4.3.2.3.2 Secondary structure prediction  
Sequence complementarity within a primer, such as an inverse repeat, can lead to the formation 
of hairpins and homo-dimers, while sequence complementarity between F and R primers 
means there is potential for hetero-dimer formation. Secondary structures caused by strong 
interactions can impair the PCR amplification efficiency of the target transcript by i) 
sequestering reagents and primers from the available pool by out-competing the template for 
amplification (amplification of short-primer dimers is easier than amplification of the longer 
target sequences and therefore more favourable) (van Pelt-Verkuli et al., 2008), ii) causing 
inefficient hybridisation to the target sequence within the template (Nolan et al., 2006), and iii) 
producing a potentially significant contribution to the measured fluorescence by binding SYBR 
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green. Involvement of a primer‘s 3‘ terminus in a secondary structure increases the potential of 
the structure to interfere with specific amplification of the target sequence. 
 
Beacon Designer Free Edition software from Premier Biosoft International  
(http://www.premierbiosoft.com/index.html) was used to predict the propensity of each primer 
to form hairpins, and to homo- and hetero-dimerise.  The calculated Gibbs free energy (∆G) of 
a predicted secondary structure gives an indication of how likely it is to interfere with correct 
primer hybridisation during PCR, with low energies being less likely to interfere. Technical 
notes provided on the Premier Biosoft website 
(http://www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html) were used to guide 
analysis of in silico results.  For vetting the candidate primer sets, secondary structures with 
∆G values greater than those listed below were considered to be likely to interfere with the 
PCR reaction.;  -3 kcal/mol for internal hairpins, -2kcal/mol for 3‘ hairpins, -6kcal/mol internal 
homo-and hetero-dimers, and -5kcal/mol for dimers involving the 3‘ end. Full details of 
secondary structures predicted for each primer pair can be found in Appendix F. 
4.3.2.3.3 Primer and product characteristic prediction  
Ideal qPCR primers are typically approximately 20 base pairs in length and bind only to their 
target sequence. The presence of at least one guanine (G) or cytosine (C) residue at the 5‘ 
termini is known as a G/C clamp and is favourable for specific primer binding. Ideal primer 
sets have similar melting temperatures, and the annealing temperature for each primer should 
be within 5
o
C of its partner. Furthermore, primer pairs should have similar G/C contents, 
ideally between 40% and 60%. 
 
The melting temperature and GC content of each primer and the size of the product produced 
by each primer set was calculated using Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome). 5‘ G/C 
clamps were identified manually.  
 
Due to inter-run variation, reference gene analysis for each qPCR reaction must be done on the 
same plate as the target gene analysis. As such, primer sets for reference genes must be 
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compatible with the reaction conditions required by the target gene primer sets, namely the 
melt temperatures, annealing temperature and elongation times. Increasing the elongation time 
increases the likelihood of off-target amplification. Primer sets for reference genes were 
therefore also vetted on the basis of melting and annealing temperature, and product size 
compatibility to the GRK5 targeting primer sets. 
 
Primer pairs for reference genes which produced a product more than 35bp shorter or longer 
than the predicted product produced by the selected GRK5 primers (see Section 4.3.4.3) were 
deemed to be incompatible with the GRK5 primers. Reference gene primer pairs with melt 
temperatures more than 5
o
C higher or lower that the selected GRK5 primers were also 
excluded. The compatibility of reference gene annealing temperatures with the selected GRK5 
primer sets was assessed experimentally in Section 4.3.2.4. Predicted characteristics for each 
pair of candidate primers and their products can be found in Appendix F. 
4.3.2.3.4 Results of in silico assessment 
In silico assessment of GRK5 primer pairs identified six sets that fulfilled the selection criteria. 
These were GRK5 MG1, GRK5 MG2, GRK5 PB1, GRK5 PB2, GRK5 RTP, GRK5 Vgt. Of 
these, two were selected for further assessment based on the similarity of their product lengths, 
as they could be used with the same contingent of reference gene primers.  The selected sets 
were; GRK5 RTP (product length 103bp) and GRK5 PB2 (product length 111bp). 
 
In silico assessment of the reference gene primer pairs identified six sets suitable for further 
analysis. They were; GADPH (product length 87bp), GNB2L1 (product length 138bp), HPRT1 
(product length 94bp), PPIB (product length 106bp), SDHA (product length 86bp), and 
YWHAZ (product length 94bp). A seventh reference gene, TBP (product length 132bp), did 
not quite meet selection criteria due to the predicted formation of a 3‘ homo-dimer with a 
calculated ∆G of -5.3 kcal/mol, which was 0.3 kcal/mol higher than the cut off point used for 
vetting. Due to the slimness of this margin, and the unknown effect of reaction conditions on 
the formation of secondary structures, TBP was also selected for experimental testing. 
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4.3.2.4 PCR-based Primer Testing 
PCR assessment of the primers was undertaken as it is a simple and cost-effective way to gain 
information about the way primers perform under reaction conditions. To assess the 
performance of each primer set, its products were examined by electrophoretic separation. 
Separation of products from primer sets which bound specifically to their target sequence, and 
did not form significant secondary structures would produce gels containing a single band at 
the expected molecular weight. The presence of additional bands would be evidence for the 
occurrence of off-target binding and secondary structure formation. PCR assessment was also 
used to gain an understanding of the approximate expression levels of GRK5 and the reference 
genes, as for accurate qPCR it is preferable for the expression levels of the reference and target 
genes to be similar so that the resulting CV values are similar. The annealing temperature used 
for PCR can affect the specificity of the amplification. Higher annealing temperatures result in 
more specific amplification, as only primers with high sequence homology with the template 
(and thus the maximum number of Watson-Crick hydrogen bonds) can anneal. As such, an 
annealing temperature gradient was performed for all primer sets, to indicate the specificity of 
their amplification over a range of temperatures. 
 
The performance of the primer pairs was examined over a range of annealing temperatures, to 
a) determine the minimum appropriate annealing temperature for GRK5 primer sets, and b) 
identify reference gene primers that were compatible with these conditions.  
4.3.2.4.1 PCR methods 
PCR reactions were performed using KAPATaq Ready Mix DNA Polymerase from 
KapaBiosystems, and an Eppendorf Mastercycler ep gradient S PCR machine. The 20µL 
reactions were performed in singlet, the details of which are shown in Table 4.5. ‗Water‘ and 
‗no-template‘ controls were run for each primer set. The ‗water‘ controls were included to 
detect potential nucleic acid contamination of the PCR buffer and nuclease-free ddH2O, while 
the ‗no-template‘ controls controlled for the presence of primer-dimers as their formation is 
more favourable in the absence of template. 
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Reaction Type 
Reagent Test Water control No template control 
2X KAPATaq Ready Mix DNA Polymerase 10µL 10µL 10µL 
cDNA (20ng/µL) 1µL 0µL 0µL 
Forward primer 0.5µL 0µL 0.5µL 
Reverse primer 0.5µL 0µL 0.5µL 
Nuclease-free ddH2O 8µL 10µL 9µL 
Table 4.5 Reaction components and volumes for PCR assessment of candidate primer sets 
 
 
The final concentrations of KAPATaq Ready Mix DNA Polymerase components for all 
reactions were; 0.025 U/µL Taq, 1X buffer, and 0.2mM dNTPs. The final concentrations both 
the forward and reverse primers in the ‗test‘ and ‗No template control‘ reactions was 250nM.  
 
The following thermal profile was used for PCR. An initial denaturation at 95
o
C for 2 minutes 
was followed by 30 cycles of; denaturation at 95
o
C for 30 seconds, annealing for 30 seconds, 
and extension at 72
o
C for 15 seconds. A final extension of 1 minute was performed at 72
o
C. 
The annealing temperature was varied across the heat plate. Test wells for each primer set were 
run at 48
o
C, 50.7
o
C, 53
o
C, 54.8
o
C and 55.8
o
C. As the annealing temperature decreases, the 
potential for primers to anneal non-specifically increases. For this reason, the annealing 
temperature used for the ‗Water‘ and ‗No-Template‘ controls was 47.3oC. The lid was heated 
to 105
o
C to avoid sample evaporation. 
 
The PCR products from the ‗test‘ and ‗control‘ reactions were separated on 1.5% agarose gels 
containing 0.01% SYBRsafe dye (Invitrogen), at 250 volts for approximately 25 minutes. 
DNA bands were visualised by UV transillumination using the ChemiGenius
2
 CCD Imaging 
System (Syngene), and photographed using GeneSnap software (Syngene).  
4.3.2.4.2 Results  
The results for all primer sets are shown in Figure 4.1. 
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4.3.2.4.2.1 Secondary structure formation  
The presence of bands in the ‗no-template‘ controls at <100bp indicates the formation of 
primer dimers or other secondary structures. These bands were also present at varying 
intensities in the ‗test‘ PCR products from some primer sets, indicating that primer secondary 
structure was occurring (Figure 4.1). A band indicative of secondary structure was seen for the 
following primer pairs; SDHA, GAPDH, GRK5 (RTP), HPRT1, PPIB and GNB2L1. The 
intensity of this band differed between primer sets. A dark band was seen with GADPH, 
SDHA and PPIB, suggesting extensive secondary structure formation. In comparison, the 
<100bp bands for GRK5 (RTP), HPRT1 and GNB2L1 were faint. The ‗no-template‘ control 
was important for informed analysis as the bands seen in these controls would otherwise be 
indistinguishable from off-target products. 
4.3.2.4.2.2 Specificity  
In the lanes in which the ‗test‘ products were run, the presence of additional bands that were 
not also found in the ‗no-template‘ control would indicate the presence of additional products, 
likely caused by off-target binding. However, a single product of the expected size was seen 
for all primer sets over all annealing temperatures assayed. The ‗water‘ controls did not contain 
any bands, indicating that cross-contamination of reagents had not occurred during set up 
(Figure 4.1). 
4.3.2.4.2.3 Band intensity 
The intensity of the bands produced was used to give an approximate indication of the relative 
expression levels for the target gene of each primer set. The range of band intensities detected 
was large, with the following order; GADPH > GNB2L1 > PPIB > SDHA > HPRT1 > TBP > 
GRK5 (PB2) > GRK5 (RTP). 
Several primer sets showed an increase in band intensity with an increase in annealing 
temperature. This may be due to increased activity of the thermophillic polymerase, and 
suggests that there is the potential for using higher annealing temperatures to increase product 
formation. 
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4.3.2.4.3 Primer selection for qPCR assessment 
Based on assessment of their PCR products, both sets of primers for GRK5 amplification 
(GRK5 RTP, and GRK5 PB2) were chosen for qPCR analysis, as they i) showed no evidence 
of off-target binding, and  ii) showed minimal or no evidence of secondary structure formation.  
 
Primer sets for four reference genes were also selected for qPCR-based analysis. They were: 
GNB2L1, HPRT1, TBP, and YWHAZ. They were selected as their expression levels were the 
most similar to that of GRK5, they showed no evidence of off-target binding, and they showed 
the lowest levels of primer-dimer formation. 
 
The low levels of primer secondary structure formation seen when the GRK5 (RTP), HPRT1 
and GNB2L1 primer sets were used was not considered grounds for exclusion as the 
composition of the reaction buffer—such as Mg2+ concentration—can affect secondary 
structure formation.  
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4.3.2.5 qPCR assessment 
The template used for qPCR assessment was generated using the protocol described in Section 
4.3.2.1. All qPCR reactions were performed using SYBR
®
 GreenER qPCR SuperMix 
Universal from Invitrogen, and a Stratagene Mx3005P qPCR machine. 
4.3.2.5.1 Primer Test and Selection of Assay Details 
4.3.2.5.1.1 qPCR assay details 
The compatibility of the primers with the standard qPCR protocol provided by Invitrogen for 
use with the SYBR
®
 GreenER qPCR SuperMix Universal reagent 
(http://tools.invitrogen.com/content/sfs/manuals/sybrgreener_supermix_uni_man.pdf) was 
tested prior to commencement of protocol optimisation. For this trial, each primer set was 
tested in singlet, with a reaction volume of 20µL. Each reaction contained: 10µL SYBR
®
 
GreenER qPCR SuperMix Universal, 200nM of both the F and R primers, 5ng of template 
cDNA, and sufficient NPH2O to bring the volume to 20µL.   
 
qPCR was performed using the PCR thermal profile and melt curve described in the standard 
methods (Section 4.2.6). The melt curve analysis was used to determine if primer-based 
secondary structures were being formed. These structures are generally seen as peaks around 
75
o
C. 
4.3.2.5.1.2 Results  
Amplification and dissociation curves for all primers tested are shown in Figure 4.2. As 
evidenced by the dissociation curves, each primer pair produced a single peak indicating a 
single product. Primer-dimers were not detected for any primer sets. The amplification curve 
for both GRK5 primers, and the primers for reference genes GNB2L1, TBP, and YWHAZ, 
have the classical curved shape typical of qPCR reactions (Bustin, 2004). The amplification 
curve for HPRT1 however does not conform to this shape, showing a slow and almost linear  
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increase in fluorescence between cycles 23.6 and 40. This atypical amplification curve 
indicates the PCR reaction is proceeding with poor efficiency. The primers for HPRT1 were 
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not analysed further. The remaining primers appeared to be compatible with the thermal profile 
of the standard assay, and as such, the profile was not altered. 
 
The intensity of the bands seen during PCR assessment of the primers (Section 4.3.2.4) 
suggested that the primer sets may be compatible with annealing temperatures higher than the 
55.8
o
C, which was the highest temperature used for that assessment. This was confirmed by the 
successful priming seen during qPCR assessment, when 60
o
C was used as the annealing 
temperature. 
 
The Ct values produced by both GRK5 primers were extremely similar. This is the expected 
results, as they are measuring the expression of the same gene. The difference in the Tm of their 
respective products is indicative of their different amplicons. 
4.3.2.5.2 Determination of primer set amplification efficiencies 
As PCR is an exponential reaction, small differences in primer set amplification efficiencies 
can result in Ct values that are not truly representative of the relative concentrations of their 
targets in the template. If the amplification efficiency for each primer set is determined, the Ct 
values can be mathematically adjusted to compensate for this, allowing more accurate 
interpretation of the results. The amplification efficiency of a qPCR reaction can be determined 
by diluting the template to produce a standard curve. The relationship between the Ct value 
intervals and the dilution factor is shown by the slope of the standard curve, and is used to 
determine the efficiency of amplification.  
4.3.2.5.2.1 Standard curve generation 
The amplification efficiencies of the remaining primer sets (GRK5 RTP, GRK5 PB2, TBP, 
YWHAZ and GNB2L1) were determined by analysis of qPCR performed over five dilutions of 
the template. The template cDNA was diluted in nuclease-free NPH2O to the following 
amounts per reaction: 20ng, 10ng, 4ng, 2ng, and 0.4ng. Primers for GRK5 and YWHAZ were 
used at a concentration of 200nM, while primers for TBP were used at a concentration of 
300nM. All reactions were performed in duplicate. The qPCR and melt curve thermal profiles 
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described in Section 4.2.6 were used. Standard curves were generated automatically by the 
Stratagene MxP3005™ software, by plotting the Ct values against the initial template quantity.  
4.3.2.5.2.2 Determination of amplification efficiencies 
Data points which showed reaction inhibition or the production of unwanted 
products/secondary structures were excluded from generation of the standard curve as these 
occurrences would impair the amplification efficiency, and would not be considered acceptable 
in qPCR assay data.  
 
The amplification efficiency of each primer set was determined from the slope of standard 
curve by the Mx3005P™ software. The following equation was used: 
 
Equation 4.1  Amplification efficiency = [10
(1-slope)
]-1 
 
A reaction with 100% efficiency correlates to a slope of -3.322. The ‗goodness-of-fit‘ of the 
standard curve to the data is indicated by the R squared (R
2
) value. A value of 1 indicates a 
perfect fit.    
4.3.2.5.2.3 Results 
Examination of the amplification curves for GRK5 (RTP), GRK5 (PB2), GN2BL1, and 
YWHAZ showed that the curves were deviating from the ideal shape in reactions containing 
20ng and 10ng of template (see Appendix D). This deviation was likely due to inhibition of the 
PCR reaction by something present in the template solution, possibly carried over from RNA 
extraction or the RT reaction (Nolan et al., 2006). Exclusion of these points from the standard 
curves altered the calculated efficiencies of the primer curves. The three remaining points were 
considered to be sufficient to generate the standard curves. The resulting standard curves, and 
their calculated efficiencies and R
2
 values are shown in Figure 4.3. Lower concentrations of 
template were not trialled, as the Ct values produced by the GRK5 primer set were already 
high. Ideally, Ct values fall between 10 and 30 cycles.  
 
- 95 - 
 
The standard curve for TBP was generated at a later date, and as such a different template was 
used. Examination of the amplification curves showed evidence of inhibition in reactions 
containing 20ng of template, and as such these data were excluded (See Appendix D). One of 
the reactions containing 0.4ng template had an unusual amplification curve. Examination of the 
dissociation curve for this reaction showed the presence of a second product (see Appendix D). 
This reaction was excluded, but since its replicate was unaffected it was used. The remaining 
data points were used to generate the standard curve. As above, the standard curve, 
amplification efficiency, and R
2
 value for TBP are shown in Figure 4.3. 
 
Ideally, primer sets should have an amplification efficiency between 90% and 110%. At 87.2% 
the primer efficiency for YWHAZ is slightly outside this range. However, as the calculations 
used to analyse the qPCR data (see Section 4.2.6.2) correct for the amplification efficiencies of 
both the target and reference gene, it was considered to be acceptable. 
  
For the calculated amplification efficiencies of each primer set to be used accurately, the qPCR 
assay reactions need to contain a template concentration that is within the range used to 
generate the standard curves, i.e. between 0.4-4μg for YWHAZ and GRK5, and between 0.4-
10μg for TBP. For this reason, 3µg of template was selected as an appropriate starting template 
quantity for use in qPCR assays. 
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4.3.2.6 Final primer selection and cloning 
The qPCR products generated by the GRK5 (RTP), TBP and YWHAZ primer sets were 
sequenced to confirm the identity of their amplicons. Due to their short length (~100bp), the 
PCR products had to be legated into an expression vector and cloned to facilitate sequencing. 
This process exploits the fact that Taq polymerase adds an additional adenosine to the 3‘ end of 
both strands of its products. This allows the products to be easily inserted into vectors with T 
overhangs, such as the poem
®
-T Vector system used below. Primer sequencing can then be 
performed, using M13 primers which bind to the plasmid sequence on either side of the insert. 
4.3.2.6.1 Preparation of qPCR products for ligation 
Initial attempts to legate the qPCR products into the pGEM
®
-T Vector were unsuccessful. It 
was thought that the carryover of reagents from previous applications, such as qPCR, may have 
been inhibiting the ligation reaction. Typically products are cleaned and concentrated on 
column-based systems prior to ligation. However, such systems generally do not retain nucleic 
acids less than ~200bp long, making them incompatible with the qPCR products generated by 
the TBP (132bp), YWHAZ (94bp) and GRK5 (103bp) primer sets. Instead, the qPCR products 
were used as a template for a PCR reaction containing no dye, and the products of this reaction 
were used for ligation. This limited the carryover of SYBR green from the qPCR reaction.  
4.3.2.6.1.1 PCR protocol  
Each 50µL reaction was performed in singlet, details of which are provided in Table 4.7. 
The following thermoprofile was used for amplification: 95
o
C for 2 minutes, followed by 30 
cycles of 95
o
C for 30 seconds, 60
o
C for 30 seconds, and 72
o
C for 15 seconds. A final extension 
of 1 minute was performed at 72
o
C.  
 
After PCR amplification, 10µL of each reaction was run on a 2% agarose gel containing 0.01% 
SYBR safe (Invitrogen), at 80V for 40 minutes to confirm successful amplification.  The 
remainder of each sample was used for ligation. 
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 Gene  
Reagent GRK5 YWHAZ TBP NTC 
Biotaq DNA polymerase (Bioline, 5U/µL) 0.5µL 0.5µL 0.5µL 0.5µL 
50mM MgCl2 (Bioline) 3µL 3µL 3µL 3µL 
dNTPs 3µL 3µL 3µL 3µL 
10 X NH4 Reaction Buffer (Bioline) 5µL 5µL 5µL 5µL 
Appropriate qPCR product 1µL 1µL 1µL 0µL 
Forward primer 0.9µL 0.9µL 1.5µL 0.9-1.5µL 
Reverse primer 0.9µL 0.9µL 1.5µL 0.9-1.5µL 
Nuclease-free NPH2O 35.7µL 35.7µL 34.5µL 35.5-36.7µL 
Table 4.6 Reaction components for pre-ligation PCR of qRT-PCR products for sequencing 
4.3.2.6.1.2 PCR Results  
Agarose gel separation of an aliquot of the PCR products resulted in a band of the expected 
size for each primer set (Figure 4.4). A faint band <100bp was also seen for TBP and 
YWHAZ. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.4 Products from “clean up‟ PCR separated on a 2% agarose gel containing 
0.01% SYBR safe. A= template, B= no template control. All produced products of 
the expected size. For GRK5 (left) a single clean band was seen, while TBP (middle) 
and YWHAZ (right) produced a second band <100bp in size which represent 
primer dimers 
100bp 
200bp 
YWHAZ TBP GRK5 
A B A B A B 
- 99 - 
 
4.3.2.6.2 TA Ligation  
The following reagents were used to ligate the PCR products into a vector for cloning: the 
pGEM
®
-T Vector System (Promega, vector sequence available at www.promega.com/vectors), 
T4 DNA Ligase (Fermentas), and the 10X T4 DNA Ligase Buffer (Fermentas). The pGEM
®
-T 
Vector is an expression vector containing the lacZ gene and an ampicillin resistance gene. A 
multiple cloning site (MCS), at which foreign DNA such as qPCR products are inserted during 
ligation, is located within the lacZ gene. Transcription of the lacZ gene results in the 
production of the LacZ protein, also known as β-galactosidase, whose normal activity is to 
catalyse the conversion of lactose into galactose and sugar. Ligation of foreign DNA, such as a 
PCR product, into the vector results in the disruption of the lacZ gene, and thus inhibition of  
β-galactosidase production. 
  
A ligation reaction was set up for each primer pair. Ten microlitre reactions were used. The 
relative volumes of the ligation mixture components are shown in Table 4.7. The mixtures 
were incubated at 4
o
C overnight. 
 
Reagent Volume (µL) 
PCR product 3.5 
pGEM
®
-T Vector System 0.5 
T4 DNA Ligase (1000CEU/µL) 1 
Ligation Buffer 5 
        Table 4.7 Ligation reaction components and their volumes 
4.3.2.6.3 Transformation of competent cells with ligated vector 
The ligated pGEM
®
-T vectors generated in Section 4.3.2.6.2 were used to transform competent 
DH5α E. Coli cells. This step results in the amplification of the vector, and allows the vectors 
containing an insert to be identified via blue/white colony selection.  
4.3.2.6.3.1 Transformation 
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The DH5α cells were thawed on ice before use. Five microlitres of each ligated vector was 
added to a 1.7ml microtube containing 50µL of competent cells (one tube per vector). The 
cell/ligate mixtures were ‗heat shocked‘ using the following thermoprofile; 10 minutes on ice, 
followed by 1.5 minutes at 37
o
C, and 2 minutes on ice. Two-hundred microlitres of Luria broth 
was then added to each tube, and the contents mixed by gentle tapping. The tubes were 
incubated for 30 minutes at 37
o
C before plating. 
4.3.2.6.3.2 Plating 
Immediately prior to plating, 100mm Luria plates (+10% ampicillin) were prepared by adding 
10µL of isopropyl-[β]-D-thiogalactopyranoside (IPTG) (Fermentas) and 50µL of X-Gal (5-
bromo-4-chloro-3-indolyl-[β]-D-galactopyranoside) (Zymo Research) to the surface of the 
media. The DH5α cells/ligation mix was then added to the plate, and the solutions spread with 
a flamed glass rod. The plates were sealed and incubated overnight at 37
o
C.  
4.3.2.6.4 Blue/white colony selection, generation of stab plates, and insert screening 
The presence of ampicillin in the growth medium selected for DH5α cells which had been 
transformed, and thus gained the gene for ampicillin-resistance carried on the vector. Inclusion 
of IPTG, the activator for lacZ gene transcription, in the culture allowed DH5α cells 
transformed with the pGEM
®
-T Vector to express β-galactosidase. Blue/white colony selection 
was used to identify cells transformed with the pGEM
®
-T+PCR product vectors. Cells 
transformed with pGEM
®
-T vectors lacking a PCR product insert produce functional β-
galactosidase which converts the colourless modified galactose sugar known as X-GAL into a 
bright blue product, resulting in blue colonies. In cells transformed by pGEM
®
-T+PCR product 
vectors, the expression of functional β-galactosidase was prevented by the insertion of the PCR 
product, resulting in white colonies.  
 
Due to the small size of the PCR product inserts, in practise the phenotype expressed by 
pGEM
®
-T+PCR product vector transformed cells ranged from pale blue to white. The size of 
the insert for each selected colony was screened via PCR, using M13 F/R primers to amplify 
the inserts and vector sequences on either side. 
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Pale blue/white colonies were picked from the plate using a yellow pipette tip and ‗stabbed‘ on 
to a 100mm Luria plate (+10% ampicillin) marked with a numbered grid. The pipette tip was 
then used to introduce the sequence into a 0.2mL PCR tube containing 10µL 2x KAPA Taq 
Readymix, 0.5µL of M13 F/R primer mix, and 9.5µL of ddH2O. Four pale blue/white colonies 
were picked for each vector, resulting in the following colonies on the stab plate; T1-4, Y1-4, 
and G1-4. The PCR was run using the following thermoprofile: 2 minutes at 94
o
C, followed by 
25 cycles of; 2 minutes at 94
o
C, 30 seconds at 52
o
C, and 30 seconds at 72
o
C. This was 
followed by a final 1 minute and 30 seconds at 72
o
C. The PCR products were run on a 2% 
agarose gel containing 0.1% SYBR Safe for ~30minutes at 80V (Figure 4.5). 
 
Figure 4.5 M13 PCR screen showing the insert present in each culture. GRK5 colonies G1-4 produced a 
bad of the same size., however both TBP and YWHAZ colonies contained inserts of two different sizes. One 
of each size was selected for sequencing (T2 and T3, Y3 and Y4), along with G1 and G2. 
 
All four clones generated using the GRK5 PCR product-ligated vector (G1-4) produced insert 
bands of the same size (Figure 4.5). Both the TBP and YWHAZ clones produced inserts of two 
different sizes. A clone representing each insert size for TBP (T2 and T3) and YWHAZ (Y3 
And Y4) was selected for sequencing, along with two GRK5 PCR product-ligated vector 
transformed clones (G1 and G2). The clones were prepared for sequencing as described below. 
4.3.2.6.5 Plasmid preparations 
Plasmid preparations were generated for the clones selected based on the PCR insert screen. 
The stab-plate colonies were used. The colonies corresponding to T2, T3, Y3, Y4, G1 and G2 
were ‗picked‘ using a yellow pipette tip and each was used to seed ~5mL of Luria broth (with 
0.1% ampicillin) in a labelled McCartney bottle. The bottles were incubated at 37
o
C overnight 
with agitation. 
TBP YWHAZ GRK5
T1   T2   T3   T4 Y1   Y2   Y3   Y4 G1   G2   G3   G4
300bp
100bp
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4.3.2.6.6 DNA extraction 
The DNA was extracted for sequencing using an ‗Isolate Plasmid Mini Kit‘ from Bioline (Cat 
# BIO-52027). For each sample, 2mL of plasmid preparation was transferred to two 2mL 
centrifuge tubes (total of 4mL plasmid prep). The tubes were spun at the maximum centrifuge 
speed for 2 minutes. The supernatant was discarded from both tubes. To resuspend the pellets, 
250µL of resuspension buffer was added to one tube, and the tube tapped until the pellet was 
fully resuspended. The cell suspension was then transferred to the second tube, and the tube 
tapped until the pellet was resuspended. The first tube was discarded. Two hundred and fifty 
microlitres of Lysis Buffer P was added to the cell suspension, and the two solutions mixed by 
inverting the tube 5 times. This was followed by the addition of 350µL of Neutralisation 
buffer. The contents of the tube were mixed by inverting the tube 5 times. The tube was then 
spun at maximum centrifuge speed for 10 minutes to pellet the cellular debris. The supernatant 
was transferred to a labelled Spin Column P placed in a collection tube. The column was spun 
at 10,000 x g for 1 minute, and the filtrate discarded. The column was washed with 500µL of 
Wash Buffer AP and 700µL of Wash buffer BP, spinning the column at 10,000 x g for 1 
minute and discarding the filtrate after each addition. The column was then spun at maximum 
centrifuge speed for 2 minutes to remove all traces of the wash buffered. The Spin column was 
transferred to a labelled elution tube, while the collection tube and filtrate were discarded. Fifty 
microlitres of elution buffer was added directly to the column matrix and incubated at room 
temperature for 2 minutes. The column was then spun at 10,000 x g for 1 minute to elute the 
DNA. The DNA concentration of the samples was then determined using a ND1000 NanoDrop 
spectrophotometer, using Elution buffer as a blank. Concentrations ranged from 130.7 to 
256.9ng DNA per µL. 
4.3.2.6.7 Sequencing 
The inserts were sequenced by Macrogen Inc. (http://dna.macrogen.com/eng/) using 
ABI3730xl DNA Analyzer (Applied Biosciences) sequencing machines. The resulting 
sequences were supplied as FASTA files and were searched against the NCBI human transcript 
reference database (limited to Homo sapiens) using the BLAST search engine. The TBP, 
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YWHAZ and GRK5 (RTP) primer sets were aligned with their products using MEGA 5.0 
software. 
4.3.2.6.7.1 Results 
The sequence of each insert (with primers aligned) is shown in Appendix E. 
 
Both inserts generated from the GRK5 (RTP) primer qPCR products (G1 and G2) were of the 
expected size (103bp) and had a sequence identical to that of the predicted product.  
 
The sequences for the ‗T2‘ and ‗T3‘ inserts generated from the TBP primer qPCR products 
were not identical. The ‗T3‘ insert was consistent in size (132bp) and sequence with the 
predicted product. The ‗T2‘ insert however, was only 52bp long, and its sequence consisted of 
a combination of the forward and reverse primer sequences, identifying the insert as a primer-
dimer. Similarly the inserts generated from the YWHAZ primer qPCR products contained two 
different products. One, the ‗Y3‘ insert was consistent in sequence and length (94bp) with the 
expected product. The ‗Y4‘ insert however was short (43bp) and represented the hetero-
dimerisation of the forward and reverse primer. 
4.3.2.6.7.2 Interpretation of sequencing results 
As both the sequenced inserts generated from the GRK5 (RTP) products were identical in 
sequence to the target amplicon, the GRK5 (RTP) primer set was deemed to be fit for use.  
Both YWHAZ and TBP products produced one insert that corresponded to the target amplicon, 
and a second insert that corresponded to a primer-dimer. This suggests that these primers are 
not suitable for use with the reaction conditions described in Section 4.2. However, due to the 
‗clean up‘ PCR reaction run to prepare the qPCR products for ligation, it is unclear whether the 
primer-dimers sequenced for YWHAZ and TBP were present in the qPCR products, or if they 
were introduced during the PCR. Examination of the gel run after the PCR (Figure 4.4) and the 
melt curves produced by the qPCR products (Figure 4.6) suggested that the primer-dimers 
were introduced during the PCR step, as there is no evidence of primer-dimer formation of the 
qPCR product melt curves.  
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4.3.3 Conclusions and future work 
The sequencing results identified the presence of primer-dimers in the TBP and YWHAZ 
qPCR/PCR products used for the ligation. As an additional PCR step using the primers was 
required to prepare the qPCR products for sequencing, it is unclear whether these primer-
dimers are products from the qPCR or if they were introduced by the PCR step used to remove 
the fluorescent dye. While no evidence of primer dimers was seen in the melt curves associated 
with the qPCR products, further optimisation of the qPCR protocol described in Section 4.2 
may be necessary to ensure that the qPCR results are accurate.  
 
Increasing the annealing temperature from 60 to 61
o
C should represent an increase in reaction 
stringency sufficient to eliminate potential primer-dimer formation. This proposed increase in 
stringency should be reflected in the resulting melt curves, in particular, as a decrease in the 
width of the recorded peak when compared with that recorded using an annealing temperature 
of 60
o
C. As qPCR assays for GRK5 need to be run on the same plate as the reference genes, 
the GRK5 primer set will also need to be tested for complimentarity with the increased 
annealing temperature. The amplification efficiency for all three primer sets would then need 
to be re-calculated; using standard curves generated using the more stringent thermoprofile. 
 
Figure 4.6 Melt curves for the YWHAZ (green), TBP (red) and GRK RTP 
(blue) qRT-PCR products used as a template for sequencing.  
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Unfortunately, the Stratagene qPCR machine used in this study was damaged in the magnitude 
6.3 earthquake which occurred in Canterbury on the 22 of February 2011. The machine was 
not available for use for the remainder of the project. This prevented the final optimisation 
steps from being completed. qPCR data generated before sequencing of the qPCR products 
was considered to be indicative of the relative gene expression, and is presented in Chapter 5. 
However, these data will need to be confirmed by reanalysis of the cDNA using a qPCR 
protocol which incorporates the proposed changes. 
- 106 - 
 
5 
DEVELOPMENT OF A PROTOCOL FOR RNA INTERFERENCE-
INDUCED KNOCKDOWN OF GRK5 EXPRESSION IN HEK293 
CELLS  
5.1 INTRODUCTION  
The original aim of this research was examine the role of GRK5 in desensitisation of the V1bR 
to AVP, having first established the methods to achieve this. Over-expression studies have 
previously been used to investigate the role of GRKs in cell signalling (for example Gaudreau 
et al., 2002; Menard et al., 1996). This involves transfecting intact cells with homologous 
cDNA to induce the expression of the protein of interest at a level dramatically higher than 
seen endogenously. However over-expression of a protein can result in artefactual protein-
protein interactions that do not occur when the target protein is expressed at endogenous levels. 
This is particularly problematic when dealing with proteins such as GRKs which have a degree 
of functional redundancy, and as a consequence can act in a compensatory manner under such 
conditions (Violin et al., 2006). Furthermore the presence of both endogenously expressed and 
transfected GRKs can complicate the interpretation of results. A more physiologically relevant 
approach is to determine the effect of removing the target protein from the system. There are a 
number of experimental approaches that can be used to selectively induce a loss-of-function 
effect, by a) reducing the activity of the target protein, or b) reducing its expression (Nature 
Cell Biology Editorial, 2003). 
 
Previous research in the Mason laboratory used pharmacological agents to investigate the role 
of various proteins and cellular processes in V1bR desensitisation, by measuring the effect on 
receptor responsiveness of altering their levels of activity (Hassan & Mason, 2005). 
- 107 - 
 
Historically heparin, Zn
2+
, and mastoparan have been used to inhibit GRK function. However 
all three have off-target effects which may affect GPCR signalling (Hasbi et al., 1998; 
Higashijima et al., 1988; Kobayashi et al., 1989). Recently, a new generation of GRK-targeted 
pharmacological inhibitors have been identified. Some are reported to be specific for GRK2 
(Hull et al., 2010; Iino et al., 2002; Thal et al., 2011), though the specificity testing performed 
has been largely limited to computer modelling and inhibitory tests against PKA. Short peptide 
GRK-inhibitors have also been developed (Winstel et al., 2005), and are highly selective for 
GRKs compared with PKA and PKC. They showed no inhibitory effect on the activity of these 
kinases when used at concentrations that were 100-fold higher than their Km values for GRKs. 
However these peptides were shown to have only modest selectivity between GRK isoforms 
(Winstel et al., 2005). As there are currently no GRK5-specific inhibitors available, an 
alternative approach was required for this research. 
 
There are a number of methods available with which protein knockdown, (i.e. reduced 
expression) or knockout (i.e. no expression) can be induced (Dykxhoorn & Lieberman, 2005). 
GRK5-knockout animals (generated using recombination techniques) have been used by others 
to investigate the role of GRK5 in vivo, by examining the behaviour, physiology, and/or tissues 
of GRK5-knockout animals compared with wild type animals (Fong et al., 2002; Gainetdinov 
et al., 1999; Li et al., 2009; Suo et al., 2007; Tarrant et al., 2008). Primary cell cultures can 
also be prepared from knockout animals, and compared to equivalent cultures from wild type 
animals, allowing the role of the protein in the signalling of a particular cell type to be 
examined (Tanoue et al., 2004). However, knockout mutants are time consuming and 
expensive to produce, and represent a complex system in which the knockdown of the target 
protein occurs in all tissues. 
 
Knockdown of GRKs has previously been achieved using specific antibodies (Dhami et al., 
2002), antisense oligonucleotides (Nagayama et al., 1996), and RNAi (Ren et al., 2005). RNAi 
is the preferred methodology for loss-of-function experiments as the development of the 
specific and effective interfering agent is relatively efficient (Nature Cell Biology Editorial, 
2003). RNAi is a homology-dependant silencing system found in all eukaryotes  (Agrawal et 
al., 2003) that can be exploited to induce post-transcriptional silencing of specific genes (Fire 
et al., 1998). The introduction or expression of small double stranded interfering RNAs 
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(siRNAs) homologous to the target gene mRNA sequence results in knockdown of the 
expression of that gene at the protein level, by guiding the destruction of its mRNA before 
translation occurs (Cullen, 2006). 
 
As RNAi-mediated knockdown is based on homology between nucleic acids, it can be targeted 
against a sequence unique to the target protein therefore giving it the potential to be more 
specific than pharmacological inhibitors. Furthermore, RNAi can be used in a simple system 
(such as an immortal cell line) with relative ease compared to the preparation of knockout 
animals (Agrawal et al., 2003). However, RNAi has its drawbacks with the potential for off-
target effects (Jackson et al., 2003), toxic phenotypes (Fedorov et al., 2006) and induction of 
the interferon-response (Bridge et al., 2003). Proper validation of the knockdown protocol can 
minimise these undesirable effects and is discussed in Section 5.3. 
 
Since its inception as a research tool, RNAi has been used extensively to investigate the 
function of GRKs and other components of GPCR-related signalling pathways (for example: 
Ahn et al., 2003; Chen et al., 2009; Kim et al., 2005; Premont et al., 1996; Rajagopal et al., 
2006; Ren et al., 2005; Shenoy et al., 2009; Violin et al., 2008; Zidar et al., 2009).  
5.1.1 Mechanism of RNA interference 
RNAi is thought to be an ancient antiviral immune response present in all known eukaryotes. 
The eukaryotic genome consists of double stranded DNA (dsDNA), of which one strand is 
transcribed to single stranded RNA and translated to protein. The partner strand acts as a ‗back 
up‘ copy, allowing the accurate repair of damage to the active strand (Wadhwa et al., 2004). 
Most RNA viruses induce the production of long dsRNA by a cell as part of their replication 
cycle. In the event of such a viral challenge, the production of long dsRNA triggers RNAi-
mediated degradation of RNA with sequence homology to the infecting duplex, resulting in the 
silencing of genes that may be harmful to the host organism (Cullen, 2006). In mammals it 
appears that RNAi has been replaced as the primary anti-viral defence mechanism by the 
interferon response, in which long dsRNA (among other stimuli) induce non-specific RNA 
degradation, global inhibition of translation, and finally apoptosis (Cullen, 2006; Dykxhoorn et 
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al., 2003). As such, experimental activation of the RNAi pathway with dsRNA longer than 30 
nucleotides (used with high efficiency in plants and invertebrates) has limited applicability for 
work in mammalian cells (Cullen, 2006; Dykxhoorn et al., 2003). Investigations into the 
mechanism of RNAi in Caenorhabditis elegans (Grishok et al., 2000) and Drosophila 
melanogaster (Elbashir et al., 2001; Hammond et al., 2000; Parrish et al., 2000; Yang et al., 
2000; Zamore et al., 2000) have demonstrated that enzymatic-cleavage of the long dsRNA into 
5‘ phosphorylated short interfering dsRNAs (siRNAs) by the RNase Dicer is required for 
homologous silencing, indicating that siRNA are the molecules which induce target 
knockdown.  
 
While there are several methods of RNAi delivery available (reviewed in Shim & Kwon, 
2010), transient transfection with synthetic siRNAs is the preferred method for inducing 
transient RNAi-mediated knockdown in mammalian cells, as siRNAs are less likely to induce 
the interferon response and they immediately initiate efficient and potent silencing (Dykxhoorn 
et al., 2003). For these reasons, transient transfection with synthetic siRNAs was the chosen 
method for this research. The mechanism of RNAi-mediated silencing induced by transfection 
of cells with synthetic siRNA is shown schematically in Figure 5.1 and described below.  
 
The short synthetic siRNAs are transfected into the cell with the aid of a liposomal carrier 
molecule. siRNAs initiate silencing of a gene via the ‗classical‘ mechanism of RNA as follows; 
once in the cytoplasm, the siRNA interacts with the RNA-induced silencing complex (RISC). 
This activates RISC which proceeds to unwind the sense and antisense strands of the siRNA. 
The sense strand dissociates, leaving the antisense strand bound to RISC. Here it acts as a 
guide, using base pairing to target RISC to mRNA with which it has sequence homology. 
RISC interacts directly with the mRNA, resulting in mRNA cleavage. 
  
The protocol used in this research to induce RNAi-mediated knockdown of GRK5 expression 
is provided in Section 5.2. The development and validation of this protocol is described in 
Section 5.3. 
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5.2 METHODS AND MATERIALS 
5.2.1 Materials 
For source information regarding materials referred to in this Chapter, refer to Appendix A. 
5.2.2 Solutions and media 
For details of the solutions and media referred to in this Chapter, refer to Appendix B. 
Figure 5.1 Mechanism of RNAi-induced degradation of target mRNA. Synthetic siRNAs are transfected into 
the cytoplasm leading to RISC assembly. RISC unwinds the siRNA duplex exposing the antisense sequence. 
This sequence then targets RISC to mRNA with which it has sequence homology, resulting in RISC-catalysed 
mRNA cleavage.  
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5.2.3 Handling of siRNA 
As nucleic acids, siRNA duplexes are susceptible to degradation by nucleases. To maintain 
nuclease-free conditions, the measures described in Section 4.2.3 were also taken when 
handling siRNA. The duplexes were used to transfect HEK293 cell cultures. For this reason all 
handling of the siRNA duplexes and associated buffers and media was performed in a Laminar 
flowhood or Biohazard containment hood, with sterile RNase-free consumables to ensure that 
sterility was maintained. 
5.2.4 siRNA details 
All siRNA were obtained from Dharmacon, and provided as 2‘hydroxyl, annealed, and 
desalted duplexes (see Table 5.1 for sequence and details). The sequence for the GRK5-
targeted siRNA was obtained from Ren et al, (2005) and custom manufactured. 
 
GRK5-Targeted siRNA 
Sequence 5’-GCCGUGCAAAGAACUCUUU-3’ 
Length 21bp 
Molecular Weight 13,300.2 g/mol 
Extinction coefficient 361,162 L/mol
.
com 
Table 5.1 GRK5-targeted siRNA duplex details 
5.2.5 Resuspension of siRNA 
Resuspension of the siRNA duplexes was performed according to the manufacturer‘s 
instructions. The duplexes were resuspended to give a 20µM stock solution using the following 
procedure. The tube containing the siRNA was spun briefly to collect the duplexes. 5X siRNA 
buffer (Dharmacon) was diluted 1X and the appropriate volume was added to the tube. The 
solution mixed by repipetting gently five times with a Gilson P1000 pipette. Care was taken 
not to introduce bubbles into the solution. The siRNA/buffer mix was incubated at room 
temperature for 30 minutes on an orbital shaker, set to 80+ rotations per minute. The tube was 
then spun briefly to collect the solution and a small aliquot taken to determine its concentration 
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using Nanodrop UV spectroscopy with 1X siRNA buffer was used as a blank. The A260nm 
was recorded and used to calculate the actual concentration of the duplex solution using the 
following equation; 
 
Equation 5.1 
     [(A260nm x 40) / MW] x 1000 = µM  
 
The solution was then aliquoted into 0.6mL microtubes, to avoid repeated freeze/thaws (which 
can damage the siRNA) and stored at -80
o
C. 
5.2.6 Plating and reverse transfection of HEK293 cells with siRNA duplexes  
Reverse transfection of HEK293 cells with GRK-targeted was performed at the time of plating. 
The transfection complex was prepared as a master mix (allowing for an additional 10% in 
volume), and was added to each well/plate immediately before addition of the cells. 
 
Cells destined for qRT-PCR analysis were plated into 24-well NUNC culture plates, with an n 
value of 2 wells per treatment at a density of 15,000 cells per cm
2
. Cells destined for Western 
blotting analysis were plated into 35mm-diameter culture dishes, with an n value of 1 dish per 
treatment at a density of 15,000 cells per cm
2
. The plating volumes used were 500µL per well 
of a 24-well plate, and 2.5mL per 35mm-diameter dish. Medium controls, consisting of MEM-, 
were run in all experiments. 
The relative timing of each part of the protocol is shown in Figure 5.2 
5.2.6.1 Preparation of medium controls, and dilution of siRNA 
This section of the protocol was performed immediately prior to passaging the cells.  
 
Medium controls were aliquoted as appropriate into the culture plates in the following 
volumes; 100µL per well of a 24-well plate, and 500µL per 35mm-diameter dish. GRK5-
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targeted siRNA was diluted with MEM in 1.7mL microtubes to a concentration of 10nM, and 
kept at room temperature until use.  
 
5.2.6.2 Preparation of the transfection complex and cells, and reverse transfection 
Preparation of the transfection complex and HEK293 cells was performed simultaneously. Cell 
passaging was performed as described in Section 2.4.1.2, unless otherwise specified. Relative 
volumes for transfection complex components are given in Table 5.2. 
Preparation of transfection complex Preparation of cells
siRNA diluted to 10nM
Medium controls set up
RNAiMAX added to diluted 
siRNA and incubated for 
20-30 minutes
Transfection complex 
aliquoted into wells/dishes
Cells trypsinised and 
resuspended in MEM+
Cell suspension spun for 8 
minutes at 850 rpm
Supernatant removed and 
cells resuspended in 
MEM+
Cells counted and diluted 
to 60,000 cells/mL
Cell suspension added to 
wells/dishes
Ti
m
e
Figure 5.2 Flow-diagram showing the relative timing of steps in the transfection of 
HEK293 cells with siRNA. 
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Reagent quantity 
Reagent per well of 24 well plate per 35mm-diameter dish 
10nM siRNA (diluted in MEM)  100µL 500µL  
Lipofectamine™ RNAiMAX  0.5µL 2.5µL 
Table 5.2 Relative volumes of RNAi transfection complex components. 
 
The cells were trypsinised and the resulting cell suspension transferred to a 50mL centrifuge 
tube, which was spun at 850rpm for 8 minutes to pellet the cells. Towards the end of the spin, 
the transfection reagent Lipofectamine™ RNAiMAX (RNAiMAX) was added to the diluted 
siRNA at a ratio of 0.5µL RNAiMAX per 100µL. RNAi MAX is a liposomal carrier molecule 
which enables the siRNA to enter the cell. The solutions were mixed by tapping the tube and 
then incubated at room temperature for 20-30 minutes. On completion of the cell pelleting 
spin, the medium was carefully removed from the cell pellet via vacuum aspiration, and the 
tube tapped vigorously to spread the pellet up the side. The cells were then resuspended in 3mL 
of MEM+, and a 50µL aliquot taken for counting. The cell suspension was then diluted to give 
an appropriate volume at 60,000 cells per mL. The transfection complexes were then added to 
the wells/dishes (100µL per well of a 24-well plate, 500µL per 35mm-diameter dish) followed 
by the appropriate volume of cell suspension, which was added to the centre of each well/dish 
(500µL per well of a 24-well plate, 2.5mL per 35mm-diameter dish). The cells were incubated 
at 37
o
C in a CO2 incubator. 
5.2.7 Analysis of GRK5 expression 
Extraction of whole cell protein was performed 60-96 hours after siRNA transfection. Cells 
were 60-100% confluent at this time point. The protein was extracted and the expression of 
GRK5 protein analysed using the Western blotting protocols described in Section 3.2. 
Extraction of RNA was performed 24-72 hours after siRNA transfection. Cells were ~40-90% 
confluent at this time point. RNA was extracted and GRK5 mRNA expression levels analysed 
using the qRT-PCR protocols described in Section 4.2.  
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5.3 DEVELOPMENT OF AN RNA INTERFERENCE PROTOCOL FOR 
THE KNOCKDOWN OF GRK5 EXPRESSION IN HEK293 CELLS 
It is becoming increasingly clear that the mechanisms responsible for siRNA-mediated 
homologous silencing are complex and incompletely defined. As such, careful experimental 
design, the use of appropriate controls and protocol validation are crucial for accurate use of 
RNAi. In 2003, Nature Cell Biology published an editorial outlining the basic methodological 
requirements and recommendations for publishing the results of experiments using RNAi 
(Nature Cell Biology Editorial, 2003). These requirements and other important methodological 
considerations are described below. 
5.3.1 Important methodological considerations for RNA interference 
experiments 
5.3.1.1 Ensuring specificity: minimizing off-target and non-specific effects 
Careful siRNA design is essential for accurate use of RNAi. There is potential for siRNA to 
induce both off-target, and non-specific effects. Off-target effects, in which the siRNA interact 
with non-target miRNAs based on sequence homology, can be minimised by careful selection 
of the siRNA sequence to ensure it is unique to the target gene. This can be assessed by using 
BLAST to search the sequence against the appropriate NCBI databases. siRNA have also been 
shown to be capable of inducing a variety of non-specific effects, such as cytotoxic phenotypes 
(Fedorov et al., 2006) and the interferon response (Sledz et al., 2003). Titration of the siRNA 
is recommended to minimise the potential for the induction of non-specific effects (Nature Cell 
Biology Editorial, 2003). In their 2003 paper documenting induction of interferon stimulated 
genes by siRNAs, Sledz and colleagues noted that for some interferon stimulated genes, this 
effect was concentration dependant (Sledz et al., 2003). The ability of many siRNAs to induce 
effective knockdown at very low concentrations, coupled with the fact that the RISC assembly 
is saturable under some conditions (Cuccato et al., 2011), makes titration prudent for both 
experimental and economic reasons.  
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5.3.1.2 Assessing knockdown 
siRNA have been shown to be capable of acting as micro RNA (miRNA) by binding 
imperfectly to mRNA (Doench et al., 2003). Unlike classical siRNA-mediated silencing in 
which mRNA is degraded, miRNA-mediated silencing produces gene silencing by inhibiting 
translation of the mRNA to protein (Dykxhoorn & Lieberman, 2005). To ensure that the 
siRNA are acting  via the classical pathway, it is recommended that the effect of siRNA-
transfection on expression is assessed by measuring both the protein and mRNA (Nature Cell 
Biology Editorial, 2003).  
5.3.1.3 Use of appropriate siRNA controls 
Further confidence that the phenotype produced by a siRNA is caused by selective silencing of 
the target gene can be gained by use of a ‗multiplicity‘ control, i.e. a second siRNA targeting a 
different section of the same mRNA (Nature Cell Biology Editorial, 2003). While siRNAs for 
the same gene can have very different efficiencies, this control is useful to confirm results. 
Non-targeting (NT) siRNA are sometimes used as a control. However, these are thought by 
some to be an uninformative control as they are often too different from the targeting siRNA 
(Nature Cell Biology Editorial, 2003). Demonstration that the ‗rescue‘ of expression of the 
target gene by plasmid mediated-expression of the siRNA-targeted mRNA results in the 
reversal of the knockdown phenotype is considered to be the best control currently available 
(Nature Cell Biology Editorial, 2003). However as this is a considerable undertaking in itself, it 
is not considered to be essential for publication, provided that the siRNA has been titrated and 
the mechanism of knockdown confirmed as classical siRNA-mediated RNAi (Nature Cell 
Biology Editorial, 2003) 
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5.3.2 Development of a protocol for inducing siRNA mediated GRK5 
knockdown 
 
5.3.2.1 Selection of GRK5-targetd siRNA 
An siRNA duplex used successfully by Ren et al. (2005) to achieve a high level of protein 
knockdown (>95%) was selected for use as the GRK5-targeting duplex for this research 
(details in Table 5.1). To confirm specificity of the duplex sequence for GRK5, BLAST was 
used to search the siRNA sequence against the NCBI Transcript Reference database (organism 
limited to Homo sapiens). The siRNA was found to have 100% homology to the human GRK5 
mRNA transcript (NM_005308.2), and an E value for this interaction of 0.002. The most likely 
off-target interaction had a homology of 73%, and an E value of 1.6. This indicates that the 
GRK5-siRNA target sequence is unlikely to interact with other mRNA sequences. However, as 
the sequence had partial homology to other genes, it is possible that it may induce silencing via 
miRNA-mediated effects. 
5.3.2.2 Titration of GRK5-targeted siRNA concentration 
As described in Section 5.3.1.1, it is recommended that the lowest possible concentration of 
siRNA be used to minimise the potential for off-target effects. To determine the lowest 
concentration of siRNA which could be used without compromising maximum knockdown, a 
titration experiment was done. To determine if the measured knockdown was occurring via the 
classical mechanism of RNAi, the GRK5 mRNA levels were measured by qRT-PCR.  
5.3.2.2.1 Generation of a titration curve for GRK5-targeted siRNA  
Knockdown was induced as described in Section 5.2.6, with the following exceptions: the 
GRK siRNA was diluted to 1, 5, 10 and 50nM in MEM. Two wells of a 24 well plate were 
transfected per solution. A medium control, or ‗0nM siRNA‘, consisting of 100µL of MEM- 
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was also run. Wells were supplemented by the addition of 500µL of MEM+ per well 24 hours 
after plating. RNA was extracted 48 hours after transfection for qPCR-based analysis (as 
described in Section 4.2.). The expression data from each concentration was compared to that 
of cells which received the control treatment (0nM).  
 
5.3.2.2.2 Results 
qRT-PCR analysis indicated that the GRK5 siRNA-targeted duplex produced GRK5 mRNA-
degradation in a dose-dependant manner, as shown in Figure 5.3. Concentrations as low as 
1nM were seen to cause a measurable decrease in GRK5 mRNA levels (56.8% knockdown). 
Increasing the siRNA concentration resulted in an increase in knockdown, up to a 
concentration of 5nM (72.7% knockdown). No difference was seen in knockdown produced by 
the use of concentrations from 5nM to 50nM siRNA. No difference in cell confluence or 
morphology was seen between treatments. The siRNA-dependant decrease in GRK5 mRNA 
also indicates that the knockdown is occurring via the classical siRNA-mediated pathway, 
rather than the miRNA-mediated inhibition of translation. To ensure that this trend was also 
seen in the expression of GRK5 protein 35mm-diameter dishes were then transfected with 0, 5,  
 
 
 
Figure 5.3 Titration curve showing the effect of increasing the GRK5-targeting siRNA 
concentration on the expression of GRK5. HEK293 cells were transfected with increasing 
concentrations of GRK5-targeted siRNA duplexes, and the resulting knockdown quantified using qRT-
PCR and expressed relative to TBP and YWHAZ (n=1). 
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or 10nM GRK5-targeting siRNA and the relative expression of GRK5 assessed using Western 
blotting. This showed that 10nM siRNA was inducing measurably greater knockdown than 
5nM siRNA (~50% vs. ~25%) at the protein level (data not shown). 
5.3.2.2.3 Conclusion 
The titration curve suggested that 5nM siRNA is the optimal concentration for KD of GRK5 
using the current GRK5 targeted duplex, as it was the lowest concentration seen to produce the 
maximal response. However, comparison of the effect of 10nM and 5nM on GRK5 protein 
expression indicated that 10nM was inducing greater knockdown. As such, a siRNA 
concentration of 10nM was used for subsequent experiments.  
5.3.2.3 Selection of a time point for assay for the effect of GRK5 knockdown on 
desensitisation: Time course of protein knockdown 
To select a time point suitable for performing the desensitisation assay (i.e. at which the protein 
was maximally knockdown), it was necessary to determine the time course of GRK5 protein 
knockdown. This was done was transfecting multiple dishes of cells and staggering the time of 
cell lysis.  
5.3.2.3.1 Generation of time course 
Four 35mm-diameter dishes were plated with HEK293 cells and reverse transfected with the 
GRK5-targeted siRNA diluted to 10nM, and as described in Section 5.2.6. In addition, a 
medium control was also plated and lysed at 72 hours. The transfected cells were lysed via the 
standard protocol in Section 3.2.3 at the following time points: 60, 72, 84 and 96 hours 
following transfection. Cells to be lysed at 84 and 96 hours were passaged at 72 hours to 
prevent them from becoming over-confluent. For passaging, the medium was removed from 
the dish by vacuum aspiration and replaced with 800µL of T/E. The plates were tilted to ensure 
that the cells were covered with T/E, and the excess T/E aspirated. The dishes were placed on 
the microscope stage for 8 minutes, at which time the cells could be seen to have dissociated 
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from each other and the surface of the dish. The cells in each dish were then resuspended by 
the addition of 1mL of pre-warmed MEM+, and the cell suspension was repipetted 4 times, 
flushing the dish with each ejection. The cell suspension from each dish was transferred to a 
50mL falcon containing 3mL pre-warmed MEM+. The base of each dish was then washed a 
second time with another 1mL aliquot of pre-warmed MEM+. This was then pooled with the 
first aliquot from that dish. Each cell suspension was swirled to mix and was split between two 
new 35mm-diameter dishes which were incubated at 37
o
C until lysis. Following lysis the 
samples were analysed using the Western blotting protocol described in Section 3.2. 
5.3.2.3.2 Results 
The expression of GRK5 protein was substantially decreased at all time points tested (Figure 
5.4). The difference between each time point however was small. The least knockdown 
appeared to be occurring at 60 hours, while, 72 hours produced slightly greater knockdown 
than the other time points. No difference in expression was seen between 84 and 96 hours. 
Both the expected 68kDa band, and the additional 55kDa detected with the anti-GRK5 
antibody used were seen to be knocked down at all time points. This suggests that the 55kDa 
band may represent an alternative isoform of GRK5 (as proposed in Section 3.3.3.2.7.1). 
 
Figure 5.4 Time course showing the progression of GRK5 protein knockdown as detected using 
Western blotting. The intensity of bands detected at 68kDa (GRK5) and 55kDa (a potential GRK5 
isoform) is plotted. Representative data is shown.  
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5.3.2.3.3 Conclusions 
From this it appears that 72 hours after transfection with GRK5-targeted siRNA is the optimal 
time point for the desensitisation assay to be performed. However, any time point between 72 
and 96 hours could be used to similar effect, depending on the timing required by other aspects 
of the desensitisation protocol (see Chapter 6).  
5.3.2.4 Validation of detection methods for use with knockdown protocol 
Both qRT-PCR and Western blotting make use of internal controls or reference genes, relative 
to which GRK5 expression is normalised. As such, it is essential that in both instances the 
expression of the reference genes is not altered by the test treatment. 
5.3.2.4.1 Validation of TBP and YWHAZ as appropriate reference genes for qRT-PCR 
analysis of GRK5-knockdown experiments 
The effect of increasing concentrations of GRK5-targeted siRNA on the concentration of 
YWHAZ and TBP was assessed in the experiment described in Section 5.3.2.2.2. Linear 
regressions were fitted to the data to determine if reference gene expression was affected as the 
siRNA concentration increased. There was no evidence from this data that the test treatment 
alters the expression of TBP and YWHAZ. Small variation seen between concentrations was 
likely due to differences in sample processing (the reason for which GRK5-mRNA 
measurement is normalised to the reference genes), however no overall trend was seen. 
YWHAZ and TBP were therefore deemed to be suitable for use as reference genes during 
analysis of GRK5-directed RNAi experiments. 
5.3.2.4.2 Validation of actin as an appropriate internal control for Western blotting analysis 
of GRK5-knockdown experiments 
The affect of a test treatment on the expression of the internal control can be assessed by 
comparing the CV values from a Western blot in which both control and test protein is run 
with that of the a Western blot in which only untreated protein is run (Liu & Xu, 2006).  If the 
test treatment is affecting the expression of the internal control protein, the CV from the test 
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Western blot will be greater than that of the control Western blot. To assess the effect of the 
RNAi protocol described in Section ??? on the expression of actin, the CV value was 
calculated for actin bands from protein treated with 0, 5 and 10nM of GRK5-targeted siRNA, 
and compare to the control actin CV of 8.8 ± 6.0% (mean, SEM) as calculated in Section ???. 
The actin CV value of the test Western blot was 6.0%. As such, there is no evidence to suggest 
that actin expression is being affected by siRNA treatments. 
5.3.2.5 Conclusions 
The RNAi protocol described in Section 5.2.6 can be successfully used to induce a knockdown 
in the expression of GRK5 protein. qRT-PCR analysis of GRK5-targeting siRNA-treated cells 
confirmed that this knockdown was proceeding via the classical siRNA-mediated degradation 
of GRK mRNA. Titration of the siRNA concentration determined that the optimal siRNA 
concentration was 10nM, as it produced maximal knockdown (~50%) of GRK5 mRNA and 
protein, and did not induce a cytotoxic phenotype. The extent of the protein knockdown 
achieved was less than that reported in the literature (Ren et al., 2005), however it should be 
sufficient to produce a change in the magnitude of GRK5-dependent processes.  
5.3.3 Selection of a non-targeting control siRNA duplex 
5.3.3.1 Non-targeting siRNA details 
Two non-targeting (NT) siRNA were obtained from Dharmacon and resuspended as described 
in Section 5.2.5. They were NT siRNA #3 (D-001210-03), and NT siRNA #1 (D-001210-01) 
(details in Table 5.3). The molecular weight of the non-targeting duplexes was not provided by 
the manufacturers. For resuspension calculations, duplex molecular weight was assumed to be 
13,300g/mol (that of the average siRNA according to the Dharmacon website). 
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 Non-Targeting siRNA #3 (NT#3) Non-Targeting siRNA #1 (NT#1) 
Sequence 5’-AUGUAUUGGCCUGUAUUAG-3’ 5’-UAGCGACUAAACACAUCAA-3’ 
Length 19bp 19bp 
MW ~13,300 g/mol* ~13,000 g/mol* 
Table 5.3 Non-targeting siRNA details *assumed weight. 
5.3.3.2 In silico assessment of non-targeting siRNA sequences 
Both non-targeting duplexes were searched against the NBCI Transcript Reference database 
(organism limited to Homo sapiens) using BLAST. For NT#1, the maximum measured 
homology was 68%, with an E value for this interaction of 146.0. For NT#3, the maximum 
measured homology was 68%, with an E value of 6.0.  
5.3.3.3 Experimental assessment of non-targeting siRNA sequences 
5.3.3.3.1 Protocol of experimental assessment 
Non-targeting siRNA are typically used under identical conditions (of siRNA amount and 
transfection reagent) as the targeting-siRNA, and act as a type of control. As the GRK5-
targeting siRNA was used at a concentration of 10nM, both non-targeting duplexes were 
trialled at this concentration. For generation of non-targeting duplex transfection complexes the 
RNAi protocol described in Section 5.2.6 was used, with the non-targeting duplexes 
substituted for GRK5-targeting siRNA. HEK293 cells were plated in to 35mm-diameter dishes 
and cultured for 84 hours prior to lysis. 
5.3.3.3.2 Results 
Use of either the NT#3 or NT#1 duplexes at 10nM resulted in a cytotoxic phenotype in ~50% 
of the transfections carried out (shown in Figure 5.5), leading to a marked difference in the 
confluence of the cells over time. Both duplexes also appeared to produce subtle changes to the 
morphology of the cells, making them slightly more angular (Figure 5.5). These effects were 
not seen in cells transfected with the GRK5-targeted siRNA at equivalent (Figure 5.5) or even 
higher concentrations (data not shown).  
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The effect of the non-targeting siRNA on GRK5 protein expression was also tested. Due to the 
inconsistency of the cytotoxic phenotype shown in Figure 5.5, the transfection complex for 
each non-targeting duplex was prepared in duplicate. These (along with 10nM GRK5-targeting 
siRNA and medium controls) were used to transfect cells from the same batch, and the protein 
harvested at 84 hours. Both non-targeting siRNA produced a measurable knockdown in GRK5 
expression, the extent of which was not consistently replicated between transfections (Figure 
5.6). This decrease is likely due to induction of non-specific mRNA degradation and/or 
translational inhibition rather than a specific silencing of GRK5.  
 
 
5.3.3.4 Conclusions 
Due to their induction of cytotoxic effects and possibility non-specific GRK5 protein 
knockdown, neither non-targeting duplex was considered to be suitable for use as a siRNA 
control. 
 
Figure 5.6 Effect of siRNA treatment on GRK5 protein expression. Due to the inconsistent effects produced 
by NT#1and NT#3 duplexes, two separate transfection complexes (resulting in NT#1a & b, and NT#3 a & b) were 
prepared identically for each duplex and used to transfect cells from the same passage.  
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6 
EFFECT OF GRK5 EXPRESSION ON THE DESENSITISATION OF 
THE VASOPRESSIN V1b RECEPTOR: DESGIN AND 
VALIDATION OF AN EXPERIMENTAL PROTOCOL 
6.1 INTRODUCTION 
As discussed in Chapter 1, GRK5 has been linked to AVP-mediated desensitisation of the 
V1bR receptor. The aim of this thesis was to determine whether GRK5 is involved in 
desensitisation of the V1bR in response to AVP stimulation, by measuring the effect of RNAi-
mediated GRK5 knockdown on the magnitude of the desensitisation achieved. The various 
protocols required for this experiment have already been described in detail. They are i) the 
generation of a model cell system by transient transfection of HEK293 cells to express the 
rV1bR (Chapter 2), ii) the RNAi-mediated knockdown of GRK5 mRNA and protein (Chapter 
5), iii) stimulation/desensitisation of the V1b receptor (Chapter 2), iv) measurement of receptor 
activity by IP assay (Chapter 2), and v) confirmation of RNAi-mediated knockdown of GRK5 
mRNA (Chapter 4) and protein (Chapter 3).  
 
The purpose of this chapter is to describe an experimental design which would coordinate the 
use of all the protocols developed and/or described in Chapters 2, 3, 4, and 5. The 
compatibility of overlapping protocols was assessed (described in Section 6.3) to ensure that 
the functionality of each step was not compromised. In the experimental protocol described 
below, chronic stimulation of HEK293-rV1bR cells is used to induce desensitisation, and their 
response to AVP measured by IP assay. Sampling of cells after AVP stimulation for 0, 5, 15, 
30 and 60 minutes allows the progression of desensitisation to be monitored. Similar 
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desensitisation assays have been previously reported for protease-activated receptor 1 and 2 
(Paing et al., 2002; Ricks & Trejo, 2009). Finally, the GRK5-targeted siRNA-mediated 
knockdown of GRK5 mRNA and protein in cells treated identically to those used for the 
desensitisation experiment is assessed using qRT-PCR and Western blotting. 
6.2 MATERIALS, MEDIA AND SOLUTIONS 
Details of all materials referred to in this chapter can be found in Appendix A. Details of all 
solutions and media referred to in this chapter can be found in Appendix B. 
6.3 EXPERIMENTAL PROTOCOL FOR DETERMINATION OF THE 
EFFECT OF GRK5 KNOCKDOWN ON DESENSITISATION OF THE 
RESPONSE TO AVP 
6.3.1 Overview 
The proposed experimental protocol is designed to take place over six days, with a suggested 
‗time zero‘ (the time at which the plated/ siRNA-treated cells are placed in the incubator) of 
10pm on day 1. This allows for at least 3 hours of preparation time before the start of the IP 
assay on day 5. The relative timing of each section of the experiment is shown in Figure 6.1. 
6.3.2 Plating and treatment with RNAi 
6.3.2.1 Plating of HEK293 cells for the desensitisation assay, qRT-PCR and 
Western blotting 
Cells for all purposes are plated at a density of 15,000 cells per cm
2
, with a plating volume of 
250µL per cm
2
.  This equates to 30,000 cells in 500µL per well of a 24-well plate, and 150,000 
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cells in 2.5mL per 35mm-diameter dish. The suggested plating plan for this experiment is 
shown schematically in Figure 6.2 and described in detail below. 
 
Cells to be used for the desensitisation assay and subsequent analysis by IP assay will be plated 
into two 24-well Primeria™ MultiWell™ culture plates (See Figure 6.2, A). These plates were 
chosen as they have been treated to promote cell adhesion. This helps to minimise cell loss 
during the washes and medium changes that occur during labelling and the desensitisation 
assay (Cummings, 2011).  A total of forty wells are plated for this purpose. At the time of 
plating, 20 of these wells are reverse transfected with 10nM GRK-targeted siRNA, and the 
remaining 20 wells act as the medium control (See Section 6.3.2.2 and Figure 6.2, A).  
 
 
 
36hrs
28hrs
20hrs
Plating & RNAi: HEK293 cells are plated and reverse transfected with either GRK5-
targeted siRNA or a medium control
Transient transfection: HEK293 cells are transfected with pN1-rV1bR 
Labelling: HEK293 cells  are washed with inositol-free medium and labelled with 
[H3]myo-inositol
Desensitisation: HEK293 cells are washed with MEM+0.1% BSA +10mM LiCl ,  then
stimulated with MEM+0.1% BSA +10mM LiCl ±100nM AVP for 0, 5, 10, 15, 30 or 60 
minutes. Stimulation is halted 
by addition of ‘stop solution’
Isolation of IP metabolites: Cell lysates are neutralised and separated using anion 
exchange chromatography to isolate [H3]-IPs
Measurement of IP metabolites: Radioactivity of isolated IPs are measured using 
liquid scintillation counting
48hrs after 
plating:
RNA is 
harvested
84hrs after 
plating:
protein is 
harvested
DAY 1
DAY 2
DAY 3
DAY 4
DAY 5
DAY 6
Figure 6.1 Relative timing of steps in the experimental protocol for determining the role of GRK5 in 
desensitisation of the V1bR 
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Cells used to monitor GRK5 mRNA expression are plated into standard cell culture 24-well 
plates (NUNC). Six wells are plated for each RNAi-treatment (see Figure 6.2, B). At the time 
of harvest, two wells are pooled per replicate, giving a final replicate number of three for each 
RNAi treatment. Cells to be used for Western blot analysis of GRK5 protein expression are 
plated into 35mm-diameter dishes (BD Falcon). Three dishes are plated for each RNAi 
treatment, resulting in a replicate number of three (see Figure 6.2, C). 
6.3.2.2 RNAi treatments 
RNAi-treatments are applied by reverse transfection at the time of plating. This protocol is 
described in detail in Section 5.2.6. Briefly, the cells receive one of two treatments; i) a 
medium control (shown in orange in Figure 6.2), or ii) transfection with 10nM of the GRK5- 
targeting siRNA duplex (shown in green in Figure 6.2). The transfection complex or medium 
alone is aliquoted into the appropriate wells/dishes immediately prior to addition of the cells, at 
a volume of 100μL per well of a 24-well plate, and 500μL per 35mm-diameter culture dish.  
6.3.2.3 Confirmation of GRK5 knockdown 
To confirm the siRNA-mediated knockdown of GRK5 mRNA and protein, the cells plated for 
this purpose are harvested. RNA is extracted from the designated cells 48 hours after plating, 
and changes in GRK5 mRNA levels are measured using the qRT-PCR protocols described in 
Section 4.2. Protein is harvested from the designated cells at 84 hours (immediately before the 
desensitisation assay), and changes in GRK5 protein levels are detected using the Western 
blotting protocols described in Section 3.2. 
6.3.2.4 Transient transfection of HEK293 cells to express V1bR  
The HEK293 cells destined for use in the desensitisation assay are transiently transfected with 
the pN1-rV1bR plasmid 36 hours after plating and reverse transfection with siRNA or medium 
alone. This step results in the expression of the rV1bR, allowing the HEK293 cells to acts as a 
model system for investigating the desensitisation of the V1b receptor. The transfection 
protocol is described in detail in Section 2.4.2.2. Briefly, the transfection complex is made by 
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mixing the pN1-rV1bR plasmid with MEM and FuGENE
®
 6. One hundred micolitres of the 
transfection complex is then be added to each well  
of the 24-well Primeria™ MultiWell™ culture plates (Figure 6.2, A). 
 6.3.2.5 Labelling of the HEK293 cells with [
3
H]-myo-inositol 
The labelling protocol is described in detail in Section 2.4.3.1. For these experiments, the 
HEK293 cells are incubated in inositol-free medium spiked with [
3
H]-myo-inositol for 20 
hours before the desensitisation assay is performed. The radiolabelled inositol is incorporated 
into the IP metabolic pathway, allowing the activity of the rV1BR to be monitored by 
measuring the amount of [
3
H]-IPs produced following stimulation of the cells with AVP (or 
exposure to the basal medium i.e. 0nM AVP. Briefly, the culture medium is removed by 
vacuum aspiration and replaced with 500μL of DMEM+ containing [3H]-myo-inositol 
(0.25μL/mL). The cells are then returned to the incubator, and cultured for 20 hours. 
6.3.2.6 Desensitisation assay 
To examine the effect of reducing GRK5 expression on the progression and extent of V1bR 
desensitisation, cells will be stimulated with 0nM (basal) or 100nM AVP for a variety of 
durations, as described below (see Figure 6.2, A).  
 
Following labelling, the cells are washed once with 500µL of pre-warmed MEM (containing 
0.1% BSA + 10mM LiCl) to remove traces of unincorporated myo-[
3
H]-inositol phosphate. 
Five hundred microlitres of MEM (0.1% BSA + 10mM LiCl) ±100mM AVP is then added to 
each well, as indicated in Figure 6.2 (A). The cells are incubated at 37
o
C for the duration of the 
stimulation, i.e. for 0, 5, 15, 30 or 60 minutes. The desensitisation treatment is halted by the 
addition of 500μL of ice cold ‗stop‘ solution to each well (as described in Section 2.4.3.2). The 
presence of LiCl in the wash and treatment solutions prevents inositol monophosphatase-
mediated-degradation of IP1 to free inositol, resulting in the accumulation of [
3
H]-IPs produced 
in response to AVP stimulation. 
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6.3.2.7 IP assay: Isolation and quantitation of the [
3
H]-IPs by anion-exchange 
chromatography and liquid scintillation counting 
The [
3
H]-IPs are isolated using anion-exchange chromatography. This protocol is described in 
detail in Section 2.4.3.3. Briefly, 40 Bio-Rad AG1-X8-resin (formate form) columns are 
poured, with a bed depth of ~2cm. The cell lysates are returned to pH 7.0 by the addition of 
neutralisation solution, homogenised by vigorous scraping and repipetting, and loaded 
carefully onto a column (one sample per column). The columns are washed with 10mL of 
NPH2O and 8mL of elution buffer II to elute free inositol and glycerophosphoinositides. The 
[
3
H]-IPs are then eluted by washing the columns with 3mL of elution buffer VI.  
 
To allow the amount of [
3
H]-IPs in each elution to be measure, 1mL of each elution is mixed 
with 10mL of OPTIPHASE ‗HISAFE‘ 3 scintillation cocktail (Perkin-Elmer), and left in the 
dark overnight. The following day, the radioactivity of the samples is determined by liquid 
scintillation counting (as described in Section 2.4.3.4) and expressed as CPM. 
6.3.2.8 Analysis and expected results 
6.3.2.8.1 Effect of GRK5-knockdown on desensitisation of the rV1bR 
GraphPad Prism 4.0 is used to calculate the mean and SEM for all replicates. The mean CPM 
from wells stimulated with 100nM AVP will then be expressed as a percentage of the CPM of 
the control cells (0nM AVP; basal treatment) which is treated for the same duration (i.e. 5 
minutes stimulated vs. 5 minutes basally treated). This allows the AVP-stimulated-increase in 
[
3
H]-IP levels at each time point. This data can then be graphed to show the relationship 
between time and IP accumulation in response to AVP for the medium control (i.e. no siRNA 
treatment) and GRK5-targeting siRNA-treated cells. 
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In cells which have not been subjected to siRNA treatment (i.e. the medium only controls) 
stimulation with 100nM AVP is expected to cause a rapid initial increase in [
3
H]-IP 
accumulation. This will occur while the rV1bR is able to respond to AVP stimulation, but once  
 
receptor desensitisation begins, the increase in [
3
H]-IPs is expected to taper-off, possibly 
reaching a plateau if rV1bR are completely desensitised.   
 
This is depicted graphically in Figure 6.3. If V1bR desensitisation involves phosphorylation of 
the receptor by GRK5, the ability of the rV1bR to undergo desensitisation should be impaired 
in GRK5-targeted siRNA-treated cells. This would be seen as a continued increase in [
3
H]-IP 
levels overtime, as the activated receptors continue to activate the PLCβ-mediated intracellular 
signalling pathway in response to AVP stimulation. 
Figure 6.3 Graphical representation of the expected change in the IP accumulation profile following 
treatment with GRK5-targeted siRNA if GRK5 is involved in desensitisation of the V1bR. The solid line 
shows the predicted accumulation of [
3
H]-IPs over time for control cells. As the receptors undergo desensitisation, 
they cannot activate their signalling pathway. This results in a plateau if the receptors have been completely 
desensitised, as no new [
3
H]-IPs can be produced. The broken line represents the change in the IP accumulation 
profile predicted in GRK5-targeted siRNA-treated cells if GRK5 is involved in V1bR desensitisation. As receptor 
desensitisation is reduced due to reduction in GRK5 expression, receptors continue to activate the intracellular 
signalling pathway, resulting in the continued production of [
3
H]-IPs. 
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6.4 DEVELOPMENT OF THE EXPERIMENTAL PROTOCOL FOR 
DETERMINATION OF THE EFFECT OF GRK5 KNOCKDOWN ON 
DESENSITISATION OF THE RESPONSE TO AVP 
Measures were taken to ensure that when the protocols described in Section 6.3 were used 
concurrently they did not affect each other in a manner that would compromise the efficiency 
of the individual protocols. In the experimental protocol, the HEK293 cells used for the 
desensitisation assay are transfected twice, the first, a reverse transfection at the time of plating 
with siRNA and RNAiMAX, and the second, 36 hours after plating with the pN1-rV1bR and 
FuGENE
®
 6. 
 
The compatibility of the siRNA and pN1-rV1bR transfections was tested as follows (Sections 
6.4.1-3) to ensure that: 
1) The time required for siRNA-mediated knockdown of GRK5 protein was compatible 
with the time required after pN1-rV1bR transfection for HEK293 cells to express 
functional rV1bR at the cell membrane (Section 6.4.1). 
2) That the presence of RNAiMAX from the siRNA-transfection does not affect the 
efficiency of pN1-rV1bR transfection (which would be detected as a reduction is 
responsiveness to AVP stimulation, and would compromise the desensitisation results) 
(Section 6.4.2), and 
3) The transfection of GRK5-targeted siRNA-treated cells with the pN1-rV1bR/ 
FuGENE
®
 6 transfection complex did not affect the extent of GRK5 protein 
knockdown achieved (Section 6.4.3). 
 
The duration of stimulation with 100nM AVP required to produce rV1bR desensitisation was 
also assessed, and is described in Section 6.4.4. 
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6.4.1 The temporal compatibility of rV1bR desensitisation with the 
knockdown of GRK5 protein 
The time course of siRNA-mediated knockdown of GRK5 protein expression was previously 
determined in Section 5.3.2.3 (Figure 5.4). Knockdown was seen to be greatest at 72 hours 
after transfection. This margin was small however, with <10% difference seen between GRK5 
expression at 72, 84 and 96 hours. It was therefore determined that any time point between 72 
and 96 hours could be used for the desensitisation assay with approximately equal effect. 
 
In the protocol for transient transfection of HEK293 cells previously used in the Mason 
Laboratory, the cells were plated at a density of 30,000 cells/cm
2
 and transiently transfected 24 
hours later, at which time their confluence ranged from 50-80%. The cells were then cultured 
for at least 48 hours to allow expression of the rV1bR (Cummings, 2011). The plating density 
used in this protocol is twice that used for the RNAi experiments (15,000 cells/cm
2
). The lower 
plating density is necessary for the RNAi experiments as the cells need to be cultured for 72-96 
hours after plating and reverse transfection, to ensure maximal knockdown of the GRK5 
protein is achieved. To combine the siRNA and pN1-rV1bR transfection protocols, it was 
necessary to increase the time between plating and transfection with the pN1-rV1bR plasmid to 
36 hours. This allowed the cells to become sufficiently confluent for V1bR-transfection 
(>50%) and aligned the optimal time for receptor assay (48 hours after transfection) with an 
acceptable time for GRK5 knockdown (84 hours after plating and reverse transfection with 
GRK5-targeted siRNA). 
 
The suitability of the timing of this protocol was tested by measuring the AVP-stimulated 
increase in [
3
H]-IP production over basal [
3
H]-IP levels. The cells were plated and incubated 
for 36 hrs before transfection with the pN1-rV1bR. The cells were incubated for a further 28 
hours, and then labelled with [
3
H]-myo-inositol. Twenty hours later (84 hours after plating) the 
cells were stimulated with 100nM AVP for 15 minutes, and the resulting increase in [
3
H]-IP 
production measured. This protocol produced a 481.5% ± 37.5% (n=2) increase in [
3
H]-IP 
levels above the basal level, indicating that proposed timing of the experiment was compatible 
with expression of functional rV1bR. 
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6.4.2 The effect of RNAiMAX on the efficiency of the pN1-V1bR transfection 
It was unknown how the presence of both RNAiMAX and FuGENE
®
6 would affect the 
transfection of the pN1-rV1bR. To determine if the presence of RNAiMAX impaired the 
transfection efficiency, the [
3
H]-IP response above basal was compared between cells which 
received one of two treatments at the time of plating: either 100μL of MEM (control), or 
100μL of MEM + 0.5μL RNAiMAX (RNAi 1 and 2, ‗mock siRNA-transfection‘) (Figure 6.4). 
During previous use of the pN1-rV1bR the cells were plated in 500μL of MEM+. However in 
RNAi experiments, the 500μL of cell suspension is added to a well already containing 100μL 
of transfection complex or medium control, resulting in a total volume of 600μL of solution 
per well at the time of subsequent transient transfection with the receptor. To determine if the 
additional volume was affecting the efficiency of the pN1-rV1bR transfection, and if returning 
the volume to 500μL would improve transfection efficiency, 100μL was removed from four 
wells ‗mock transfected‘ with RNAiMAX (RNAi 2). 
As shown in Figure 6.4, no significant difference was detected between the [
3
H]-IP response 
above basal in cells that received the medium control and cells that were ‗mock transfected‘ 
with RNAiMAX. Furthermore, the difference in the volume of medium in the wells at the time 
 
control RNAi 1 RNAi 2
0
100
200
300
400
500
Treatment
%
 o
f 
b
a
s
a
l
Figure 6.4 The effect of RNAiMAX and the volume of medium-per-well on the efficiency of 
transfection with the pN1-rv1bR plasmid. RNAi 1-treated cells were ‗mock transfected‘ with 
RNAiMAX at the time of plating. There was 600μL of solution in each well at the time of transfection with 
the pN1-rv1bR plasmid. RNAi 2-treated cells were also ‗mock transfected‘ with RNAiMAX. In addition, 
100μL of solution was removed from the wells prior to transfection, returning the volume to that 
previously used. No significant difference was seen between any of the conditions trialled. 
- 137 - 
 
of transfection with the pN1-rV1bR plasmid did not appear to have a significant effect on 
transfection efficiency (Figure 6.4). This indicates that the double transfection proposed in 
Section 6.3 does not affect the performance of transient transfection of the HEK293 cells with 
the pN1-rV1bR plasmid. 
6.4.3 The effect of pN1-rV1bR transfection on the extent of siRNA-mediated 
GRK5 protein knockdown 
To determine if the subsequent transfection of GRK5-targeted siRNA-treated HEK293 cells 
with the pN1-rV1bR plasmid affected the extent of GRK5 protein knockdown, Western 
blotting was used to compare GRK5 expression under the following conditions: i) medium 
control (MC) (i.e. not transfected with either siRNA or pN1-rV1bR), ii) knockdown control 
(KC) (i.e. transfected with siRNA, but not with pN1-rV1bR), iii) RNAi 1 (i.e. transfected with 
GRK5 and pN1-V1bR), and iv) RNA 2 (i.e. transfected with GRK5 and 100μL of medium 
removed prior to transfection with pN1-V1bR) (See Figure 6.5). 
 
A large decrease was seen in GRK5 protein expression in KC-treated cells compared to MC-
treated cells. The extent of this knockdown was not affected by transfection of the cells with 
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Figure 6.5 The effect of transfection conditions on the siRNA-mediated knockdown of GRK5 protein 
expression. Transfection of HEK293 cells with 10nM GRK5-targeted siRNA results in a significant decrease 
in GRK protein expression (KC) compared to its expression in medium control (MC) treated cells. 
Subsequent transfection of siRNA-treated cells with the pN1-rV1bR plasmid did not appear to affect the 
extent of GRK5 knockdown (RNAi 1), though removal of 100μL of medium from the well prior to pN1-
rV1bR transfection resulted in large loss of GRK5 knockdown (RNAi 2). 
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pN1-rV1bR (Figure 6.5, RNAi 1). However, removal of 100μL of medium prior to pN1-rV1bR 
transfection resulted in a dramatic decrease (~20%) in the extent of GRK5 knockdown (Figure 
6.5, RNAi 2). 
 
This indicated that transient transfection with the pN1-rV1bR did not affect the siRNA-
mediated knockdown of GRK5 protein, provided that no medium was removed from the well. 
6.2.4 Time course of desensitisation: determining the duration of chronic 
stimulation with 100nM AVP required to achieve desensitisation 
Previous studies using HEK293 cells transiently transfected with the rV1bR induced receptor 
desensitisation using a 5 minute pre treatment with 5nM AVP (Gatehouse, 2008). This was 
sufficient to reduce the responsiveness of the receptor to a subsequent 15 minute stimulation 
with 100nM AVP to 68.5 ± 7.9% that of cells that did not receive the pre-treatment 
(Gatehouse, 2008). For this research, desensitisation caused by chronic stimulation with 
100nM AVP was used, as it allowed the progression of rV1bR desensitisation to be tracked 
over time, giving the best chance of detecting GRK-targeted siRNA-mediated effects on 
rV1bR responsiveness. 
On two separate occasions, the time course of rV1bR desensitisation was measured by 
stimulating cells with 100nM AVP for 0 to 60 minutes (Figure 6.6). In both time courses 
performed, a rapid initial increase in [
3
H]-IP levels was detected after 5 minutes of stimulation 
with 100nM AVP. No increase in [
3
H]-IP levels were seen between 30 and 60 minutes, 
indicating that desensitisation was complete after 30 minutes (Figure 6.6). In both experiments, 
the level of measured [
3
H]-IP levels displayed a temporary decrease between 5 and 10-20 
minutes, after which the [
3
H]-IP levels resumed accumulating. The appearance of this 
unexpected profile may be coincidental, caused by variation is transfection efficiency and/or 
cell loss during washes. However, it is possible that the decrease between 5 and 10-20 minutes 
was caused by incomplete inhibition of inositol monophosphatase (the enzyme which degrades 
IP1 to free inositol), i.e. activation of the receptor by AVP stimulation produces an initial 
increase in [
3
H]-IPs (seen as an increase between  0 and 5 minutes). The remaining active 
inositol monophosphatase processes [
3
H]-IP1 to free inositol (which is not retained by the 
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anion exchange system used). This results in the decrease in [
3
H]-IPs levels seen between 5 
minutes and 10 minutes. In this scenario, LiCl-mediate inhibition of inositol monophosphatase 
is complete after 10-20 minutes, allowing any [
3
H]-IP produced to accumulate, resulting in the 
additional increase seen between 10-20 and 60 minutes. However, this scenario is contrary to 
evidence from previous use of IP assay in the Mason laboratory which suggested that a 2 
minute exposure to LiCl during the washes was sufficient to block the breakdown of [
3
H]-IP1. 
 
The following durations were chosen for AVP-stimulation treatments for the experimental 
protocol described in Section 6.3. They were 0, 5, 15, 30 and 60 minutes. The high frequency 
of time points during the initial stages of receptor activation will allow the [
3
H]-IP 
accumulation to be tracked. Furthermore, these time points will serve to confirm the decrease 
in [3H]-IP between 5 and ~20 minutes as a biologically relevant event, or discount it as an 
experimental artefact. Although receptor desensitisation was seen to be complete after 30 
minutes of stimulation with 100nM AVP, 60 minutes was selected as the longest duration. This 
was to enhance the ability of the assay to detect any differences between the desensitisation 
profile of controls cells, and that seen in GRK5-targeted siRNA-treated cells. If desensitisation 
is impaired by siRNA treatment, these cells will accumulate [3H]-IP for ~30 minutes longer 
that the control cells. This should insure that any change in the ability of the receptor to 
undergo desensitisation can be detected. 
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Figure 6.6 The increase in 100nM AVP-increased [
3
H]-IP levels overtime. The desensitisation 
profiles produced by stimulation with 100nM AVP for 0 to 60 minutes A) plotted individually, and B)  
the mean (and SEM) of the two assays.  
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7 
DISCUSSION  
7.1 SUMMARY 
Desensitisation of the V1bR in vitro may involve phosphorylation (probably of the receptor) 
by an unidentified kinase (Hassan & Mason, 2005). The involvement of other kinases that 
commonly phosphorylate GPCRs which activate the phosphoinositide pathway (PKC and 
CKα1) have been discounted, suggesting that GRK-mediated phosphorylation may be 
responsible. Previously, tentative evidence of a physical association between the V1bR and 
GRK5 has been reported (Berrada et al., 2000), making GRK5 an isoform of particular 
interest. The lack of isoform specific pharmacological inhibitors for GRKs necessitated a 
change in methodology from that previously used by the Mason laboratory to investigate the 
involvement of various protein and cellular processes in V1bR desensitisation (Hassan & 
Mason, 2005). As such, one aim of this research was to generate and validate the methods 
required to determine if GRK5-mediated phosphorylation is involved in desensitisation of the 
V1bR to AVP stimulation.  
 
A protocol for RNAi-mediated knockdown of GRK5 was established, to allow the effect of 
reduced expression of GRK5 protein to be determined in HEK293 cells transfected to 
transiently express the rV1bR. In this system rV1bR activity was determined by measuring the 
AVP-induced production of IPs. GRK5 knockdown was monitored using qRT-PCR to measure 
GRK5 mRNA levels, and Western blotting was used to measure GRK5 protein levels. The 
methodologies for both detection techniques were established as part of this research. qRT-
PCR analysis of RNA extracted from cells 48 hours after treatment, showed that transfection 
with 10nM GRK5-targeted siRNA reduced GRK5 mRNA levels to 28.7% ± 1.9% (n=3, 
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p<0.001) of that seen in untransfected control cells. TBP and YWHAZ were used as reference 
genes in the qRT-PCR, and they were shown to be unaffected by the GRK5 siRNA treatment. 
Western blotting analysis of protein harvested 84 hours after treatment showed that the relative 
GRK5 protein expression in GRK5-siRNA treated cells was reduced to 53.4% ± 3.4% (n=5, 
p<0.0005) of that seen in untransfected control cells. Actin was used as an internal control and 
was shown to be unaffected by the GRK5 siRNA treatment. Finally, an experiment was 
designed, and partially tested, to coordinate the protocols needed to induced and measure 
GRK5 knockdown (siRNA transfection, qRT-PCR, and Western blotting) with the protocols 
required to use a model cell system (HEK293 cells transiently transfected with the pN1-rV1bR 
plasmid) to determine the effect of knockdown on IP-accumulation following AVP-stimulation 
of the V1bR system (by measuring the production of [
3
H]-IPs in [
3
H]-myo-inositol labelled 
cells). This protocol can be used in future to determine if GRK5 is involved in the 
desensitisation of rV1bR to stimulation with AVP. 
7.2 COMMENTS ON METHODS USED AND OPTIMISED IN THIS 
RESEARCH 
7.2.1 Use of HEK293 cells transiently transfected to express the rV1bR as a 
model cell system 
The use of a model cell system, rather than the primary pituitary cell cultures used previously 
(Hassan et al., 2003; Hassan & Mason, 2005), was necessary to allow the use of RNAi-
mediated knockdown of GRK5 expression. HEK293 cells were selected as they are relatively 
easy to transfect (Shaw et al., 2002b), and represent a homogenous cell population. Use of a 
cell line derived from human tissue was advantageous due the availability of siRNA duplexes 
and primary antibodies targeted against human GRKs. Furthermore, the availability of human 
genome/transcriptome information was useful during optimisation of the qRT-PCR protocol. 
 
As with all model systems, departures from endogenous conditions can affect the ability to 
extrapolate data obtained using the model system to the in vivo situation. In investigating 
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GPCR signalling, it is important to remember that to some extent, the mechanisms by which 
the receptors signal and are regulated dependant on the cell-type and expression-level of key 
proteins in the pathway (Violin et al., 2006).  However, model cell systems enable the use of 
techniques (such as RNAi) which are difficult, if not impossible to use in primary cell cultures, 
and which provide useful insights into signalling pathways.  
 
To generate the model system used for this research HEK293 cells were transiently transfected 
with the rat V1bR. The rV1bR displays high sequence homology to the human V1bR 
[reference] and has previously been used in the Mason laboratory. While there is potential for 
inter-species differences in pharmacological properties (Ventura et al., 1999), rV1bR expressed 
both transiently (Gatehouse, 2008) and stably (Cummings, 2011) has been shown to 
successfully activate the human PLCβ-mediated intracellular signalling pathway. This was 
demonstrated by an increase in IP production in AVP-stimulated HEK293 cells transiently 
transfected with the rV1bR. Crucially, this increase was shown to be dependent on the 
expression of the rV1bR, as it did not occur in untransfected HEK293 cells (Gatehouse, 2008). 
rV1bR expressed in HEK293 cells was also able to interact with components of the 
desensitisation machinery as the responsiveness of the rV1bR to stimulation with AVP was 
impaired by both repeated and chronic AVP stimulation.  As such, this model system fulfils the 
requirements needed for this research. 
 
The use of transient transfection for inducing the expression of a protein comes with the 
potential for variability between transfection events. When receptors are being expressed, 
radioligand binding assays can be performed to assess variation in transfection efficiency, 
though this is a time consuming and costly process. Multiple repetitions of the experiment 
proposed in Chapter 6 will be required to ensure the measured effects are real. 
 
7.2.2 Establishing, validating and optimising a Western blotting protocol for 
measuring the relative expression of GRK5 protein  
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A Western blotting protocol was established as part of this research to allow changes in the 
expression of GRK5 to be monitored. A protocol of immunodetection of actin was also 
optimised, and actin expression used as an internal control against which GRK5 expression 
was normalised. The Western blotting conditions were optimised by systematically altering the 
transfer time, blocking solution, antibody concentrations and antibody diluents. The optimised 
assays for GRK5 and actin were tested for sensitivity, accuracy and reproducibility. The 
optimised assay for actin performed well (see Section 3.3.4.3). A strong linear relationship was 
detected between the amount of protein present and the intensity of the actin band, as 
determined by linear regression of band intensity produced by serial dilution of protein (R
2
= 
0.9307) (Figure 3.13). Furthermore, the slope of the line detected for actin was not 
significantly different to that of an idealised data set (two-tailed p value = 0.409) (i.e. in which 
25% less protein loaded resulting in a band 25% less intense). The actin assay was able to 
detect a signal when as little as 4μg of whole protein was loaded, making it very sensitive. The 
reproducibility of the assay was assessed by running the same amount of protein in multiple 
lanes, and calculating the CV (see Section 3.3.4.3.2). This was repeated 4 times, with a mean 
CV of 8.8 ± 4.5% (mean, SEM). This value is very similar to those previously published for β-
arrestin (6.5% ± 0.9%) and β-tubulin (7.6 ± 1.4%) (Liu & Xu, 2006) 
  
The optimised GRK5 assay was not as accurate as the actin assay (see Section 3.3.3.2.7). A 
linear relationship was detected between the amount of protein present and the intensity of the 
band measured. The R
2
 value for the ‗line of best fit‘ for the serially diluted protein was 
0.8924, indicating that 89.24% of the variation seen was due to the amount of protein loaded. 
The p value for this slope was <0.0001, indicating there is a significant correlation between the 
amount of protein loaded and the intensity of the band produced (Figure 3.11). The measured 
slope was compared to the slope produced by the idealised data set, and as with actin, no 
significant difference was seen between the two slopes (two-tailed p value = 0.9559). As 
above, the reproducibility of the assay was assessed by calculating the CV for multiple lanes 
loaded with the same amount of protein (Section 3.3.3.2.7.2). In contrast to the low value 
obtained for actin, and the published CV values shown above, the mean CV for GRK5 was 
20.6 ± 6.0% (mean, SEM, n=3).   
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Use of the optimised GRK5 protocol described in Section 3.2 routinely resulted in the 
detection of multiple additional bands. Possible explanations for the identity of these bands are 
discussed in detail in Section 3.3.3.2.7.1. One explanation proposed was that some of the bands 
seen in addition to the 68kDa one that is consistent with the putative GRK5 band, represent 
alternative isoforms or phosphorylation states of GRK5. Though no GRK5 isoforms have yet 
been positively identified in the literature, multiple isoforms of GRK4 and 6 (to which GRK5 
is closely related) have been found. Furthermore, unexplained additional bands are often 
shown in published immunoblots against GRK5. One such band, located at ~55kDa has been 
proposed to be an alternative isoform of GRK5 (Jones et al., 2002) This is supported by the 
results from the research reported here, which demonstrated a GRK5-targeted siRNA mediated 
decrease in both the expected 68kDa band, and the unidentified 55kDa band. However it is 
likely that the remaining additional bands detected are due to off-target binding of the primary 
GRK5 antibody.  
 
One of the difficulties of Western blotting is that its accuracy and reliability are reliant on the 
use of good antibodies. The Santa Cruz primary anti-GRK5 antibody used for this research was 
shown to vary considerably between batches, and for this reason its use has been abandoned by 
some researchers when batches are of inferior quality. While the reaction conditions used in the 
protocol developed for this research were thoroughly optimised, the quality of the Western 
blotting protocol produced was limited by the quality of the primary anti-GRK5 antibody. As 
Western blots allow the molecular weight of the detected proteins to be measured, this protocol 
it is still considered to be useful for indicating the relative expression of the GRK5 68kDa band 
between samples, and was used successfully in the optimisation of the RNAi protocol to assess 
the effects of different conditions trialled. A more accurate value for relative expression could 
be determined via use of a standard curve of purified protein. However, practical constraints 
(such as gel size and inter-gel variability) make use of a standard curve difficult. Furthermore, 
Western blotting is a best a semi-quantitative technique, and in many cases (such as this) it is 
sufficient to simply show a relative decrease in target protein expression.  
7.2.3 Establishing, validating and optimising a qRT-PCR protocol for 
measuring the relative levels of GRK5 mRNA between samples.  
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Primer sets for qRT-PCR were subjected to three levels of testing prior to selection. The first 
level, ‗in silico analysis‘, was used to predict both the specificity of a primer set for its target 
(using BLAST searches) and its potential to form secondary structures (using Beacon designer 
software). A second level of analysis, using PCR, was done for primer sets with low potential 
for undesired interactions (as determined by in silico analysis). PCR analysis was used to 
indicate how the primer sets behaved over a range of annealing temperatures. All of the primer 
sets tested showed high specificity, as indicated by the lack of additional bands seen when the 
PCR products were electrophoretically separated. Primer sets which showed little to no 
production of secondary structure (e.g. primer dimers), and bands of a similar intensity to those 
produced by the GRK5 primer sets were then selected for analysis under qRT-PCR conditions.  
Examination of the amplification and melt curves identified some primer sets that displayed 
unusual amplification characteristics and or producing secondary structures. These primer sets 
were discarded. Standard curves were then produced by the remaining primer sets and used to 
calculate the amplification efficiency for each primer set, and select a primer set for GRK5 
(GRK5 RTP, efficiency= 100.5%) and primer sets for two reference gene (YWHAZ, 
efficiency= 87.9%, and TBP, efficiency= 91.0%)  
 
The specificity of the primer sets was checked by comparing the actual sequence of their qRT-
PCR products with the predicted sequence. The GRK5-targeted primer set (GRK5 RTP) 
amplified a single product identical to the predicted sequence, indicating that the primer set 
was appropriate for use with the current protocol. However, both of the reference gene-targeted 
primers sets (TBP and YWHAZ) amplified two products, one corresponding to the predicted 
sequence and a second short product resulting from primer-dimer formation. This result was 
unexpected, as careful analysis of the melt curves (which show the melting points of any 
amplified products) suggested the presence of only one product. It is possible that the primer-
dimers were introduced during an additional PCR step used to prepare the products for ligation 
and cloning (by effectively diluting the concentration of qRT-PCR reagents which can interfere 
in downstream reactions). As suggested in Chapter 4, the specificity of the primer-template 
interaction (and thus, confidence in the results) could be ensured by increasing the annealing 
temperature used by 1
o
C, and rerunning the standard curve protocol described in Section 
4.3.2.5.2 at this annealing temperature. This is suggested for future use of the protocol, once 
the qRT-PCR machine is again available. 
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7.2.4 Establishing, validating and optimising an RNAi protocol for 
knockdown of GRK5 expression  
An RNAi protocol for knockdown of GRK5 was developed as part of this research (Chapter 5).  
Use of 10nM GRK5-targeted siRNA reduced GRK5 mRNA levels (as measured by qRT-PCR) 
to ~25% of that seen in untransfected cells, while GRK5 protein levels (as measured by 
Western blotting) were reduced to ~50% that measured in untransfected cells. Titration of the 
GRK5-targeted siRNA indicated that no further increase in GRK5 knockdown was induced 
with siRNA concentrations higher than 10nM. No cytotoxic phenotype was observed at any 
concentration trialled (0 – 50nM). Two siRNA duplexes were obtained from Dharmacon 
(NT#1 and NT#3) and trialled for use as a non-targeting control. However both produced 
cytotoxic phenotypes when used with the GRK5-targeted siRNA transfection protocol (as 
would be required for their use as a control), and as such neither was deemed to be appropriate 
for use as a non-targeting control. Non-targeting controls are thought by some to be of limited 
use as they can be too different from the targeting duplex to be truly informative (Nature Cell 
Biology Editorial, 2003). Instead, for future validation of the results obtained with the current 
GRK5-targeted siRNA, it would be preferable to replicate GRK5 knockdown with a second 
GRK5-targeted siRNA duplexes. This could be advantageous in three ways: i) it would 
confirm that any functional phenotype obtained using the current duplex was indeed due to 
knockdown of GRK5 expression, ii) as different siRNA for the same mRNA can have very 
different knockdown efficiencies, it may induce GRK5 knockdown greater than that achieved 
with the current duplex, and, iii) the transfection protocol used for the second duplex 
(including siRNA concentration) could be optimised to reduce the chance of off-target effects 
such as cytotoxic phenotypes (which is not valid for non-targeting controls). In this thesis, 
HEK293 confluence and morphology was monitored during the RNAi experiments to assess 
the effect of the treatment on cell viability. This could in future be assessed more quantitatively 
using a cell viability assay such as a MTT cell proliferation assay. The ability to assess some 
aspects of the RNAi protocol described in Chapter 5 was prevented by the lack of availability 
of the Stratagene qRT-PCR machine used for this research after the February 22
nd
 earthquake. 
This prevented the GRK5-targeted siRNA titration experiment from being repeated. qRT-PCR 
was the favoured protocol for this as it allows more accurate quantitation than Western 
blotting. Additionally, HEK293 cells were plated, transfected and the RNA harvested at 24, 48 
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and 72 hours after transfection with the intention  of using this time course to select the best 
time point for RNA harvesting, but this experiment was unable to be completed. 
 
The sequence of the GRK5-targeted siRNA duplex used in this research was taken from a 
paper by Ren et al. (2005). They reported achieving >95% knockdown of GRK5 protein with 
this duplex. The effect of siRNA transfection of mRNA was not examined. The extent of the 
reported knockdown was greater than that obtained in this research (~50%). This may be due 
to differences in experimental design. For example, Ren et al. (2005) plated their HEK293 cells 
in 100-mm dishes, and simultaneously transfected with 20ng siRNA and a receptor plasmid 
(using GeneSilencer from Gene Therapy Systems as a transfection reagent) when the cells 
reached 30-40% confluence. The cells were passaged after 48 hours and split into plates for 
various different assays, which were performed at least 3 days after transfection. Ren et 
al.(2005) assessed knockdown exclusively by Western blotting analysis. They also used the 
Santa Cruz antibody used in this research for immunoblotting of GRK5; however they 
subsequently stopped using the antibody as later batches did not produce acceptable results 
(correspondence with co-author Dr S. Ahn). No other details on the immunoblotting protocol 
used (e.g. amount of protein loaded, diluents, and antibody concentrations) for Western 
blotting detection of GRK5 were published. 
 
As stated above, the level of GRK5 mRNA and protein knockdown measured following 
transfection with GRK5-targered siRNA differed by ~25%. This is potentially due to 
difference in the accuracy of the two detection methods used (i.e. qRT-PCR and Western 
blotting). However, as the relationship between mRNA and protein levels is complex, 
depending on the rates of transcription, translation and degradation of the protein, the mRNA 
levels are not always predictive of subsequent protein levels (Chen et al., 2002). This 
emphasises the need to measure the expression of the target protein at the time of the 
functional assay. 
7.3 COORDINATION OF ALL METHODOLOGIES TO DESIGN AN 
EXPERIMENTAL PROTOCOL FOR DETERMINING THE EFFECT OF 
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GRK5 KNOCKDOWN ON DESENSITISATION OF THE IP RESPONSE 
TO AVP 
A protocol was designed that would allow the effect of GRK5 knockdown on desensitisation of 
the rV1bR-dependant response to AVP to be determined. It coordinated the transfection of 
HEK293 cells with GRK5-targeted siRNA (to knockdown GRK expression) with transfection 
with the pN1-rV1bR plasmid (to induce V1bR expression), and a desensitisation assay. The 
expression of GRK5 protein and mRNA are measured by Western blotting and qRT-PCR, 
respectively, while the responsiveness of the receptor is determined by measuring the AVP 
stimulated IP production. The proposed desensitisation assay involves stimulating HEK293 
cells expressing the rV1bR with 0 or 100nM AVP for 0, 5, 15, 30 or 60 minutes, and 
measuring the IP accumulation over time. An increase in the IP accumulation with time in cells 
previously transfected with GRK5-targeting siRNA would suggest that GRK5 is involved in 
V1bR desensitisation. The compatibility of the two transfections was tested, by examining i) 
the effect of pN1-rV1bR transfection on siRNA-mediated knockdown, and ii) the effect of a 
mock siRNA transfection on the responsiveness of pN1-rV1bR-transfected cells to AVP. The 
double transfection did not appear to negatively impact the individual success of either 
transfection, making the combined protocol suitable for use. 
 
The experimental design outlined in Chapter 6 only allows for duplicates of each treatment in 
the desensitisation assay. While replicates of three or more would be preferable, the size of the 
experiment is limited by the time-dependency of several of the steps. This is particularly 
problematic at steps which involve multiple medium changes For example; the cells are 
labelled 64 hours after plating and then incubated for 20 hours before the functional assay. For 
this the cells are washed once, and then medium spiked with [3H]-myo-inositol is added. The 
HEK293 cells grow in a monolayer, which has the tendency to lift during medium changes, 
even when grown on special plates which promote adhesion. This results in loss of cells from 
the wells. This cell loss can be minimised by taking extreme care when adding medium to the 
wells. This is, however, very time consuming, and can introduce variability into the experiment 
as there can be a large difference in time (hours) between the first and last well receiving the 
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treatment. As such, the use of a larger number of replicates is not practicable. Instead, it is 
recommended that the whole experiment is repeated numerous times to confirm the results. 
7.4 SUGGESTIONS FOR FUTURE RESEARCH 
This study has provided the methods required to determine the effect of GRK5 knockdown on 
desensitisation of the rV1bR to AVP. The experimental protocol designed as part of this thesis 
to coordinate these methods can now be used to examine the role of GRK5. Introduction of a 
second GRK5-targeted siRNA will confirm that the phenotype induced by the current siRNA 
is caused by knockdown of GRK. Furthermore, once the Stratagene qPCR is available, 
increasing the annealing temperature used during qRT-PCR analysis will ensure that the primer 
sets for the reference genes TBP and YWHAZ are not able to form primer dimers.  
 
Once the involvement of GRK5 in V1bR desensitisation has been assessed, it will be necessary 
to look at other GRKs such as GRKs 2, 3 and 6, to establish which kinase is responsible for the 
probable phosphorylation of the V1bR during desensitisation. Furthermore, as internalisation 
has been shown to play a role in V1bR desensitisation to AVP, knockdown experiments 
investigating the role of would also be informative. The protocols for Western blotting and 
qRT-PCR could be adapted for this purpose, as the Western blotting conditions for actin 
detection have already been optimised, and reference genes (TBP and YWHAZ) selected for 
qRT-PCR. 
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APPENDIX A 
MATERIALS 
5 X siRNA buffer  Dharmacon 
100bp Ladder  Gibco, Invitrogen Corporation 
AG1-X8 anion-exchange resin  Bio-Rad 
Agarose  Gibco, Invitrogen Corporation 
Acrylamide solution  Bio-Rad 
Ammonium Formate  Sigma-Aldrich Company 
Ammonium Persulfate  Sigma-Aldrich Company 
Arginine Vasopressin (AVP)  Sigma-Aldrich Company 
Bromochloropropate (BCP)  Molecular Research Centre, Inc. 
BCA protein assay kit  Pierce 
Beta-mercaptoethanol  Sigma-Aldrich Company 
Bis solution (2%)  Bio-Rad 
Bovine Serum Albumin  Gibco, Invitrogen Corporation 
Bromophenol blue  Sigma-Aldrich Company 
Coomassie Brilliant Blue G  Sigma-Aldrich Company 
Donkey anti-rabbit IgG HRP-conjugated IgG  Amersham 
Dulbecco‘s modified Eagle‘s medium (-inositol)  MP Biomedical 
DMSO  Sigma-Aldrich 
EDTA disodium salt  Boehringer Mannheim 
Ethanol 100%  BDH 
Fetal Bovine Serum  Gibco, Invitrogen Corporation 
Formic Acid  Sigma-Aldrich Company 
Glacial acetic acid  BDH 
GlutaMax  Invitrogen 
GRK5 (C-20) blocking peptide  Santa Cruz Biotechnology, Inc. 
GRK5-targeting siRNA  Dharmacon 
Glycine  Sigma-Aldrich Company 
High DNA Mass Ladder  Gibco, Invitrogen Corporation 
Horse anti-rabbit IgG HRP-conjugated IgG  Sigma-Aldrich Company 
Horse anti-rabbit IgG HRP-conjugated IgG  Novus Biologicals 
HEK293 cell line  ATCC 
Hybond-C-extra Nitrocellulose Membrane  Amersham 
Hydrochloric acid (HCl)  BDH 
KAPA Taq ReadyMix DNA Polymerase  Kapa Biosystems 
Lithium chloride (LiCl)  Sigma-Aldrich Company 
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Minimum Essential Medium (MEM)  Gibco, Invitrogen Corporation 
Methanol   Burdick & Jackson  
Milk Powder (0.1 % fat)  pams
®
   
Myo-[
3
H]-inositol  Amersham Biosciences  
Nitrocellulose membranes  Hybond 
Mini Protease inhibitor  Roche 
Nanopure H2O  Biology building 
Non-Essential Amino Acids  Gibco, Invitrogen Corporation 
Non-targeting siRNA #1  Dharmacon 
Non-targeting siRNA # 3  Dharmacon   
OPTISAFE ‗HISAFE‘ 3 scintillation cocktail  Perkin-Elmer 
PageRuler Prestained Protein Ladder  Fermentes Life Sciences 
Polyprep® chromatography columns  BioRad 
Ponceau S stain  Sigma-Aldrich Company 
Potassium chloride (KCl)  BDH 
Potassium dihydrogen phosphate (KH2PO4)  BDH 
PureLink RNA Mini Extraction Kit  Invitrogen 
Rabbit anti-GRK 5 (c-20) polyclonal IgG (SC-565)   Santa Cruz Biotechnology 
Rabbit anti-actin polyclonal IgG (A2066)  Sigma-Aldrich Company 
RNase-Away  Invitrogen  
Scintillation cocktail (NMCS104)  Sigma-Aldrich Comparny 
Sodium bicarbonate (NaHCO3)  BDH 
Sodium chloride (NaCl)  BDH limited 
Sodium hydrogen phosphate (Na2HPO4)  BDH 
Sodium dodycel sulfate  Sigma-Aldrich Company 
Sodium formate  Sigma-Aldrich Company 
Sodium hydroxide  BDH 
Sodium pyruvate  Gibco, Invitrogen Corporation 
Super Signal West Pico Chemilluminecsence reagent       Thermo Fisher Scientific 
Sodium Tertraborate  MP Biomedicals 
Sucrose  BDH 
SuperScript III First-Strand Synthesis System for RT-PCR Invitrogen 
SYBR GreenER qPCR SuperMix Universal  Invitrogen 
SYBRsafe dye  Invitrogen 
Tris  Invitrogen 
TRIzol Plus RNA Purification Kit  Invitrogen 
Trypan blue  BDH 
Trypsin/EDTA (TE)  Gibco, Invitrogen Corporation 
TEMED  Invitrogen 
Tween-20  Sigma-Aldrich Company 
Trizma base  Sigma-Aldrich Company 
Trizol Plus RNA Purification Kit  Invitrogen 
Trypsin-EDTA  Gibco, Invitrogen Corporation 
UltaPure Distilled Water  Gibco, Invitrogen Corporation 
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SOLUTIONS, MEDIA & GELS 
B.1 CHAPTER 2: MODEL CELL SYSTEM & ASSOCIATED METHODS 
B.1.1 Minimum Essential Medium (MEM) 
MEM was prepared by dissolving one packet of commercially prepared powdered MEM 
(Gibco, Cat # 41500-034) in ddH2O (18.2ΩM). The medium was completed by addition of 
1.5g of sodium bicarbonate, and 10ml of sodium pyruvate. The volume was then made up to 
1L and pH adjusted to 7.1. The medium was sterilised by negative pressure filtration through a 
0.45µm filter, and transferred into sterile Schott bottles. The medium was stored at 4
o
C for up 
to 2 months. A sub of the medium from each bottle was transferred to McCartney bottles, 
which were incubated at 37
o
C/CO2 5% for 3 days to check the sterility. Prior to use, the 
medium was supplemented with 10% FBS, and for medium more than 2 weeks old, 1% 
GlutaMAX. 
B.1.2 Phosphate buffered saline (PBS) 
The reagents listed below were dissolved in ddH2O and made up to 200ml for 5 x PBS or 1L 
for 1 x PBS. The pH was adjusted to 7.4 before use. The solution was stored at room 
temperature. 
 
 Na2HPO4 (anhydrous)   1.15 g 
 NaCl      8.0 g 
 KCl      0.2 g 
 KH2PO4     0.2 g 
B.1.3 Trypan blue: stock solution 
A 0.2% stock solution of trypan blue was made and stored at 4
o
C until use. 0.02g of Trypan 
Blue was dissolved in 10ml of ddH2O and filtered through a 0.2µm filter into a clean glass vial. 
B.1.4 Trypan blue: working solution  
Trypan blue working solution was made fresh as required for cell counts by diluting trypan 
blue stock solution (B.1.3) 4/5 with 5 x PBS.  
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B.1.5 Labelling solution 
For each experiment, the labelling solution was made up at a volume that allowed 500µL per 
well, plus 3mL spare. [
3
H]-myo-inositol (2.5μL/mL) was added to sterile inositol-free DMEM 
containing 0.1% BSA, and 1% GlutaMax. E.g., for 24 wells, 14.85mL of DMEM- and 0.15mL 
GlutaMax were combined in a glass beaker. 0.015g of BSA was then added and swirled to 
dissolve. The media was filter sterilised through a 0.2μm filter into a sterile beaker. 12.5mL 
was then transferred to a 50mL falcon tube, and incubated at 37
o
C in a CO2 incubator for 
approximately 1 hour before use. Immediately before use, 31.25μL [3H]-myo-inositol was 
added to the tube.  
B.1.6 “Stop” solution 
The reagents listed below were dissolved in the order listed into approximately 450ml of 
ddH2O. The solution was made up to 500ml with dH2O and stored at 4
o
C. 
B.1.7. “Neutralization” solution 
A 7.5% HCl solution was made by adding 37.5mL of 37% hydrochloric acid to 462.5mL of 
ddH2O. 5mL of this solution was combined with 5mL of inositol-free culture medium and 5mL 
of ―stop‖ solution, and the acidity adjusted to pH7. by addition of ddH2O. The neutral solution 
was stored at 4
o
C. 
B.1.8. Elution Buffer II 
Elution buffer II was made fresh on the day of inositol phosphate separation by dissolving the 
following reagents 100mL of ddH2O.  
 
 Sodium borate   0.191g 
 Sodium formate   0.408g 
B.1.8. Elution Buffer VI 
Elution buffer VI was made fresh on the day of inositol phosphate separation by dissolving the 
following reagents in 100mL of ddH2O. 
 
 Formic acid    436µL 
 Ammonium formate  12.612g 
B.1.9. Regeneration Solution 
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The following reagents were dissolved in 100mL ddH2O. The solution was made fresh as 
required. 
 
 Formic Acid    436µL 
 Ammonium formate  18.920g 
B.2CHAPTER 3: WESTERN BLOTTING & ASSOCIATED METHODS 
B.2.1 20% SDS 
SDS (10g) was mixed with 50ml nanopure H2O, and heated to 68
o
C until dissolved. The 
solution was then cooled and stored at room temperature 
B.2.2 0.5M Tris Buffer (pH 6.8) 
Tris (12.114g, MW 121.1) was dissolved in 150ml nanopure H2O, the pH adjusted to 6.8 with 
concentrated HCl (without overshooting). The volume was made up to 200ml with NPH2O. 
The solution was stored at room temperature.  
B.2.3 0.5M Tris Buffer (pH 6.8) 
Tris (12.114g, MW 121.1) was dissolved in 150ml nanopure H2O, the pH adjusted to 6.8 with 
concentrated HCl (without overshooting). The volume was made up to 200ml with NPH2O. 
The solution was stored at room temperature.  
B.2.4 1.5M Tris Buffer (pH 8.8) 
Tris (36.342g, MW 121.1) was dissolved in 150ml nanopure H2O, the pH adjusted to 8.8 with 
concentrated HCl (without overshooting). The volume was made up to 200ml with NPH2O. 
The solution was stored at room temperature. 
B.2.5 SDS Lysis Buffer 
The following reagents were added to 8mL of NPH2O, and the solution stirred to dissolve the 
sucrose.  
 
 1M Tris HCl (pH 6.8)  1.25 ml 
 20% SDS    2 ml 
 Sucrose (MW 342.30)  1 g 
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The volume was then adjusted to 15.14ml using NPH2O. The solution was stored at -20
o
C. 
B.2.6 BCA assay working Reagent 
The BCA assay working reagent was prepared in the day of the assay by mixing reagents A 
and B at a ratio of 50:1. This reagent could be stored at room temperature for several hours 
before use. 
B 2.7 1X SDS Buffer 
The following reagents were added to 8mL of NPH2O, and the solution stirred to dissolve the 
sucrose. 
 
 1M Tris HCl (pH 6.8)  1.25 ml 
 20% SDS    2 ml 
 Sucrose (MW 342.30)  1 g 
 
The volume was then adjusted to 18ml with NPH2O. The solution was stored at -20
o
C. 
B.2.81 1% Bromophenol Blue Solution 
A 1% (wt/vol) solution of Bromophenol blue was prepared by dissolving 0.1g bromophenol 
blue powder in 10mL 70% ethanol. This solution was stored at room temperature. 
B 2.9 0.1% Bromophenol Blue Solution 
10μl of 1% Bromophenol blue solution was added to 90μl of Nanopure H2O, and the resulting 
solution stored at room temperature. 
B.2.10 „Fresh‟ 10% Ammonium persulfate (APS) 
10% APS solution was prepared fresh for each gel by dissolving APS in Nanopure H2O 
(0.1g/ml). The solution was discarded after use. 
B.2.11 8% Separating gel 
The reagents listed below were added in order and mixed by swirling between additions. The 
resulting gel solution was transferred into the casting frame, covered in a layer of Nanopure 
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H2O and left to set for 45-60 minutes at room temperature. The water was then poured off and 
the cavity dried in preparation for pouring of the stacking gel. 
 
 Nanopure H2O    2417 μl 
 40% Acrylamide Solution   1160 μl 
 2% Bis Solution    800 μl 
 1.5 M TRIS (pH 8.8)   1500 μl 
 20% SDS     30 μl 
 10% ammonium persulfate  60 μl 
 TEMED     3 μl  
B.2.12 Stacking gel 
The below reagents were added in order and swirled to mix between additions. 1ml of the 
resulting solution was added to the top of the separating gel and the comb inserted. The gel was 
left to set for 30-45 minutes. The gel could be used immediately or stored overnight at 4
o
C. 
 
 Nanopure H2O    1049 μl 
 40% Acrylamide solution   242 μl 
 2% Bis solution    167 μl 
 0.5 M TRIS (pH 6.8)   500 μl 
 20% SDS     10 μl 
 10% Ammonium persulfate  20 μl 
 TEMED     2.5 μl 
B 2.13 10 x Tris Glycine Buffer 
The following chemicals were dissolved in 500ml Nanopure H2O (heating to 68
o
C if 
necessary) and made up to 1L with Nanopure H2O. The solution was stored at room 
temperature. 
 
 Glycine    144 g 
 Tris (MW. 121.1)   30 g 
B.2.14 Running Buffer 
The following reagents were mixed and made up to 900ml with Nanopure H2O. The resulting 
buffer stored at room temperature. 
 
 10 x Tris-Glycine    90 ml 
 20% SDS    4.5 ml 
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B.2.15 Transfer Buffer 
The following reagents were added in order and mixed between additions. The solution was 
stored at room temperature and chilled at -20
o
C for one hour before use; 
 
 10 x Tris-Glycine buffer   100 ml 
 Nanopure H2O    700 ml 
 Methanol     100 ml 
 20% SDS     0.5 ml 
B.2.16 Ponceau S Stain 
The following reagents were mixed and the resulting solution stored at room temperature; 
 
 Ponceau S     0.005 g 
 Acetic acid     2.5 ml 
 Nanopure H2O    47.5 ml 
B.2.17 Coomassie Brilliant Blue G Solution 
The following reagents were mixed and the resulting solution stored at room temperature; 
 
 Coomassie Brilliant Blue R-250  0.25 g 
 Nanopure H2O    125 ml 
 Methanol     100 ml 
 Acetic acid     25 ml 
B.2.18 Coomassie Brilliant Blue Destain Solution 
The following reagents were mixed and the resulting solution stored at room temperature; 
 
 Methanol     225 ml 
 Acetic acid     50 ml 
 Nanopure H2O    225 ml 
B.2.19 PBS with 0.1% Tween 20 (PBST) 
0.1ml of Tween 20 was added per 100ml of PBS. The resulting solution was shaken vigorously 
to mix and stored at room temperature. 
B.2.20 PBST with 2% Milk powder (PBSTM 2%) 
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Milk powder (0.1% fat) was dissolved in PBST (0.2g/10ml) 
B.3 CHAPTER 4: QRT-PCR & ASSOCIATED METHODS 
B.3.1 0.5M EDTA Solution 
93.05g of EDTA disodium salt (FW= 372.2) was mixed dissolved in 400ml of fresh NP water 
under RNase-free conditions. The pH was adjusted to 8.0 with approximately 10g of NaOH 
pellets (pH measured with pH paper) in order to get the EDTA into solution. The volume was 
made up to 500ml with NPH2O. The solution was stored in an RNase-free Schott bottle at 
room temperature. 
B.3.2 50 x TAE Buffer 
242g Tris base (FW=121.14) was dissolved in 750ml of fresh NP water. 57.1ml of glacial 
acetic acid and 100ml of 0.5M EDTA (pH 8.0) were added and the solution made up to 1L 
with fresh NPH2O 
B.3.3 1 x TAE Buffer 
On the day of use, 1 part 50 x TAE buffer was mixed with 49 parts fresh RNase-free NPH2O. 
B.3.4 1% agarose gel  
0.5g agarose was mixed with 500ml 1 x TAE, in a 100ml Schott bottle and micro-waved with 
regular swirling until a clear solution was obtained. 5ul SYBRsafe was added and the bottle 
was placed in a dark place until cool enough to touch, then poured into a gel tray, covered in 
tinfoil and left to set for 20 minutes. Before the gel was poured, the casting frame and comb 
were sprayed with RNase-OUT and wiped with RNase-free Kim wipes.  
B.3.5 1.5% agarose gel  
0.15g of agarose per 10ml 1 x TAE were mixed and microwave to dissolve agarose. SYBR 
Safe was added (0.1ul per ml of agarose gel solution) and the solution allowed cooling to about 
50
o
C. The gel was then poured into a gel tray and left to set for 30mins prior to use. 
B.3.6 2% agarose gel  
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1g of agarose per 50ml 1 x TAE were mixed and microwave to dissolve agarose. SYBR Safe 
was added (0.1ul per ml of gel agarose solution) and the solution allowed cooling to about 
50
o
C. The gel was then poured into a gel tray and left to set for 30mins prior to use. 
B.4 CHAPTER 5: RNA INTERFERENCE & ASSOCITED METHODS 
B.4.1 1 X siRNA buffer 
One part 5 X siRNA buffer (Dharmacon, catalogue number B-002000-UB-100) was mixed 
with four parts RNase-free NPH2O (Gibco, catalogue number 10977-023). 
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APPENDIX C 
GRK5 cDNA SEQUENCE WITH CANDIDATE PRIMER ALIGNMENT 
 
GRK5 cDNA* sequence with the following GRK5-directed primers aligned: Vgt, ZhC, RTP, 
PB1, PB2, PB3, MG1, MG2, MG3.  
 
* The GRK5 cDNA sequence was obtained by converting the mRNA sequence using Sequence 
Editor software available at http://www.fr33.net/seqedit.php. The GRK5 mRNA sequence 
and exon information was retrieved from the NCBI database at 
http://www.ncbi.nlm.nih.gov/nucleotide/51896033 . 
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APPENDIX D 
qPCR RAW DATA FROM STANDARD CURVE GENERATION 
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APPENDIX E 
SEQUENCED QRT-PCR PRODUCTS WITH PRIMERS ALIGNED  
 
 
 
 
 
GRK5 
 
F: GACCACACAGACGACGACTTC 
    CTGGTGTGTCTGCTGCTGAAG 
 
R:  CGTTCAGCTCCTTAAAGCATTC 
     GCAAGTCGAGGAATTTCGTAAG  
 
>G1                  
CGTTCAGCTCCTTAAAGCATTCTGTTTCTATCATCTCGTTTTGCCATGGGATGGACACAGAGCCCGTGGAGAACTTGGAGTAGAAGTCGTCGTCTGTGTGGTC      
Size: 103bp      
>G2                  
CGTTCAGCTCCTTAAAGCATTCTGTTTCTATCATCTCGTTTTGCCATGGGATGGACACAGAGCCCGTGGAGAACTTGGAGTAGAAGTCGTCGTCTGTGTGGTC      
Size: 103bp      
 
 
TBP 
 
F:TGCACAGGAGCCAAGAGTGAA  
   ACGTGTCCTCGGTTCTCACTT 
 
R: CACATCACAGCTCCCCACCA  
    GTGTAGTGTCGAGGGGTGGT 
 
>T2                  
CACATCACAGCTCCCCACCACCTCCTTCTTGTTCACTCTTGGCTCCTGTGCA        Size: 52bp                                                                                 
            
>T3                  
TGCACAGGAGCCAAGAGTGAAGAACAGTCCAGACTGGCAGCAAGAAAATATGCTAGAGTTGTACAGAAGTTGGGTTTTCCAGCTAGGTTCTTGGACTTCAAGATTCAGAACATGGTGGGGAGCTGTGATGTG   
Size:132bp        
 
 
YWHAZ 
 
F:ACTTTTGGTACATTGTGGCTTCAA 
  TGAAAACCATGTAACACCGAAGTT 
 
R: CCGCCAGGACAAACCAGTAT 
     GGCGGTCCTGTTTGGTCATA 
 
>Y3       
 
          
ACTTTTGGTACATTGTGGCTTCAAAAGGGCCAGTGTAAAACTGCTCCCATGTCTAAGCAAAGAAAACTGCCTACATACTGGTTTGTCCTGGCGG      Size: 
94bp        
 
>Y4                  
ACTTTTGGTACATTGTGGCTTCAATACTGGTTTGTCCTGGCGG       Size: 43bp              
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APPENDIX F 
PRIMER DETAILS, PREDICTED PRODUCTS AND SECONDARY 
STRUCTURES 
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